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1. General Introduction 
1.1. G-protein coupled receptors 
1.1.1. GPCRs as drug targets and their classification 
 
The superfamily of G-protein coupled receptors (GPCRs) is one of the largest and most 
studied families of proteins, over 800 GPCRs are encoded in the human genome1-2. A major 
characteristic of GPCR proteins is that they have seven α-helical transmembrane domains, 
an extracellular N-terminus and an intracellular C-terminus connected by three intracellular 
and extracellular loop domains (cf. Figure 1). Diverse kinds of endogenous ligands bind to 
GPCRs, such as biogenic amines, peptides, amino acids, glycoproteins, prostanoids, 
phospholipids, fatty acids, nucleosides, nucleotides and Ca2+ ions, as well as pheromones, 
fragrances or flavors are recognized by sensory 7TM receptors3. Moreover, the endogenous 
ligands of around 140 GPCRs are not identified, these GPCRs are the so-called orphan 
GPCRs4, this field is relatively wide open for new discoveries. GPCR agonist and antagonist 
drugs have therapeutic benefit across a broad spectrum of human diseases5, like peptic ulcers, 
pain, asthma, schizophrenia, depression and hypertension. According to sequence homology 
and functional roles, the mammalian members of this superfamily can be classified into three 
major families: A, B and C. Family A, also referred as the rhodopsin-like family, represents the 
largest and best studied subgroup of 7TM receptors. It includes aminergic and some 
peptidergic GPCRs as well as receptors addressed by nucleotides, lipids and other small 
molecules6. The other two main subfamilies are the family B (secretin receptor family) and 
metabotropic glutamate receptors, γ-aminobutyric acid receptors and the Ca2+ sensing 
receptor for family C7. The receptor topology varies between the families, e.g. with respect to 
the location of the orthosteric binding domain (OBD). For family A, the OBD is located within 
the 7TM domains, for family B in the large extracellular loop regions, and for family C the OBD 
is existent at the extracellular Venus-flytrap-like domain8. 
 
The crystal structure of bovine rhodopsin gave the first insight into the three-dimensional 
architecture of GPCRs9. Further structures were solved, e. g. those of the human β2-
adrenoceptor10-11, the turkey β1-adrenergic receptor12, the human adenosine 2A receptor13, the 
dopamine D3 receptor14, opsin15-16 and the chemokine CXCR4 receptor17. The crystal 
structures of GPCRs provided insights into the molecular mechanisms of GPCR activation 
and constitutive activity and served as template for GPCR homology models to study GPCR 
conformations and ligand receptor interactions. So far, the structures of more than 30 different 
GPCRs have been solved. 
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Figure 1. Schematic structure of a generic GPCR. GPCRs all contain a common core composed of 
seven transmembrane helices (7TM) with an extracellular N-terminal domain and an intracellular C-
terminal domain. The TMs are connected by three extracellular loops (EL1-EL3) and three intracellular 
loops (IL1-IL3). (modified from the literature8) 
 
1.1.2. GPCR signaling pathways 
 
To explain the interaction between a GPCR (R), its ligand (A) and the respective G-protein (G), 
several models have been proposed. The ternary complex model was firstly described by 
DeLean and colleagues18. In this model, the binding of the activated receptor to membrane 
proteins such as G-proteins was taken into account, the process is19: 
 
However, the ternary complex model was not able to explain the phenomena such as 
constitutive activity or inverse agonism. Refinement of the ternary complex model resulted the 
extended ternary complex model, which additionally implies the equilibrium between the 
inactive Ri and the active Ra receptor states19-20. The active state receptor can form a complex 
with G-protein (G) to RaG, or agonist activation can induce a ternary complex ARaG. The term 
α refers to the multiple differences in affinity of the ligand for Ra over Ri, and γ refers to the 
multiple difference in affinity of the receptor for G-protein, when the ligand is bound to the 
receptor (cf. Figure 2A). Moreover, further refinements were made with the cubic ternary 
complex (CTC) model. The concept of the CTC is shown in Figure 2B. Accordingly, receptors 
are assumed to exist in inactive (Ri) and active (Ra) conformations, which may or may not be 
coupled to G-protein. At equilibrium, four receptor species namely Ri, Ra, RiG, and RaG make 
up the native ensemble. KG, Kact, and β are defined as the interconversions between these 
four species (Ri, Ra, RiG, and RaG). Each of the four receptor species in the native ensemble 
can bind to ligand (refers to A). The equilibrium dissociation constants for the binding of ligand 
to the members of the native ensemble are KA, αKA, γKA, and δαγKA, respectively21-23. 
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Figure 2. (A) Illustration of the extended ternary complex model19: discrimination between Ri and Ra. 
(B) Scheme of the cubic ternary complex model of GPCR ligand-receptor interactions. The cubic ternary 
complex model comprises eight distinct types of receptor species: Ri, Ra, ARi, ARa, RaG, RiG, ARiG, and 
ARaG (Ri = inactive receptor, Ra = activated receptor, A = ligand, G = G-protein). (modified from 
literature21-23) 
 
Upon activation (agonist-dependent or independent), GPCRs can transduce signals into cells 
through G-Protein coupling. There are two main classes of G-proteins, small cytoplasmic G-
proteins and heterotrimeric G-proteins24-26. In the latter case, ɑ, β and γ subunits constitute a 
heterotrimeric G-protein. Agonist binding to extracellular or transmembrane domains of a 
GPCR leads to the stabilization of a certain receptor conformation resulting in binding of the 
intracellular receptor domains to a heterotrimeric G protein. This agonist-receptor-G-protein 
complex, is termed ternary complex. Upon receptor activation, the GDP-bound G-protein 
interacts with the intracellular face and C-terminus of the receptor, inducing GDP to GTP 
exchange on the Gɑ subunit and concurrent dissociation of the activated ɑ subunit (Gɑ*) from 
the βγ-dimer8. Both G-protein subunits regulate the activity of enzymatic effectors, such as 
adenylate cyclases, phospholipase C isoforms, and ion channels, to regulate the production 
and release of small molecule ‘second messengers’. The receptor returns to the inactive state 
by intrinsic GTPase activity of the Gɑ subunit: cleavage of the terminal γ-phosphate of GTP, 
resulting in GDP, gives the inactive GDP-bound Gɑ and the subunits re-associate allowing a 
new cycle24, 27-28. A scheme of the G-protein cycle is depicted in Figure 3.  
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Figure 3. The G-protein cycle. RGS, regulator of G-protein signaling. (adopted and modified from the 
literature29) 
 
More than twenty G-protein ɑ-subunits have been described for mammalian systems. Based 
on the degree of primary sequence similarities and different regulation of effectors30, G-protein 
ɑ-subunits can be divided into 4 families, termed as Gɑs, Gɑi/o, Gɑq and Gɑ12/133, 24, 29. Stimulation 
of the Gɑs subfamily activates AC1-9, leading to an increase in intracellular cAMP (3’-5’-cyclic 
adenosine monophosphate) levels, and consequently, to an activation of proteinkinase A (PKA) 
or the mitogen-activated protein kinase (MAPK) pathway, which results in a modulation of 
gene transcription31. Activation of the Gɑi family results in an inhibition of AC5 and AC6, and 
thus in decreased intracellular cAMP formation. Proteins of the Gɑq family active 
phospholipases Cβ1-3 (PLCβ), leading to the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) into 1,2-diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). IP3 
mediates the release of Ca2+ from intracellular compartments in particular from the 
endoplasmic reticulum. DAG activates protein kinase C (PKC) which phosphorylates of 
various proteins32. It has been difﬁcult to selectively study the cellular processes mediated by 
G12 and G13, for G12/G13 as the respective receptors are often simultaneously stimulated by 
activating members of the Gq-family. It was reported that G12/G13 stimulates a Na+/H+ exchange 
and alters a variety of downstream effectors including phospholipase A2 (PLA2)33-34. Like the 
GTP-bound ɑ-subunits, the β- and γ-subunits, forming a tightly associated βγ-complex, are 
also able to interact with effector proteins such as PLCβ and ion channels24 and regulate their 
functions. Besides the modulation of GPCR signaling by ligand (agonist) binding, the signaling 
is also substantially influenced by receptor expression, desensitization, and internalization in 
response to binding of different ligands35. The desensitization of GPCRs occurs through 
molecular mechanisms, involving phosphorylation of activated receptors by G protein-coupled 
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receptor kinases (GRKs). The phosphorylation leads to binding of β-arrestin preventing 
receptor-G-protein interactions while allowing activation of arrestin-dependent signaling 
pathways36-37. β-Arrestin can also induce receptor internalization, this regulates the level of 
cell surface receptors, thus effecting signaling to downstream effector pathways38. 
 
1.1.3. Allosteric modulation of GPCRs 
 
The word allosteric comes from the Greek allos, and the arrangement of atoms in space refers 
steric19. The term ‘orthosteric ligand’ describes a receptor ligand, which binds to the binding 
site of the endogenous ligand, activating the receptor as agonist/partial agonist, blocking the 
actions of the endogenous agonist as an antagonist, or suppressing the receptor´s basal 
activity as an inverse agonist. Most GPCR drug discovery efforts to date have focused on 
targeting such sites. But as the orthosteric site is often highly conserved across subtypes of a 
given GPCR subfamily, this approach cannot always lead to highly subtype selective ligands. 
For example, the development of orthosteric selective ligands for one of the five subtypes of 
muscarinic acetylcholine receptors (M1-M5) is highly challenging. A number of MR agonists 
such as xanomeline, milameline, sabcomeline, cevimeline and talsaclidine were developed 
for the treatment of Alzheimer’s disease. However, due to their poor subtype selectivity and 
associated side effects, their use in clinical trials was limited39. Meanwhile, in addition to 
orthosteric sites, potentially all GPCRs possess additional binding sites, which are designated 
allosteric sites. Ligands, which bind to an allosteric site of a GPCR, can potentially modulate 
the binding and/or signaling properties of the orthosteric ligand40-42. Because they do not face 
the same evolutionary pressure as orthosteric sites, allosteric sites are less conserved than 
orthosteric sites, presenting novel avenues for achieving selectivity in drug action42-44. 
Furthermore, allosteric modulators with limited positive or negative cooperativity will have a 
ceiling level to their effect, it means they might be potentially safer than orthosteric ligands if 
administered in high doses44-45. Finally, given that allosteric modulators can promote a 
conformational change of the receptor, their ability to effect orthosteric ligand efficacy is not 
surprising8. Some synthetic small molecules acting in such a pathway-selective allosteric 
modulation are actually reported46-48. 
Modulators binding to an allosteric site to stabilize a certain receptor conformation lead to an 
increase or decrease of the affinity and/or efficacy of an orthosteric agonist8. Such kind of 
allosteric ligands are termed as positive allosteric modulators (PAMs) and negative allosteric 
modulators (NAMs), respectively. Besides PAMs and NAMs, some allosteric ligands can be 
neutral (or silent), showing no cooperativity with the orthosteric ligand despite binding to an 
allosteric site of the receptor8. With the discovery of allosteric modulators and the intricate 
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mechanisms underlying their pharmacological properties, classical receptor models need to 
be revised or expanded. The allosteric ternary complex model (ATCM), which also forms the 
basis for many quantitative studies of GPCR allosterism, is considered as the simplest model 
to describe allosteric interactions41 (cf. Figure 4A). This model, describing the interactions 
between an orthosteric agonist, an allosteric modulator and a receptor, was derived from the 
original TCM, which describes ligand, receptor, and G-protein interactions. A prerequisite for 
an application of the ATCM is a simultaneous binding of the orthosteric ligand (A) and the 
allosteric ligand (B) to distinct, i.e. non-overlapping sites of the receptor. The ATCM provides 
estimates of the respective equilibrium dissociation constants, KA and KB, as well as the 
“cooperativity factor” (ɑ), which is a measure of the mutual effect of the two ligands on each 
other’s affinity to the receptor49-50. Values of ɑ > 1 indicate positive cooperativity. In this case 
an allosteric ligand promotes the binding of the orthosteric ligand. Values of ɑ < 1 refers to 
negative cooperativity, i.e. the allosteric modulator inhibits the binding of the orthosteric ligand, 
whereas ɑ = 1 means that binding of the allosteric ligand to the receptor does not alter the 
affinity of the orthosteric ligand. Provided that the two sites are conformationally linked, the 
orthosteric ligand will modulate the binding of the allosteric ligand in the same way41-42. Figure 
4C and 4D illustrate another important aspect of such allosteric interactions, namely the fact 
that these effects are limited, in other words, they are saturable. The extent of the effect is 
defined by the numerical value of ɑ (the lower the deviation of ɑ from unity, the less 
pronounced is the modulatory effect of B)42. 
 
Figure 4. (A) The allosteric ternary complex model (ATCM), which describes the interaction of two 
ligands (e.g., an orthosteric agonist and an allosteric modulator) on a receptor in terms of their 
equilibrium dissociation constants (KA, KB) and the cooperativity (ɑ) between the ligands. (B) Effect of 
a competitive antagonist on orthosteric ligand receptor occupancy (pA), simple competitive interactions 
are characterized by mutually exclusive binding of the two ligands for the same site and, thus, allow for 
a theoretically limitless dextral shift of orthosteric ligand occupancy. (C) An allosteric enhancer (α = 10) 
or (D) allosteric inhibitor (α = 0.1) on orthosteric ligand receptor occupancy (pA) based on the simple 
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ternary complex model for allosteric interactions. In these examples, ligand affinity is either maximally 
diminished or enhanced by a factor of 10. (adopted and modified from the literature41-42) 
 
1.2. Muscarinic acetylcholine receptors 
1.2.1. Muscarinic receptors subtypes and signaling pathways 
 
Muscarinic acetylcholine receptors (mAChRs or MRs) belong to class A (rhodopsin-like) 
GPCRs. In humans, the family of mAChRs comprises five subtypes (M1-M5). The M1, M3 and 
M5 subtypes couple to the Gq/11 family of G proteins, resulting in phospholipase C activation, 
hydrolysis of PIP2 and an increase in intracellular Ca2+ (cf. Figure 5A). The M2 and M4 subtypes 
couple to the Gi/o family, resulting in the inhibition of adenylyl cyclase with a decrease in cAMP 
formation45, 51 (cf. Figure 5B).  
 
Figure 5. Schematic illustration of the signaling pathway of muscarinic receptors. (adopted and modified 
from the literature29) 
 
MRs are widely distributed in the periphery and the central nervous system (CNS), and play 
important roles in many functions of the CNS. The M1 subtype is widely expressed in forebrain 
regions, including the cerebral cortex, hippocampus and striatum52-55. It was reported that 
reduced M1R signaling in the CNS is associated with cognitive deficits such as Alzheimer’s 
disease56-57. Selective agonists of the M1 mAChR have been pursued as a potential avenue 
for the treatment of dementia-related disorders58. The M2 mAChRs is located, e.g. in the 
brainstem, hypothalamus/thalamus, hippocampus, striatum, cortex52-53 and in the heart51. It is 
suggested that elevated acetylcholine levels through antagonism of presynaptic M2 muscarinic 
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autoreceptors may be beneficial in the treatment of psychosis and Alzheimer’s disease59-62. In 
this respect, M1/M2 selectivity is crucial as antagonism at post-synaptic M1 receptors is 
counterproductive, as confirmed by studies with the non-selective antagonists such as 
scopolamine, which lead to cognitive deﬁcits63. In the heart, M2 receptors may be directly 
linked through G proteins to ion channels devoid of a second messenger64-66. M3 mAChRs are 
expressed at low levels in the cortex, the striatum, the hippocampus and the 
hypothalamus/thalamus53, 67-68. M3 receptors are involved in regulating longitudinal growth by 
promoting the proliferation of pituitary somatotrophic cells, suggesting the M3R as a target to 
treat growth disorders69. Furthermore, M3 receptors participate in the regulation of smooth 
muscle motility. The M3 receptor antagonist solifenacin could be bladder-selective to provide 
new approaches to the pharmacotherapy of an overactive bladder70. M4 mAChRs are found 
in hippocampus, cortex, hypothalamus/thalamus and striatum65. Selective M4 antagonists 
could be used as a medication for parkinsonism by controlling the tremor associated with 
Parkinson’s disease71. The M5 mAChR, which is expressed at consistently low levels in the 
brain, is the least studied subtype among the five muscarinic receptors72. The M5 and the D2 
receptor were found to be co-localized within the pars compacta of the substantia nigra73, and 
activation of the M5R was reported to facilitate the release of dopamine.  
Physiologically, each muscarinic subtype is activated by the endogenous ligand acetylcholine 
(cf. Figure 6). Several naturally occurring ligands binding to muscarinic acetylcholine receptors 
were described, e.g. the agonist muscarine (where the receptors name comes from), and the 
antagonist atropine (cf. Figure 6). 
 
Figure 6. Structures of acetylcholine (endogenous MR agonist) and the naturally occurring ligands 
muscarine (MR agonist from the mushroom Amanita muscaria L.) and atropine (MR antagonist from 
Atropa belladonna L.). 
 
For many years, pharmaceutical chemists aimed to find ligands, which bind selectively to one 
subtype of the MR family. As the five subtypes exhibit a high conservation of the orthosteric 
binding site, there are only very few subtype selective orthosteric agonists and antagonists. 
Many ligands exhibit merely a (weak) preference for one subtype. For example, the antagonist 
pirenzepine74 shows a preference for the M1R, the antagonists methoctramine, AF DX 384, 
tripitramine and himbacine show preference for the M2R75-77, the antagonist darifenacin prefers 
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the M3R78, and the antagonist PD102807 prefers the M4R79. These ligands are used as 
pharmacological tools rather than for therapeutic purposes (cf. Figure 7). 
 
Figure 7. Chemical structures of muscarinic receptor ligands reported to exhibit preference for one 
muscarinic receptor subtype. 
 
1.2.2. Muscarinic receptor agonists 
 
According to a general trend, MR agonists are small molecules, whereas antagonists are large 
molecules, often containing an aromatic moiety51. Arecoline (cf. Figure 8), which is a naturally-
occurring MR agonist shows no subtype selectivity. Due to the ester group, being prone to 
hydrolysis, its clinical application was limited. To improve the pharmacological properties, for 
example, the ester group was replaced with more stable five-membered heterocyclic rings 
such as oxadiazole, thiadiazole or tetrazole. The 1,2,5-thiadiazole derivative xanomeline (cf. 
Figure 8), which was reported as a cognition enhancer, potentially useful for the treatment of 
schizophrenia, has higher potency and efficacy for M1 and M4 than for M2, M3 and M5 receptor 
subtypes80. Although xanomeline prefers M1R with positive effects on verbal learning and 
short-term memory function81, it causes side effects including nausea salivation and 
diaphoresis, presumably due to the activation of other mAChR subtypes82. Moreover, it was 
reported that xanomeline showed a unique mode of mAChR activation, being different from 
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that of conventional agonists such as carbachol83, and it was reported to bind to the M1R in a 
wash-resistant manner, which may be attributed not only to hydrophobic interactions between 
xanomeline’s O-hexyl chain and the receptor, but also to the binding to a secondary binding 
site of the receptor84-85. Replacement of the side-chain and the azacyclic ring of xanomeline 
led to the discovery of potent MR agonists. The phenylpropargylthio-1azabicyclo[3.2.1] octane 
endo analogue (cf. Figure 8) is the most selective M1/M2 compound in this series, which was 
suggested to be a drug candidate for AD86. Many MR ligands, such as tritiated 3-quinuclidinyl 
benzilate ([3H]QNB), a non-selective MR antagonist, which is routinely used for receptor 
binding studies, contain a quinuclidine ring. The same holds for some moderately potent MR 
agonists, for example, talsaclidine is a quinuclidinyl-propargyl ether (cf. Figure 8), which is a 
selective M1R agonist87 and has been reported for therapy of Alzheimer’s disease88. Another 
“quinuclidine-related” M1R agonist is SB20202689, which contains a cyanooximether group in 
the structure (cf. Figure 8). As a functionally selective M1R partial agonist, SB202026 was used 
in the investigation of the cholinergic hypothesis of senile dementia of the Alzheimer type 
(SDAT). To increase receptor subtype selectivity, several pharmacophores with increased 
rigidity were developed, for example, the conformationally restricted spiro compound RS-86 
(cf. Figure 8), which was a M2R preferable agonist, and some attempts also have been made 
to change the profile towards M1R selectivity based on this structure90. Oxotremorine (cf. 
Figure 8) has long been known as a partial M1R agonist91. By means of classical isosteric 
replacement of a methylene group with oxygen and exchange the pyrrolidine moiety of 
oxotremorine by a trimethylammonium group yielded a trimethylammonium salt related to 
oxotremorine (cf. Figure 8), which displayed binding affinity comparable to that of oxotremorine, 
but showed a pronounced selectivity for M2R versus M1R92. 
 
Figure 8. Chemical structures of selected muscarinic receptor agonists. 
 
1.2.3. Allosteric modulation of muscarinic receptors 
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The lack of highly selective mAChR orthosteric ligands demands alternative approaches to 
develop subtype selective MR ligands. All five muscarinic receptor subtypes possess at least 
one extracellular allosteric binding sites for small molecules93-94. The M2 subtype was the first 
GPCR found to be sensitive to allosteric modulation95-96, so that the M2R is one of the most 
extensively characterized allosteric model systems45. The best studied allosteric modulators 
of the mAChRs are represented by neuromuscular-blocking agents, for example, gallamine, 
alcuronium, W84 and its heptamethylene congener C7/3-phth, and most of these prototypical 
common-site modulators have higher affinity to the M2R than to the other subtypes (cf. Figure 
10). The allosteric behavior of gallamine can be demonstrated by equilibrium binding assays: 
Figure 9A and 9B show the effect of the modulator gallamine on the saturation binding of 
[3H]NMS at the M2R expressed by CHO cells. Although gallamine is able to shift [3H]NMS 
binding curves to the right, the allosteric nature of the interaction is revealed as progressively 
higher concentrations of gallamine fail to cause significant dextral displacements of the 
[3H]NMS saturation curves, becoming obvious from curvilinear Schild regressions41. Also the 
inhibitory effect of gallamine on equilibrium binding of [3H]NMS could unmask the limited ability 
of this negative allosteric modulator to inhibit specific [3H]NMS binding. From Figure 9C, it can 
be seen that when a low concentration of [3H]NMS (0.1 nM) was applied, the increasing 
concentrations of gallamine resulted in an apparently complete inhibition of specific [3H]NMS 
binding. However, applying a higher concentration of [3H]NMS (2.0 nM), caused an incomplete 
[3H]NMS binding by gallamine41. Alcuronium was found allosterically increases [3H]NMS 
binding at M2 and M4 subtypes; in contrast, it inhibits [3H]NMS binding at M1, M3 and M5 
subtypes97. The alkaloid structure of alcuronium lead to the identification of related compounds 
such as strychnine, vincamine, eburnamonine, and brucine and its analogs as allosteric 
mAChR modulators98-99. 
 
Figure 9. (A) [3H]NMS saturation binding curves obtained in the presence of the following 
concentrations of gallamine: 0 (●), 1 μM (○), 3 μM (□), 10 μM (◇) and 100 μM (△). (B) Effect of 
gallamine on the ratio of [3H]NMS Kd values (“affinity-shift”) determined in the presence or absence of 
the modulator. (C) Inhibition of [3H]NMS binding 0.1 nM (○ ) and 2.0 nM (● ) by increasing 
concentrations of gallamine. Data were taken from the literature41. 
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Figure 10. Structures of prototypical “common allosteric” site mAChR modulators. 
 
In addition to the well-studied common mAChR allosteric site, Lazareno, Birdsall and 
colleagues defined a second allosteric site94, 100. For example, depending on the mAChR 
subtype, several indolocarbazole derivatives of staurosporine (cf. Figure 11) were found to 
show positive, negative and neutral cooperativity with Ach, but did not appear to interact with 
the prototypical modulators gallamine and brucine94. Similarly, WIN 51,708 (cf. Figure 11) 
interacts with staurosporine in a competitive manner, whilst interacting with gallamine and 
strychnine in a noncompetitive way100.  
 
Figure 11. Examples of “second-site” mAChR modulators. 
 
Given that allosteric modulators can induces a unique conformational change of the receptor, 
it is not surprising that they have the ability to affect orthosteric ligand efficacy. McN-A-343 (cf. 
Figure 12) was the mAChR agonist known to display functional selectivity101, it was actually 
found to interact allosterically with [3H]NMS on M2 mAChRs102. Other agents were recently 
identified as potential mAChR allosteric agonists, such as AC-42 and its close structural 
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analog 77-LH-28-1. Both AC-42 and 77-LH-28-1 (cf. Figure 12) display high selectivity to 
activate the M1 mAChR over other mAChR subtypes103. TBPB (cf. Figure 12) was reported as 
a novel highly selective agonist for the M1 receptor with no agonist activity at any other mAChR 
subtypes, mutagenesis and molecular pharmacology studies revealed that TBPB activates 
M1R through an allosteric site rather than the orthosteric ACh binding site104. A highly selective 
and efficacious allosteric potentiator for M1R is BQCA (benzyl quinolone carboxylic acid) (cf. 
Figure 12)105. N-desmethylclozapine (cf. Figure 12), the major metabolite of the antipsychotic 
clozapine, which is a functionally-selective M1 mAChR agonist that has been suggested to act 
allosterically106. 
 
Figure 12. Examples of allosteric mAChR agonists (McN-A-343, AC 42, N-desmethylclozapine, TBPB 
and 77-LH-28-1) and allosteric potentiators (BQCA). 
 
1.2.4. Crystal structures of muscarinic receptors 
 
Kobilka et. al reported the crystal structures of the M2R (with bound antagonist QNB) and M3R 
(with bound inverse agonist tiotropium) in 2012107-108. The overall structure of the M3R is similar 
to that of the M2R, structural conservation includes intracellular loops (ICLs) 1 and 2, and 
extracellular loops (ECLs) 1-3, which share highly similar despite low sequence conservation. 
The binding poses of QNB (M2R) and tiotropium (M3R) were very similar, suggesting this pose 
to be a conserved binding mode: the ligands are deeply buried within the TM receptor core 
and covered by a ‘lid’ consisting of three conserved tyrosines, which separate the orthosteric 
site from the extracellular vestibule107-108. The structures of the inactive M2 and M3 receptor 
suggested that these receptors possess a large extracellular vestibule, which was shown to 
be addressed by allosteric modulators. In this region of the receptor, the structural diversity is 
much higher than in the region of the orthosteric binding site. When an allosteric ligand binds 
to this site, an influence on the association and disassociation rates of orthosteric ligands are 
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expected. Recently, the M1 and the M4 receptor were crystallized in the inactive state bound 
with the inverse agonist tiotropium bound. The structures of the M1 and M4 receptors are 
similar to the previously solved inactive states of M2 and M3 receptors, with similar positioning 
of the seven-transmembrane (TM1-7) bundle and root mean squared deviations of 0.6-0.9 
Å107-108. By comparing structures of the M1 and the M4 receptor, subtle differences between 
the receptors are observed on the extracellular and intracellular sides corresponding to 
regions that are least conserved across the MR subtypes109. Further comparison of the 
orthosteric sites of M1R and M4R revealed the M4R is closer related to the M1 than to the M2 
subtype. Another breakthrough was the solution of the active-state structure of the M2R in the 
presence of the high affinity agonist iperoxo and the positive allosteric modulator LY2119620110. 
This structure revealed that LY2119620 binds to the vestibule just above the orthosteric 
agonist iperoxo. Moreover, it suggested that the allosteric modulator induces structural 
changes such as the inward motion of TM6, which directly contacts the allosteric modulator, 
the orthosteric agonist, and probably, the G protein as well110. The MR crystal structures offer 
important insights into the activation mechanism and allosteric modulation of MRs, and are 
supposed to contribute to the development of highly selective MR ligands. 
 
Figure 13. Muscarinic M3 receptor (PDB code 4U14108) bound with tiotropium at the orthosteric pocket. 
The orthosteric and allosteric sites are indicated in yellow and blue elliptical shaded areas, respectively. 
Image was generated by UCSF Chimera111. (adopted and modified from the literature108) 
 
1.3. Bivalent ligands 
 
Much of the pioneering work describing bivalent ligands for GPCRs was led by the group of 
Portoghese112-115, targeting opioid receptor subtypes. Bivalent ligands are defined as 
compounds containing two pharmacophores, which are covalently tethered by a linker. 
Bivalent ligands are divided into two general classes: homobivalent ligands, containing two 
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identical pharmacophores, and heterobivalent ligands, wherein the two pharmacophores are 
different113, 116-117. A number of homo- and heterobivalent GPCR ligands have been developed 
in recent years, such as histamine receptor118-119, dopamine receptor120-123, muscarinic 
receptor124-125, adenosine receptor126-127 and serotonin receptor128-129 ligands. There are 
several hypotheses to explain the enhanced activity and selectivity observed for some bivalent 
GPCR ligands. The first possibility is through a univalently bound state, the unbound 
recognition unit being in the locus of neighboring binding sites, in another word, the bivalent 
ligand increased local concentration of free pharmacophore, which increases the probability 
of a productive binding event (cf. Figure 14A). Secondly, the bivalent ligand interacts 
simultaneously with two orthosteric binding sites of a dimeric or oligomeric complex of GPCRs, 
leading to increased affinity and selectivity (cf. Figure 14B), and thirdly, the bivalent ligand 
occupies the orthosteric binding site and a second (low affinity) allosteric binding site at one 
and the same receptor protomer (cf. Figure 14C). 
 
Figure 14. Possible binding modes of bivalent ligands. (A) Increased local concentration of free 
pharmacophore. (B) Induction of GPCR dimerization. (C) Simultaneous binding to an orthosteric and 
allosteric binding site of the same receptor molecule (bitopic or dualsteric binding mode). (adopted and 
modified from the literature130) 
 
A new concept in drug design derived from bivalent ligand was focusing on bitopic or dualsteric 
ligands, these ligands can address both the orthosteric and the allosteric site of a receptor 
protein131-132. The reasons to pursue a bitopic ligand approach are various. The most important 
reason is that a bitopic ligand can theoretically achieve improvements in affinity and selectivity. 
Another advantage is that the use of pure allosteric modulators relies on the presence of 
endogenous agonist tone to mediate their effects, whereas the use of a bitopic ligands would 
engage the orthosteric site irrespective of the presence or absence of endogenous tone133. 
Examples of rationally designed bitopic MR ligands are oxotremorine-related hybrid 
molecules134. These hybrid ligands target the mAChRs, constructed with the agonist 
oxotremorine (an orthosteric pharmacophore) and hexamethonium derived allosteric 
modulators (the structure of one of these hybrid ligands will be shown in Chapter 3). Though 
these hybrid ligands didn’t show improved affinity, they gained subtype selectivity as compared 
with the parent orthosteric agonist (oxoremorine). Mohr and colleagues linked a non-selective, 
orthosteric agonist iperoxo, with a M2-selective bis(ammonio)alkane-type allosteric fragment 
to form hybrid 2 (cf. Figure 15). This approach engendered receptor subtype selective 
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activation compared with the parent agonist135. A bitopic ligand was developed for the 
adenosine A1 receptor (A1R) by linking a positive allosteric modulator and an orthosteric 
pharmacophore through a spacer of 9 carbon atoms. The resulting bivalent ligand LUF6258 
(cf. Figure 15) did not show significant changes in affinity or potency in the presence of an 
allosteric enhancer (PD81,723), taken a hint that the bivalent ligand bridges both sites on the 
receptor136. Recently, Christopoulos and colleagues linked the endogenous orthosteric agonist 
adenosine with a PAM of the A1 adenosine receptor VCP171, leaded the rational design of a 
bitopic A1 adenosine receptor ligand VCP746137, which displays biased agonism relative to 
prototypical A1AR ligands (cf. Figure 15). More examples of bitopic ligands such as THRX-
160209 will be shown in Chapter 3.  
 
Figure 15. Examples of bitopic GPCR ligands. The non-selective, orthosteric, agonist iperoxo and a M2 
selective bis(ammonio)alkane-type allosteric fragment were linked to form hybrid 2; Bitopic ligands 
LUF6258 and VCP746 target the adenosine A1 receptor. 
 
1.4. Radioligands for muscarinic receptor 
 
Several radioligands were developed as pharmacological tools for studying the receptor 
binding of MR ligands. For instance, the orthosteric antagonists [3H]QNB138, [3H]N-methyl 
scopolamine91, 139, [3H]pirenzepine140 and [3H]tiotropium141, the orthosteric agonists 
[3H]acetylcholine142 and [3H]oxotremorine-M143 have been used as radioligands. Moreover, 
[3H]NMS has been frequently used to identify allosteric interactions of agents144-145, and to 
check the common allosteric site hypothesis for the allosteric modulators alcuronium, W84, 
and gallamine146. One important approach was the development of [3H]dimethyl-W84, the first 
radiolabeled allosteric modulator of the M2 mAChR147. Table 1 shows the pKd values of the 
muscarinic receptor radioligands mentioned above. 
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Table 1. Reported pKd values of radioligands binding to muscarinic mAChRs.  
 
Radioligands 
pKd 
M1R 
pKd 
M2R 
pKd 
M3R 
pKd 
M4R 
pKd 
M5R 
[3H]QNBa 10.6 - 10.8 10.1 - 10.6 10.4 9.7 - 10.5   10.2 - 10.7 
[3H]NMSa 9.4 - 10.3 9.3 - 9.9   9.7 - 10.2   9.9 - 10.2 9.3 - 9.7 
[3H]pirenzepinea 7.9 - - - - 
[3H]tiotropiuma - 10.3 10.7   - - 
[3H]oxotremorine-Ma - 8.7   - - - 
[3H]acetylcholinea - 8.8   - 8.2   - 
[3H]dimethyl-W84a  8.5    
apKd values reported in the literature (data taken from the IUPHAR/BPS database 
(guidetopharmacology.org) in Nov. 2016). 
 
1.5. Fluorescently labeled GPCR ligands 
 
The major disadvantages of radiolabeled ligands are that they are potentially hazardous to 
human health, high costs of production and waste disposal and the requirement of special 
laboratory conditions. Besides label-free ligand binding assays such as affinity selection mass 
spectrometry (AS-MS)148 and nuclear magnetic resonance spectroscopy (NMR)-based 
binding assays149, fluorescent ligand-based receptor binding assays were developed for 
several peptide and non-peptide GPCRs as an alternative to radioligand binding assays.  
Like radioligands, fluorescent ligands can be used to determine the affinity of unlabeled 
receptor ligands150. Moreover, fluorescent ligands have been used for the screening of small 
molecules (fragments) in terms of GPCR binding. For instance, one fluorescent ligand was 
used in a fluorescence resonance energy transfer (FRET)-based assay to identify the first 
small molecule agonist for the apelin receptor, which may lead to new molecules being 
developed for the treatment of heart failure151. New non-peptide small molecule ligands for the 
formylpeptide receptor were identified from a library of 880 compounds by using a fluorescein 
labelled formylmethionine-leucine-phenylalanine-lysine based on high-throughput flow 
cytometry (HTFC)152. In addition, fluorescent ligands can be used to study receptor expression 
patterns, GPCR localization and internalization as demonstrated for the μ and δ opioid 
receptor153 and AT1 angiotensin receptor154, as well as ligand-receptor binding kinetics in living 
cells as demonstrated for the adenosine-A1 and -A3 receptor155-156. Fluorescent ligands can 
also be used to investigate the dynamics of GPCR oligomerization in living cells157-158. 
Several fluorescent ligands were also developed as useful pharmacological tools for studying 
muscarinic receptors. For example, Cu(I)-catalyzed 1,3-dipolar cycloaddition, referred to as 
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“click” chemistry, was used to incorporate of a fluorophore (Lissamine Rhodamine B) into a 
MR antagonist scaffold derived from pirenzepine159. The high afﬁnity and very slow off-rates 
of the telenzepine analogs Cy3B-telenzepine (Kd = 35 pM, M1R) and Alexa488-telenz (Kd = 
0.5 nM, M1R) were applied to investigate the dynamics of M1 receptor dimerization in living 
cells158. BODIPY-pirenzepine was used to study pirenzepine-induced formation of muscarinic 
M1R dimers160. A fluorescent tolterodine-BODIPY (boron dipyrromethene) conjugate was 
described to exhibit affinity for M1, M2 and M4 receptors in the nanomolar range, harboring the 
potential to be used for high throughput screening. However, a slow degradation of this 
compound was observed even when stored in the dark (t1/2 = 10 weeks)161. Ilien and co-
workers prepared pirenzepine derivatives linked to the boron-dipyrromethene [Bodipy 
(558/568)] fluorophore via spacers of varying lengths162-163 and coupled the lissamine 
rhodamine B fluorophore (in para position) to AC42 to study bitopic fluorescent ligands164.  
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2. Scope and objectives 
 
Muscarinic acetylcholine receptors (MRs) were identified as targets for the treatment of 
disorders such as Alzheimer’s and Parkinson’s disease. The family of MRs comprises five 
subtypes and due to the high conservation of the orthosteric binding pocket, highly subtype 
selective ligands are lacking. As the MRs’ ‘vestibule’ or ‘common’ allosteric site is less 
conserved, the dualsteric ligand approach was considered a promising strategy to develop 
ligands with high subtype selectivity. The design of subtype selective MR ligands is supposed 
to benefit from the structural information provided by the recently reported crystal structures 
of the M1R-M4R1-4.  
The recent study on a series of dibenzodiazepinone-type MR ligands revealed that the 
replacement of the terminal basic diethylamino moiety of the M2R preferring antagonist DIBA 
(cf. Figure 1A) by various bulky groups afforded derivatives with high M2R affinity5. Based on 
these results, this doctoral thesis aimed at the synthesis and characterization of DIBA-derived 
heterodimeric MR ligands by conjugation of the DIBA pharmacophore to different reported 
orthosteric and allosteric MR ligands (the agonist xanomeline, the antagonists 4-DAMP and 
propantheline, and the allosteric modulators TBPB and 77-LH-28-1) using different linker types 
(cf. Figure 1B). In addition, monomeric and homodimeric ligands had to be prepared as 
reference compounds. 
The heterodimeric ligands had to be investigated with respect to M1R-M5R affinity using the 
orthosteric radioligand [3H]NMS to obtain the MR selectivity profiles. Furthermore, the 
preparation and characterization of radio- and fluorescence labeled compounds had been 
envisaged. For this purpose, amino-functionalized branched linker elements (cf. Figure 1B) 
had to be incorporated into the dimeric ligands.  
M2R saturation binding studies (including experiments in the presence of allosteric MR 
modulators) as well as competition binding experiments with various kinds of MR ligands 
(orthosteric, dualsteric, allosteric) had to be performed aiming at an elucidation of the binding 
mode of the heterodimeric ligands at the M2R.   
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Figure 1. (A) Structure of DIBA and proposed site of attachment (blue arrow) for the conjugation to 
various MR ligands. (B) Moieties to be implemented in the linkers of dimeric MR ligands. 
 
The characterization of selected fluorescently labeled ligands had to be substantiated by flow 
cytometry, high content analysis and fluorescence microscopy. From such investigations it 
was expected to get information on the binding mode at the M2R and the suitability of the 
fluorescent ligands with respect to the characterization of unlabeled MR ligands as well as 
cellular imaging.  
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3. Synthesis and pharmacological characterization 
of dibenzodiazepinone-type heterodimeric 
muscarinic receptor ligands 
3.1. Introduction 
 
GPCRs constitute a large superfamily of cell surface receptors, which are classified into more 
than 100 subfamilies1. GPCRs are the most frequently addressed drug targets. Around 30 % 
of all marketed prescription drugs act on GPCRs2-3. Muscarinic acetylcholine receptors 
(mAChRs or MRs) belong to the class A GPCRs and comprise five receptor subtypes in 
humans, designated M1R to M5R. M1R, M3R, M5R receptors couple to G proteins of the Gq 
class, M2R, M4R receptors interact with G proteins of the Gi family4. MRs have been identified 
as targets for the treatment of various diseases such as Alzheimer’s disease and Parkinson’s 
disease, but due to the high conservation within the orthosteric binding site across all five 
mAChR subtypes, the development of subtype selective orthosteric ligands is challenging5. 
Besides the ACh binding pocket (the “orthosteric site”), muscarinic receptors contain additional 
“allosteric binding sites”6-8, which are less conserved than the orthosteric region and can 
potentially be exploited to develop subtype selective ligands9-10. The M2 subtype was the first 
GPCR to be found as being sensitive to allosteric modulation11 and numerous allosteric MR 
modulators were identified, such as compounds 1412, 1513 and 1614-15 (cf. Figure 1B). 
Homo- and heterobivalent ligands have been emerged at GPCRs field in recent years, like 
histamine16-17, dopamine18-19, and adenosine20-21 and NPY22-23 receptors. Benefits of bivalent 
ligands can include increased ligand affinity and improved selectivity24-25. As a variation of 
bivalent ligands, the concept of dualsteric11, 26-28 (bitopic orthosteric/allosteric) ligands of 
GPCRs led to novel chemical tools. The first examples of rationally designed bitopic ligands 
targeting mAChRs were derived from the orthosteric agonist oxotremorine (3) and 
hexamethonium-like allosteric modulators. This series of hybrid molecules showed a gain in 
subtype selectivity compared to 3 (e.g. compound 17, cf. Figure 1C)29. Another example of a 
designed bitopic MR ligand is THRX-160209 (compound 18, cf. Figure 1C), which is reported 
to exhibit higher affinity and subtype selectivity than the corresponding monovalent ligands 
and was suggested to bind in a multivalent manner to the M2 receptor30.  
AF-DX 38431 (8) (cf. Figure 1A) was developed from the M1 preferring M receptor antagonist 
pirenzepine32 as M2R preferring pyridobenzodiazepinone-type M receptor antagonist. 
Likewise, the dibenzodiazepinone-type M receptor antagonist DIBA (9) showed high affinity 
for the M2 receptor (Ki value: 0.3 nM)33. Moreover, Tränkle et. al suggested a dualsteric binding 
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mode of 8 at the M2 receptor34. A hybrid MR ligand formed of 8 and the allosteric modulator 
W84 (15) was reported to exhibit a pronounced positive cooperativity with NMS, pointing a 
new way for the development of allosteric enhancers35-36.  
 
Figure 1. (A) Chemical structures of reported MR agonists (1-3) and antagonists (4-11). (B) Chemical 
structures of the allosteric MR ligands 12-16. (C) Structures of the hybrid ligands 17 and 18, which were 
suggested to bind dualsterically at the M2R29-30.  
 
This study was directed towards the design, synthesis, and pharmacological evaluation of 
DIBA-derived heterodimeric MR ligands comprising five combinations of DIBA with reported 
orthosteric or allosteric MR ligands: ‘DIBA-xanomeline’, ‘DIBA-TBPB’, ‘DIBA-77-LH-28-1’, 
‘DIBA-4-DAMP’ and ‘DIBA-propantheline’ (in total nineteen heterodimeric ligands). 
Xanomeline (cf. Figure 1A) is a M1 selective MR agonist (see general introduction). TBPB (cf. 
Figure 1B) was reported to selectively activate M1 receptors through an allosteric mechanism 
as shown by mutagenesis and molecular pharmacology studies37-39. And TBPB was proposed 
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as a bitopic ligand, interacting with both the orthosteric site and an allosteric site at the M1R40. 
Similarly, the competitive mechanism or with a strong negative cooperativity between [3H]NMS 
and 77-LH-28-1 (cf. Figure 1B) was reported at M1R, and 77-LH-28-1 was also suggested to 
bind allosterically to [3H]NMS-occupied M1 receptor, and competed with the prototypical 
allosteric modulator (C7/3-phth)41. 4-DAMP and propantheline (cf. Figure 1A) are non-selective 
orthosteric MR antagonists with high affinities (Ki (4-DAMP, M1R-M5R): 0.52-3.80 nM, Ki 
(propantheline, M1R-M4R): 0.057-0.33 nM)31, 42.  
In addition to the heterodimeric ligands, four homodimeric ligands derived from xanomeline, 
two homodimeric ligand derived from DIBA, a monomeric DIBA derivative, a monomeric 
xanomeline derivative and a monomeric TBPB derivative were prepared as reference 
compounds. Furthermore, two radiolabeled heterodimeric ligands (‘DIBA-TBPB’ type and 
‘DIBA-xanomeline’ type) were prepared as molecular tools and characterized by saturation 
binding (including experiments in the presence of allosteric modulators “Schild-like analysis”), 
kinetic investigations and equilibrium competition binding studies. 
 
3.2. Results and discussion 
3.2.1. Chemistry  
3.2.1.1. Synthesis of the diazepane derivative 28 
 
Treatment of diethyl oxalate (19) with one equivalent of benzylamine (20) afforded the N-
substituted ethyl oxamate 21. The subsequent reaction with methylamine converted 
compound 21 to the unsymmetrical N,N’-disubstituted oxamide 22. Reduction of 22, using 
lithium aluminum hydride, resulted in compound 23 as reported43. Homopiperazine 25 was 
obtained from 23 by nitro-Mannich reaction using nitroethanol and paraformaldehyde. 
Compound 25 was treated with an excess of tert-C4H9OK in methanol resulted compound 
2644-46. Reduction of the nitro group in 26 to an amino group using Raney nickel, and 
subsequent Boc-protection gave compound 27. Debenzylation of 27 applying palladium-
catalyzed hydrogenolysis yielded compound 28 (cf. Scheme 1). 
 
Scheme 1. Synthesis of the diazepane derivative 28. Reagents and conditions: (a) CHCl3, reflux, 
overnight, 65%; (b) CH3NH2 (2M in THF), EtOH, rt, 8 h, 97%; (c) LiAlH4, abs. THF, 0 oC/reflux, overnight, 
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60%; (d) paraformaldehyde, toluene/EtOH 1:1 (v/v), reflux, 6 h, 88%; (e) potassium tert-butoxide, MeOH, 
40 oC, 30 min, 67%; (f) H2, Ni-Raney, EtOH, rt, overnight, 98%; (g) di-tert-butyl dicarbonate, CHCl3, rt, 
overnight, 54%; (h) 10% Pd/C, H2, THF/H2O 1:4 (V/V), rt, overnight, 77%. 
 
3.2.1.2. Synthesis of the piperazine derivative 32 
 
The synthesis of piperazine derivative 32 started with commercially available 2-bromoethan-
1-amine hydrobromide (29), which was Boc-protected to obtain compound 30. This 
intermediate was treated with an excess of piperazine (31) to afford building block 32 (cf. 
Scheme 2).  
 
Scheme 2. Synthesis of the piperazine derivative 32. Reagents and conditions: (a) di-tert-butyl 
dicarbonate, triethylamine, CH2Cl2, rt, overnight, 80%; (b) K2CO3, MeCN, reflux, 3 h, 91%. 
 
3.2.1.3. Synthesis of xanomeline derivatives 40, 41, 46 and 52-55 
 
Hydroxy- or amino-functionalized xanomeline derivatives (38 and 50) were required as key 
intermediates for the synthesis of heterodimeric ligands (cf. Scheme 3). The intermediate 34 
was synthesized from 3-pyridinecarbaldehyde (33) according a slightly modified Strecker 
synthesis from the literature47-48. Initially, 33 was treated with potassium cyanide yielding the 
cyanohydrin, after isolation, the cyanohydrin was immediately reacted with ammonium 
chloride under basic aqueous conditions to give 34. The intermediate 34 was cyclized with 
sulfur monochloride in DMF to give 3-(3-chloro-1,2,5-thiadiazol-4-yl)pyridine (35). Propane-
1,3-diol (36) or pentane-1,5-diol (42) were treated with sodium hydride and 35 to give the 
hydroxylated derivatives 37 and 43. This procedure is different from the described nucleophilic 
displacement of the chlorine of 35, where one of the hydroxyl groups was protected with tert-
butylchlorodiphenylsilane (TBDPSCl)49. 37 and 43 were quaternized with excess methyl iodide 
in acetone and then reduced to the tetrahydropyridine product 38 or 44 with the help of sodium 
borohydride in methanol (cf. Scheme 3). In order to convert the primary hydroxy groups of 38 
and 44 to bromide, an Apple reaction was applied using tetrabromomethane and 
triphenylphosphine in dichloromethane to yield compounds 3950 and 45. Alkylation of 
piperazine using the bromides 39 or 45 gave the intermediate 40 and the homodimeric ligand 
46. When compound 28 alkylated with compound 39, followed by removal of the Boc group, 
afforded the monomeric ligand 41, which was prepared for comparative purposes in 
pharmacological assays. 
The synthesis of amino-functionalized derivatives of xanomeline is shown in Scheme 3, 
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deprotonation of tert-butyl (5-hydroxypentyl)carbamate (47) with excess of sodium hydride in 
anhydrous tetrahydrofuran followed by refluxing in the presence of intermediate 35 afforded 
compound 48. Reduction and methylation of 48 led to the 1,2,5,6-tetrahydropyridine derivative 
49. Cleavage of the Boc group using trifluoroacetic acid (TFA) in dichloromethane afforded 
compound 50, which was coupled with compound 51 by using coupling reagents TBTU and 
HOBt in the presence of DIPEA to obtain intermediate 52 after subsequent removal of the Boc 
group. Furthermore, compound 50 was treated with octanedioyl dichloride or decanedioyl 
dichloride in the presence of triethylamine to yield the homodimeric compounds 53 or 54. 
Amidation of terephthalic acid with amine 50 using coupling reagents EDC and HOBt afforded 
the homodimeric ligand 55, containing a rigid central linker moiety (cf. Scheme 3). 
 
Scheme 3. Synthesis of the xanomeline derivatives 39, 40, 41, 46 and 52-55. Reagents and conditions: 
(a) KCN, H2O, AcOH, 5 oC/rt, 2 h, 98%; (b) NH4Cl, 25% aq NH3, rt, 20 h, 67%; (c) S2Cl2, DMF, 5-10 oC, 
45 min, 69%; (d) NaH, abs. THF, reflux, 2-8 h, 52% for 37, 48% for 43, 27% for 48; (e) (1) methyl iodide, 
acetone, rt, 24-36 h; (2) NaBH4, MeOH, 0 oC/rt, overnight, 41% for 38, 92% for 44, 79% for 49; (f) CBr4, 
PPh3, CH2Cl2, -5 oC/rt, 24 h, 50% for 39, 82% for 45; (g) K2CO3, MeCN, microwave, 110 oC (30 min) or 
reflux (2 h), 66% for 40, 22% for 46; (h) (1) 28, K2CO3, MeCN, microwave, 110 oC (30 min); (2) 
TFA/CH2Cl2 1:4 v/v, rt, 8 h, 66%; (i) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 56%; (j) (1) 51, TBTU, HOBt, DIPEA, 
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DMF, rt/60 oC, 3 h; (2) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 89%; (k) octanedioyl dichloride or decanedioyl 
dichloride, triethylamine, abs. THF, 0 oC/rt, overnight, 39% for 53, 65% for 54; (l) terephthalic acid, EDC, 
HOBt, DMF, rt, overnight, 26%. 
 
3.2.1.4. Synthesis of TBPB derivatives 63, 64, 66, 67 
 
The synthesis of TBPB derivatives is outlined in Scheme 4. Beginning with commercially 
available 1-fluoro-2-nitrobenzene (56), an aromatic nucleophilic substitution with ethyl 4-
aminopiperidine-1-carboxylate (57) under microwave irradiation yielded nitroaniline 58, which 
was reduced by palladium-catalyzed hydrogenation to provide o-phenylendiamine derivative 
59. The benzimidazolone formation from 59 using triphosgene afforded 60 (cf. Scheme 4). 
Subsequent removal of the ethyl carbamate group by alkaline hydrolysis gave 6151. Reductive 
amination of the N-Boc protected piperidinone (62) with the secondary amine 61, using sodium 
cyanoborohydride, followed by removal of the Boc group afforded compound 63. Alkylation of 
63 with tert-butyl (2-bromoethyl)carbamate (30) and Boc-deprotection yielded 64 as a building 
block for the synthesis of heterodimeric ligands. Acylation of 63 with 2-bromoacetyl bromide 
(65) afforded amide 66 (cf. Scheme 4). Finally, N-alkylation of the homopiperazine derivative 
28 with bromide 66 followed by removal of Boc group afforded the TBPB derivative 67. 
 
Scheme 4. Synthesis of the TBPB derivatives 63, 64, 66, 67. Reagents and conditions: (a) K2CO3, NaI, 
DMF, microwave, 180 oC, 10 min, 72%; (b) 10% Pd/C, H2, rt, overnight, 89%; (c) triphosgene, NaHCO3, 
CH2Cl2, 0 oC/rt, 2 h, 73%; (d) 10% aq NaOH, reflux, 5 h, 81%; (e) (1) 62, NaBH3CN, acetic acid, MeOH, 
0 oC/rt, overnight; (2) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 75%; (f) (1) 30, K2CO3, MeCN, reflux, 8 h; (2) 
TFA/CH2Cl2 1:4 v/v, rt, 8 h, 86%; (g) 2-bromoacetyl bromide, pyridine, CHCl3, 0 oC/rt, overnight, 91%; 
(h) (1) 28, K2CO3, MeCN, microwave, 110 oC, 30 min; (2) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 43%. 
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3.2.1.5. Synthesis of 4-DAMP derivatives 71 and 73 
 
The synthesis of the building blocks 71 and 73, required for the preparation of ‘DIBA-4-DAMP’-
type heterodimeric ligands, started from diphenylacetic acid (68) and Boc protected piperidin-
4-ol (69) (cf. Scheme 5). Unlike a reported procedure, which transformed the carboxylic acid 
68 into the corresponding acid chloride prior to esterification with alcohol 6952, the ester 70 
was formed from 68 and 69 using N,N’-dicyclohexylcarbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP) as coupling reagents. Treatment of 70 with TFA gave 71 as 
the bisdesmethyl analogue of 4-DAMP. Alkylation of 71 with bromide 30 afforded compound 
72, which was converted to 73 by removal of the Boc group (cf. Scheme 5). 
 
Scheme 5. Synthesis of the 4-DAMP derivatives 71 and 73. Reagents and conditions: (a) DCC, DMAP, 
CH2Cl2, 0 oC/rt, overnight, 97%; (b) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 56% for 42, 83% for 44; (c) K2CO3, 
MeCN, reflux, 3 h, 67%.  
 
3.2.1.6. Synthesis of propantheline derivatives 77, 78 and 80 
 
Scheme 6 depicts the synthesis of the propantheline building blocks 77, 78 and 80, which 
were used for the synthesis of the ‘DIBA-propantheline’-type heterodimeric ligands. Xanthene-
9-carboxylic acid (74) was condensed with 2-bromoethan-1-ol or 4-bromobutan-1-ol to yield 
compound 75 and 76, respectively. Treatment of 75 and 76 with an excess of piperazine 
afforded the alkylation products 77 and 78 in moderate yield (cf. Scheme 6). Alkylation of 77 
with bromide 30 gave compound 79, which was converted to the propantheline-derived 
compound 80 by Boc-deprotection using TFA. 
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Scheme 6. Synthesis of the propantheline derivatives 77, 78 and 80. Reagents and conditions: (a) 2-
bromoethan-1-ol or 4-bromobutan-1-ol, DCC, DMAP, CH2Cl2, 0 oC/rt, overnight, 68% for 75, 56% for 
76; (b) K2CO3, MeCN, reflux, 1.5 h or overnight, 59% for 77, 46% for 78; (c) K2CO3, MeCN, reflux, 2 h, 
57%; (d) TFA/CH2Cl2 1:4 v/v, rt, overnight, 88%. 
 
3.2.1.7. Synthesis of 77-LH-28-1 derivatives 86 and 88 
 
The synthesis of the 77-LH-28-1-derived intermediates 86 and 88 is shown in Scheme 7. 
Treatment of commercially available 3,4-dihydro-2(1H)-quinolinone (81) with 1-chloro-3-
iodopropane (82) in the presence of caesium carbonate in acetonitrile afforded compound 83 
as described in the literature53. Alkylation of piperidine 84 with chloride 83 in the presence of 
potassium carbonate and sodium iodide yielded compound 85. The alcohol 85 was converted 
to the corresponding bromide (86) under Apple reaction condition using tetrabromomethane 
and triphenylphosphine (cf. Scheme 7). Compound 86 was treated with piperazine 32 to afford 
the alkylation product 87, which was Boc-deprotected to yield the 77-LH-28-1 derivative 88. 
 
Scheme 7. Synthesis of the 77-LH-28-1 derivatives 86 and 88. Reagents and conditions: (a) Cs2CO3, 
MeCN, 50 oC, 12 h, 69%; (b) K2CO3, NaI, MeCN, 50 oC, 24 h, 53%; (c) CBr4, PPh3, CH2Cl2, -5 oC/rt, 
overnight, 31%; (d) K2CO3, MeCN, reflux, 2 h, 62%; (e) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 97%. 
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3.2.1.8. Synthesis of DIBA derivatives 94, 95 and 96 
 
The preparation of the dibenzodiazepinone derivatives 94, 95, and 96 is illustrated in Scheme 
8. The dibenzodiazepinone moiety 91 was obtained by heating 2-chlorobenzoic acid (89) and 
o-phenylenediamine (90) in chlorobenzene in the presence of copper54-55. Compound 91 was 
treated with chloroacetyl chloride to give the acylated derivative 92 (cf. Scheme 8). 
Nucleophilic substitution of the chlorine in 92 by 4-(piperidin-4-yl)butan-1-ol (84) gave 
compound 93. The alcohol 93 was converted to the respective bromide (compound 94) by 
using the Apple reaction conditions described above. Alkylation of compound 28 using 
bromide 94 and subsequent Boc-deprotection yielded the monomeric DIBA derivative 95 (cf. 
Scheme 8). Aiming at dimeric ligands with extended linkers, compound 32 was alkylated using 
again bromide 94, followed by Boc-deprotection with TFA to obtain compound 96. 
 
Scheme 8. Synthesis of the DIBA derivatives 94, 95 and 96. Reagents and conditions: (a) copper 
powder, chlorobenzene, reflux, 6 h, 13%; (b) 2-chloroacetyl chloride, N,N-dimethylaniline, THF, 
overnight, 84%; (c) K2CO3, MeCN, reflux, 8 h, 62%; (d) CBr4, PPh3, CH2Cl2, -5oC/rt, overnight, 78%; (e) 
(1) 28, K2CO3, MeCN, reflux, 3 h; (2) TFA/CH2Cl2/H2O 10:10:1 v/v/v, rt, 2 h, 17%; (f) (1) 32, K2CO3, 
MeCN, reflux, 3 h; (2) TFA/CH2Cl2 1:4 v/v, rt, 8 h, 66%. 
 
3.2.1.9. Synthesis of dibenzodiazepinone-derived heterodimeric ligands 97-102, 
105a, 106-108, 110, 111 and 114-120 
 
The synthesis of the dibenzodiazepinone-derived heterodimeric ligands is outlined in Scheme 
9 (97-102, 105a, 106-108) and Scheme 10 (110, 111, 114-120). The heterodimeric ligands 
97-101 were prepared through alkylation of compounds 40, 63, 71, 77 and 78, respectively, 
using bromide 94. The heterodimeric ligand 102 was prepared by alkylation of compound 1055 
(cf. Figure 1A) with bromide 86 (cf. Scheme 9). Alkylation of the homopiperazine derivative 
103 applying a mixture of the bromides 39 and 94, followed by Boc-deprotection, yielded the 
heterodimeric ligand 105a, which was propionylated to give the congener 106. Likewise, 
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alkylation of 103 applying a mixture of the bromides 66 and 94, followed by Boc-deprotection, 
gave the heterodimeric ligand 107, which was propionylated yielding the congener 108. The 
DIBA type homodimeric ligand 105b was isolated during the preparation of compound 105a 
and 107, and the non-DIBA type homodimeric ligands formed by double alkylation of 103 with 
bromides 39 and 66 were not isolated (cf. Scheme 9).  
 
Scheme 9. Synthesis of the DIBA-derived heterodimeric ligands 97-102, 105-108. Reagents and 
conditions: (a) K2CO3, MeCN, microwave, 110 oC, 30 min or reflux, 3 h to overnight, 41% for 97, 57% 
for 98, 27% for 99, 51% for 100, 38% for 101; (b) NaI, K2CO3, MeCN, reflux, 3 h, 52% for 102; (c) 
TFA/CH2Cl2/H2O 10:10:1 v/v/v, rt, 2 h, 17% for 105a (two steps), 12% for 107 (two steps); (d) DIPEA, 
DMF, rt, 2 h, 95% for 106, 96% for 108. 
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Scheme 10. Synthesis of the dibenzodiazepinone-type homo- or heterodimeric ligands 110-120. 
Reagents and conditions: (a) (1) TBTU, HOBt, diisopropylethylamine, DMF, 3 h; (2) TFA/CH2Cl2/H2O 
10:10:1 v/v/v, rt, 2 h, 14% for 110, 10% for 114, 28% for 116, 15% for 118, 4% for 120; (b) DIPEA, DMF, 
rt, 2 h, 89% for 111, 79% for 113, 88% for 115, 83% for 117, for 86% 119. 
 
Amidation of the isophthalic acid derivative 109 applying a mixture of amines 96 and 52, 
followed by Boc-deprotection, afforded the heterodimeric ligand 110 and the homodimeric 
ligand 112. Propionylation of 110 and 112 gave the congeners 111 and 113, respectively (cf. 
Scheme 10). Likewise, the heterodimeric ligands 114, 116, 118 and 120 were obtained by 
amidation of 109 using the amine mixtures 96/64, 96/73, 96/80 and 96/88, respectively, and 
subsequent Boc-deprotection (cf. Scheme 10). Propionylation of 114, 116 and 118 at the 
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central linker moiety afforded the propionamide congeners 115, 117 and 119. It should be 
noted that the respective non-DIBA type homodimeric ligands generated by double amidation 
of 109 with amines 52, 64, 73, 80 and 88 were formed, but were not isolated (cf. Scheme 10).  
 
3.2.2. Equilibrium competition binding studies with [3H]NMS  
 
The receptor binding affinities of twenty eight new MR ligands, comprising the monomeric 
xanomeline derivative 41, TBPB derivative 67, DIBA derivative 95, the ‘DIBA-DIBA’ type 
homodimeric ligands 112 and 113, the ‘xanomeline-xanomeline’ type homodimeric ligands 46 
and 53-55, as well as the ‘DIBA-xanomeline’ type heterodimeric ligands 97, 105a, 106, 110 
and 111, the ‘DIBA-TBPB’ type heterodimeric ligands 98, 107, 108, 114 and 115, the ‘DIBA-
77-LH-28-1’ type heterodimeric compounds 102 and 120, the ‘DIBA-propantheline’ type 
dimeric ligands 100, 101, 118 and 119, and the ‘DIBA-4-DAMP’ type heterodimeric ligands 99, 
116 and 117, were investigated in equilibrium binding experiments using the orthosteric 
antagonist radioligand [3H]N-methylscopolamine ([3H]6) at live CHO cells stably expressing 
the human muscarinic receptor subtypes M1-M5. M1-M5 receptor saturation binding 
experiments with [3H]6 were performed in our lab55. The pKd values amounted to 9.85 (M1R), 
10.1 (M2R), 10.1 (M3R), 10.5 (M4R) and 9.63 (M5R) were in good agreement with previously 
reported data31, 56. 
 
Figure 2A shows the sigmoidal curves of a subset of the xanomeline-type homodimeric ligands 
46 and 53-55, the monomeric ligand 41 derived from xanomeline, the monomeric ligand 95 
derived from DIBA, and five ‘DIBA-xanomeline’ type heterodimeric ligands (97, 105a, 106, 110 
and 111) at M2R. For the homobivalent ligands of xanomeline, we observed a gradual, spacer-
length-dependent (not counting the xanomeline O atom) increase in affinity at the M2R for the 
14- (46), 18- (55), 20- (53), and 22-atom (54) spacers (Ki values: 21, 4.6, 4.0 nM and 2.3 nM, 
respectively) compared to the parent compound xanomeline (Ki = 210 nM) (data not shown in 
Table 1), the covalent tethering of two xanomeline pharmacophores caused 10-100 fold higher 
affinities at M2R compared with xanomeline (2). A similar phenomenon was observed for M1R, 
compared with the parent compound xanomeline (Ki = 160 nM, data not showed in Table 1), 
ligands 46, 55, 53 and 54 showed increasing M1R affinities (Ki values: 53, 24, 5.9 and 4.5 nM, 
respectively) depending on the length of the linker, and showed 3-35 fold higher affinities at 
M1R than xanomeline (2). In contrast, the monomeric ligand derived from xanomeline 
(compound 41) obtained from replacing xanomeline’s O-hexyl chain by the amino-
functionalized moiety showed a decrease in affinity at M2R. 
All of the tested DIBA derivatives (including monomeric (95) and heterodimeric (97, 105a, 106, 
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110 and 111) ligands) exhibited Ki values in the low nanomolar range at M2R, and showed 
higher affinities at M2R than xanomeline derived monomeric (41) or homodimeric (46, 53-55) 
ligands (cf. Table 1). Compound 97, containing a xanomeline and a DIBA moiety linked by 
piperazine, showed a remarkably high M2R affinity with a Ki value of 0.08 nM. Compound 105a, 
containing 1,4-diazepane ring between DIBA and xanomeline moieties, showed low 
nanomolar range affinity with a Ki value of 0.51 nM. With a Ki value of 0.46 nM, the 
propionamide congener 106 had a comparable affinity. Remarkably, though compound 110 
and its propionamide derivative 111 comprise complex linker moieties, these two 
heterodimeric ligands had high affinity at the M2R with Ki values of 0.26 nM and 0.35 nM, 
respectively. This means that, although the linkers in compounds 97, 105a, 106, 110 and 111 
differ in the chemical nature and vary in length, these compounds showed comparable high 
M2R affinities (cf. Table 1). Moreover, all ‘DIBA-xanomeline’ type heterodimeric ligands showed 
slightly higher M2R affinities than the DIBA-derived monomeric ligand 95 (Ki 2.2 nM), indicating 
that conjugation to the second pharmacophore (xanomeline) is favorable with respect to M2 
receptor binding.  
 
The effect on [3H]NMS M2R equilibrium binding of the second subset of compounds, 
comprising the monomeric ligand 67 derived from TBPB, the ‘DIBA-TBPB’ type ligands 98, 
107, 108, 114 and 115, as well as the ‘DIBA-77-LH-28-1’ type heterodimeric compounds 102 
and 120 is depicted in Figure 2B. The heterodimeric ligands (98, 102, 107, 108, 114, 115 and 
120) all exhibited slightly higher M2 affinities (Ki values: 0.20 to 0.82 nM) than the DIBA derived 
monomeric ligand 95 (Ki value: 2.2 nM). The TBPB-like monomeric ligand 67 displayed low 
M2R affinity (Ki 1800 nM). This phenomenon suggested that chemical dimerization of DIBA 
and TBPB, as well as DIBA and 77-LH-28-1 leads to increased affinity at M2R. Interestingly, 
the heterodimeric ligands containing a piperazine moiety in the spacer (114, 115, 120) showed 
slightly increased affinities with Ki values in the range of 0.20-0.37 nM, compared to other 
heterodimeric ligands (98, 102, 107 and 108) without a piperazine moiety in the spacer (Ki 
values from 0.60 to 0.82 nM), indicating that the involvement of piperazine moiety in the linker 
favors the interaction with the M2 receptor in this set of compounds. 
 
The effect on [3H]NMS M2R equilibrium binding of the third subset of compounds, comprising 
the ‘DIBA-4-DAMP’ type heterodimeric ligands 99, 116 and 117, the ‘DIBA-propantheline’ type 
heterodimeric ligands 100, 101, 118 and 119 as well as the ‘DIBA-DIBA’ homodimeric ligands 
112 and 113 are depicted in Figure 2C. The homo- or heterodimeric ligands, which contain 
long and basic spacers (118, Ki = 0.80 nM; 119, Ki = 1.1 nM; 116, Ki = 0.84 nM; 117, Ki = 1.2 
nM), had higher M2 affinity compared to compounds with a short spacer (99, Ki = 2.2 nM; 100, 
Ki = 2.1 nM; 101, Ki = 5.8 nM). Moreover, the DIBA-derived homodimeric ligands 112 and 113, 
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showed comparable affinities at M2R (Ki value: 0.15 nM or 0.58 nM) with the heterodimeric 
ligands 116-119, which also contained complex spacer moieties. This suggested that the 
ligands with bulky spacer moieties are even better tolerated by the M2R than ligands containing 
the sample linkers in the sets of ‘DIBA-4-DAMP’ or ‘DIBA-propantheline’ type heterodimeric 
ligands.  
 
A selection of the new dibenzodiazepinone heterodimeric ligands (compounds 97, 98, 99, 100, 
101, 102, 106, 108, 111, 115, 117, 119, 120) as well as the dibenzodiazepinone-type 
monomeric ligand 95 were also studied in equilibrium binding experiments with [3H]NMS at 
the M receptor subtypes M1, M3, M4 and M5. The Ki values and hill slopes are included in Table 
1. The [3H]NMS displacement curves of ligand 97, 106 and 115 at intact CHO-hMx cells (x = 
1-5) are showed in Figure 2D-2F. All of these compounds showed a preference for the M2 
receptor, but high M2R selectivity toward all of the other four subtypes wasn’t found for any of 
the MR ligands. Affinities obtained for the subtypes M1 and M4 were higher than affinities for 
the subtypes M3 and M5. There was one exception, compound 100, which showed the affinity 
pattern M2>M1≈M5>M3>M4. For the rest of compounds, the selectivity pattern can be 
concluded as M2>M1≈M4>M3≈M5 (98, 99, 101, 102, 106, 111, 117); M2>M1≈M4>M3>M5 (97, 
115, 119, 120) and M2>M1≈M4>M5>M3 (95, 108). With the excellent Ki value of 0.08 nM at the 
M2R, compound 97 showed the best M2R selectivity among the investigated ligands, the Ki 
value of 97 at the M1R was 23-fold higher, at the M4R 31-fold higher and the affinity to M3R 
and M5R was considerably lower with Ki ratios of 175 and 425, respectively. Compared to 97, 
the MR antagonist tripitramine57, containing three pyridobenzodiazepinone moieties, and the 
monomeric pyridobenzodiazepinone derivative AF-DX 384 (compound 8, cf. Figure 1A)31 
exhibit lower M2R selectivities according to published data (Ki ratios M1R/M2R/M3R/M4R/M5R: 
6:1:142:24:125 and 5:1:11:1.5:90, respectively). 
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Figure 2. (A-C) Concentration-dependent effects of compounds 41, 46, 53-55, 67, 95, 97-102, 105a, 
106-108, 110-120 on [3H]NMS (c = 0.2 nM) equilibrium binding at intact CHO-hM2 cells. (D-F) 
Concentration-dependent effects of the heterodimeric ligands 97 (D), 106 (E) and 115 (F) on equilibrium 
binding of [3H]NMS (c = 0.2 nM (M1, M2, M3), 0.1 nM (M4) or 0.3 nM (M5)) at intact CHO-hMx cells (x = 
1-5). Data analyzed by four-parameter logistic fits, represent mean values ± SEM from at least three 
independent experiments (performed in triplicate
  
 
Table 1. MR affinities (Ki values) of the monomeric xanomeline derivative 41, TBPB derivative 67, DIBA derivative 95, the homodimeric ligands 112 and 113 
(‘DIBA-DIBA’) and 46, 53-55 (‘xanomeline-xanomeline’), as well as the heterodimeric ligands 97, 105a, 106, 110 and 111 (‘DIBA-xanomeline’), 98, 107, 108, 
114 and 115 (‘DIBA-TBPB’), 102 and 120 (‘DIBA-77-LH-28-1’), 100, 101, 118 and 119 (‘DIBA-propantheline’) and 99, 116 and 117 (‘DIBA-4-DAMP’) obtained 
from equilibrium competition binding studies with [3H]NMS at live CHO-hMx cells (x = 1-5). 
No. 
M1R M2R M3R M4R M5R 
Ki (nM) slopea Ki (nM) slopea Ki (nM) slopea Ki (nM) slopea Ki (nM) slopea 
41 n.d. n.d. 14000 ± 480 -1.0 ± 0.09 n.d. n.d. n.d. n.d. n.d. n.d 
46 53 ± 11 -1.0 ± 0.07 21 ± 6.6 -0.92 ± 0.18 50 ± 2.3 -0.95 ± 0.04 n.d. n.d. n.d. n.d. 
53 5.9 ± 1.0 -0.89 ± 0.10 4.0 ± 1.4 -0.94 ± 0.08 7.3 ± 0.69 -1.1 ± 0.03 n.d. n.d. n.d. n.d. 
54 4.5 ± 0.55 -1.3 ± 0.05 2.3 ± 0.05 -0.84 ± 0.07 n.d. n.d. n.d. n.d. n.d. n.d. 
55 24 ± 6.8 -1.2 ± 0.18 4.6 ± 1.3 -0.82 ± 0.10 n.d. n.d. n.d. n.d. n.d. n.d. 
67 n.d. n.d. 1800 ± 810 -0.87 ± 0.04 n.d. n.d. n.d. n.d. n.d. n.d. 
95 67 ± 16 0.92 ± 0.08 2.2 ± 0.16 -0.87 ± 0.08 570 ± 75 -0.93 ± 0.20 9.2 ± 0.29 -0.8 ± 0.02 160 ± 66 -1.1 ± 0.15 
97 1.8 ± 0.48 -1.5 ± 0.02 0.08 ± 0.02 -1.0 ± 0.05 14 ± 1.9 -1.2 ± 0.07 2.5 ± 0.02 -1.2 ± 0.05 34 ± 2.5 -1.1 ± 0.22 
98 3.1 ± 0.32 -1.1 ± 0.05 0.77 ± 0.02 -1.4 ± 0.20 110 ± 26 -1.1 ± 0.07 3.2 ± 0.30 -1.2 ± 0.08 83 ± 13 -1.1 ± 0.20 
99 26 ± 6.1 -1.0 ± 0.22 2.2 ± 0.12 -1.2 ± 0.17 38 ± 11 -1.35 ± 0.06 9.3 ± 4.2 -1.2 ± 0.13 54 ± 6.3 -1.1 ± 0.13 
100 4.0 ± 0.78 -1.0 ± 0.12 2.1 ± 0.37 -1.1 ± 0.22 7.8 ± 1.0 -1.4 ± 0.09 14 ± 8.1 -1.0 ± 0.14 3.4 ± 0.51 -1.2 ± 0.10 
101 33 ± 12 -1.4 ± 0.30 5.8 ± 2.3 -1.5 ± 0.22 100 ± 27 -0.85 ± 0.03 13 ± 4.4 -1.3 ± 0.13 92 ± 6.1 -1.1 ± 0.11 
102 4.7 ± 0.83 -1.0 ± 0.05 0.60 ± 0.13 -1.4 ± 0.22 140 ± 11 -1.0 ± 0.09 3.0 ± 0.23 -1.4 ± 0.07 95 ± 16 -1.0 ± 0.25 
105a 5.2 ± 0.89 -1.5 ± 0.17 0.51 ± 0.06 -2.2 ± 0.05 63 ± 5.5 -1.3 ± 0.16 n.d. n.d. n.d. n.d. 
106 4.7 ± 0.36 -1.1 ± 0.05 0.46 ± 0.03 -1.1 ± 0.06 140 ± 10 -0.93 ± 0.04 3.5 ± 1.8 -0.94 ± 0.07 100 ± 22 -1.2 ± 0.19 
107 4.9 ± 0.33 -1.5 ± 0.05 0.71 ± 0.11 -1.9 ± 0.05 61 ± 9.0 -1.0 ± 0.09 n.d. n.d. n.d. n.d. 
108 19 ± 3.1 -1.2 ± 0.23 0.82 ± 0.17 -1.1 ± 0.13 610 ± 120 -1.01 ± 0.03 7.7 ± 1.8 -0.85 ± 0.08 140 ± 33 -1.3 ± 0.10 
110 1.8 ± 0.47 -1.3 ± 0.31 0.26 ± 0.08 -1.8 ± 0.09 19 ± 6.3 -1.28 ± 0.04 n.d. n.d. n.d. n.d. 
111 1.6 ± 0.29 -1.6 ± 0.03 0.35 ± 0.03 -2.4 ± 0.15 14 ± 0.71 -0.99 ± 0.04 1.3 ± 0.19 -1.1 ± 0.14 7.4 ± 0.26 -1.0 ± 0.11 
112 2.5 ± 0.56 -2.1 ± 0.19 0.15 ± 0.02 -1.5 ± 0.13 17 ± 2.0 -1.3 ± 0.10 n.d. n.d. n.d. n.d. 
113 3.5 ± 0.59 -1.7 ± 0.34 0.58 ± 0.07 -1.3 ± 0.07 13 ± 2.1 -1.2 ± 0.08 n.d. n.d. n.d. n.d. 
114 1.9 ± 0.37 -1.2 ± 0.07 0.20 ± 0.03 -1.4 ± 0.12 17 ± 1.1 -1.2 ± 0.05 n.d. n.d. n.d. n.d. 
115 3.3 ± 0.90 -1.6 ± 0.15 0.37 ± 0.05 -1.8 ± 0.15 28 ± 2.4 -1.4 ± 0.10 2.4 ± 0.12 -1.0 ± 0.05 110 ± 8.9 -1.3 ± 0.14 
116 6.0 ± 0.66 -1.3 ± 0.19 0.84 ± 0.35 -1.6 ± 0.23 77 ± 36 -1.3 ± 0.08 n.d. n.d. n.d. n.d. 
117 4.8 ± 0.69 -1.5 ± 0.14 1.2 ± 0.19 -2.1 ± 0.16 30 ± 2.9 -1.3 ± 0.09 2.9 ± 0.52 -1.5 ± 0.32 24 ± 3.1 -1.5 ± 0.12 
118 5.2 ± 1.8 -1.7 ± 0.19 0.80 ± 0.35 -1.5 ± 0.31 29 ± 4.1 -1.2 ± 0.12 n.d. n.d. n.d. n.d. 
119 3.9 ± 1.3 -1.1 ± 0.07 1.1 ± 0.19 -2.3 ± 0.17 19 ± 2.6 -1.2 ± 0.13 4.7 ± 0.22 -1.4 ± 0.06 43 ± 8.6 -1.0 ± 0.12 
120 3.6 ± 0.69 -1.7 ± 0.20 0.24 ± 0.02 -1.3 ± 0.13 13 ± 0.76 -1.42 ± 0.09 3.8 ± 0.72 -1.5 ± 0.20 42 ± 1.0 -1.1 ± 0.22 
aCurve slope of the four-parameter logistic fit. Mean values ± SEM from 3-5 independent experiments (each performed in triplicate). Kd values55 / applied 
concentrations of [3H]NMS: M1: 0.12 / 0.2 nM; M2: 0.090 / 0.2 nM; M3: 0.089 / 0.2 nM; M4: 0.040 / 0.1 nM; M5: 0.24 / 0.3 nM. 
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3.2.3. Functional studies  
 
The heterodimeric dibenzodiazepinone derivatives 106 and 115 were investigated in an IP 
accumulation assay using HEK-293 cells transiently transfected with the human M2R and the 
hybrid G-protein Gαqi5-HA. Compound 1 caused a concentration-dependent increase in IP1 
accumulation with a pEC50 of 6.93 ± 0.09 (n = 8). By contrast, 106 and 115 did not induce an 
IP1 accumulation when studied in agonist mode (cf. Figure 3A), that is, both compounds were 
not capable of stabilizing a G-protein activating conformation of the M2R. To allow an 
estimation of the inhibitory potency of 106 and 115, we tested the ability of compounds 7, 106 
and 115 to antagonize the effect of 1 at a concentration corresponding to EC80 (0.3 μM). 
Compounds 7, 106 and 115 completely inhibited the IP1 accumulation elicited by 1 proving 
that these compounds are M2R antagonists as previously reported for 834 (cf. Figure 3B). 
 
Figure 3. Investigation of M2R agonism and antagonism of compounds 106 and 115 in an IP1 
accumulation assay using HEK-hM2-Gqi cells. (A) Concentration-dependent effect of 1, 106 and 115 on 
the accumulation of IP1. 106 and 115 elicited no response. pEC50 of 1: 6.93 ± 0.09 (mean ± SEM from 
eight independent experiments performed in triplicate). (B) Concentration-dependent inhibition of the 
IP1 accumulation (induced by 1, 0.3 µM) by 7, 106 and 115. Corresponding pKb values: 7: 8.63, 106: 
7.16, 115: 7.91. Data represent the means ± SEM from at least five independent experiments (each 
performed in triplicate). 
 
3.2.4. Synthesis and characterization of the radiolabeled ligands 
[3H]106 and [3H]115  
 
Aiming at the preparation of the high-affinity propionamides 106 and 115 in their tritiated form, 
the stabilities of 106 and 115 in aqueous solution were investigated at pH 7.4 in PBS over 48 
h. The compounds proved to be stable under these conditions (cf. Figure 4). For the synthesis 
of [3H]106 and [3H]115 an excess of the precursor amines 105a or 114 was treated with 
succinimidyl [3H]propionate to afford [3H]106 with a radiochemical yield of 36% and a specific 
activity of 2.420 TBq/mmol, and [3H]115 with a radiochemical yield of 35% and a specific 
activity of 1.815 TBq/mmol. The radioligands were obtained in high radiochemical purities (98% 
and 99%, respectively; cf. Figure 5B and 5D). Quality controls by RP-HPLC after ten months 
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of storage as solution in ethanol at -20 °C revealed an excellent stability of [3H]115 and 
approximately 10% decomposition of [3H]106 (cf. Figure 5C and 5E). 
 
Figure 4. HPLC analysis of 106 (A) and 115 (B) after incubation in PBS (pH = 7.4) at 23 °C for up to 
48 h. 106 and 115 showed no decomposition. HPLC conditions see experimental section. 
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Figure 5. Preparation, purity and identity control of the radiolabeled dibenzodiazepinone derivatives 
[3H]106 and [3H]115. (A) Synthesis of [3H]106 and [3H]115 by [3H]propionylation of the amine precursors 
105a and 114, respectively, using succinimidyl [3H]propionate ([3H]104). (B, C) HPLC analysis of 
[3H]106 (B: 0.18 μM, C: 0.17 µM) spiked with “cold” 106 (3 μM), analyzed 3 days after synthesis and 
after 10 months of storage at -20 °C in EtOH/H2O (1:1). (D, E) HPLC analysis of [3H]115 (D: 0.23 μM, 
E: 0.23 µM) spiked with “cold” 115 (3 μM), analyzed 3 days after synthesis and after 10 months of 
storage at -20 °C in EtOH/H2O (1:1). HPLC conditions see experimental section.  
 
3.2.5. Characterization of [3H]106 and [3H]115 
 
Initially, saturation binding experiments with the tritiated radioligands [3H]106 and [3H]115 were 
performed on intact adherent CHO-hM2 cells in white-transparent 96-wells plates revealing Kd 
values of 1.5 and 0.37 nM, respectively (mean values from at least three independent 
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experiments performed in triplicate) (cf. Figure 6B and 6D). At concentrations around the Kd 
value, unspecific binding amounted to approx. 40% ([3H]106) and 30% ([3H]115) of total 
binding. Saturation binding studies with [3H]106 and [3H]115 performed at CHO-hM2 cell 
homogenates, precluding the detection of unspecific binding of the radioligand to the 
microplate, resulted in lower unspecific binding (< 25% of total binding at Kd) and yielded 
binding constants of 1.1 and 0.12 nM, respectively (cf. Figure 6A and 6C). Because of the 
higher ratio of specific over unspecific binding when using cell homogenates, further studies 
(association and dissociation kinetics, competition binding experiments and saturation binding 
of [3H]115 in the presence of the allosteric modulator (15) were performed with CHO-hM2 cell 
homogenates.  
 
Figure 6. Representative saturation isotherms of specific M2R binding (shown in dashed line) of [3H]106 
(A, B) and [3H]115 (C, D) obtained from experiments either performed with CHO-hM2 cell homogenates 
(A, C) or live adherent CHO-hM2 cells (B, D). Non-specific binding (shown in blue) was determined in 
the presence of the orthosterically binding MR antagonist atropine (500-fold excess). Experiments were 
performed in triplicate. Specific binding data were analyzed by an equation describing a one-site binding. 
Error bars of specific binding and error bars in the Scatchard plots represent propagated errors 
calculated according to the Gaussian law of errors. Error bars of total and nonspecific binding represent 
the SEM. 
 
To be noticed, as the orthosteric antagonist 7, used to determine unspecific binding in 
saturation binding studies, was able to completely prevent one-site (monophasic) specific 
binding of [3H]106 and [3H]115 to the M2R, these data strongly suggest that the heterodimeric 
dibenzodiazepinone-type MR ligands 106 and 115 address the orthosteric binding site of the 
M2R. 
The association of both, [3H]106 and [3H]115, to the M2R was monophasic and resulted in 
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comparable kon values (cf. Figure 7A and 7C, Table 2). Plateaus were reached after 
approximately 40 min and 20 min, respectively. With a half-life of 53 min, [3H]106 completely 
dissociated from the M2R. By contrast, the dissociation of [3H]115 was incomplete, reaching a 
plateau at 48% of initially bound radioligand, with a half-life of 32 min (cf. Figure 7B and 7D). 
This result suggests in part a (pseudo)irreversible (long lasting) binding of [3H]115. One reason 
could be conformational adjustments of the receptor upon ligand binding58, another reason 
might be an enhanced rebinding capability of the dimeric ligand by a simultaneous interaction 
with two or more binding sites59. The kinetically derived dissociation constants Kd(kin), 
calculated according to Kd(kin) = koff/kon, amounted to 0.33 nM for [3H]106 and 0.057 nM for 
[3H]115 and were in good agreement with the Kd values obtained from saturation binding 
experiments ([3H]106: Kd = 1.1 nM, [3H]115: Kd = 0.12 nM), indicating that both radioligands 
follow (in part) the law of mass action60. An overview of the M2R binding characteristics of 
[3H]106 and [3H]115 is provided in Table 2. 
 
Figure 7. Association and dissociation kinetics of [3H]106 (A, B) and [3H]115 (C, D) determined at CHO-
hM2 cell homogenates at 23 °C. (A) Association of [3H]106 (c = 2.0 nM) to the M2R. Inset: ln[Beq/(Beq−Bt)] 
versus time, kobs = slope = 0.071 min−1. (B) Dissociation of [3H]106 (preincubation: 4 nM, 1 h) from the 
M2R determined in the presence of atropine (1000-fold excess); monophasic exponential decline, t1/2 = 
53 min. Inset: ln[Bt/B0] versus time. Slope·(−1) = koff = 0.010 min−1. (C) Association of [3H]115 (c = 0.6 
nM) to the M2R. Inset: ln[Beq/(Beq−Bt)] versus time, kobs = slope = 0.15 min−1. (D) Dissociation of [3H]115 
(preincubation: 0.6 nM, 1 h) from the M2R determined in the presence of atropine (1000-fold excess), 
monophasic exponential decline, t1/2 = 32 min. Inset: ln[Bt/B0] versus time. Slope·(−1) = koff = 0.005 min-
1. Data represent the mean ± SEM from three (A, B, D) or two (C) independent experiments (each 
performed in triplicate). 
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Table 2. M2R binding characteristics of [3H]106 and [3H]115. 
 
radio-ligands 
Saturation binding Binding kinetics 
Kd 
[nM]a 
Kd 
[nM]b 
Kd(kin) 
[nM]c 
kon 
[min−1nM−1]d 
koff [min−1]e 
t1/2 [min]e 
[3H]106 1.5 ± 0.26 1.1 ± 0.20 0.33 ± 0.08 0.044 ± 0.009 
0.013 ± 0.001 
53 ± 6 
[3H]115 0.37 ± 0.03 0.12 ± 0.02 0.057 ± 0.0004 0.32 ± 0.03 
0.019 ± 0.0008 
32 ± 2 
aDissociation constant determined by saturation binding at live CHO-hM2R cells; mean ± SEM from three 
independent experiments (performed in triplicate). bDissociation constant determined by saturation binding at 
CHO-hM2 cell homogenates; mean ± SEM from at least three independent experiments (performed in triplicate). 
cKinetically derived dissociation constant ± propagated error (Kd(kin) = koff/kon). dAssociation rate constant ± 
propagated error, calculated from kobs, koff and the applied radioligand concentration (cf. experimental section). 
eDissociation rate constant and half-life; mean ± SEM from three independent experiments (performed in triplicate).  
 
3.2.6. M2R equilibrium competition binding with [3H]106 and [3H]115 
 
Figure 8A shows the concentration-dependent effects of the orthosteric MR antagonists 7 and 
11 as well as of the allosteric modulator 15 on M2R equilibrium binding of [3H]106, and Figure 
8B presents the concentration-dependent effects of various reported orthosteric (2, 7), 
allosteric (14, 15, 16) and dualsteric (8, 11) MR ligands as well as 115 on M2R equilibrium 
binding of [3H]115. All investigated compounds were capable of totally inhibiting (displacing) 
specific M2R binding of [3H]106 or [3H]115, suggesting either a competitive mechanism or a 
strongly negative cooperativity between the studied compounds and the radiolabeled 
dibenzodiazepinone derivatives61. Generally, Ki values obtained from equilibrium competition 
binding experiments with [3H]106 and [3H]115 were in good agreement with reported Ki values 
(cf. Table 3). However, Ki values determined with [3H]106 and [3H]115 were consistently higher 
than Ki values from competition binding experiments with [3H]NMS (compounds 2, 7, 8, 11, cf. 
Table 3). The reason for this discrepancy might be due to a multivalent binding mode of the 
heterodimeric radioligand (reflected by an in part long-lasting binding), therefore, higher 
competitor concentrations were required for the displacement of [3H]115. Equilibrium 
competition binding experiments with [3H]115 and 8, as well as with [3H]115 and 11, were also 
performed after preincubation of CHO-hM2 cell homogenates with 8 or 11 for 90 min. However, 
incubation with the competitors prior to the addition of [3H]115 did not result in an increase in 
the apparent affinities of 8 and 11 (cf. Figure 9). 
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Figure 8. Concentration-dependent effects of various reported orthosteric (2, 7), dualsteric (8, 11), 
allosteric (14, 15 and 16) MR ligands and 115 on M2R equilibrium binding of [3H]106 (c = 2.0 nM, Kd = 
1.1 nM) (A) and [3H]115 (c = 0.3 nM, Kd = 0.12 nM) (B) determined at CHO-hM2 cell homogenates at 
22 °C. Data analyzed by four-parameter logistic fits, represent mean values ± SEM from at least three 
independent experiments (performed in triplicate). 
 
 
Table 3. Comparison of M2R binding data (Ki or IC50 values) of various orthosteric 
(2, 7), allosteric (14, 15 and 16), dualsteric (8, 11) MR ligands and 115 determined 
with [3H]106, [3H]115 or [3H]NMS 
ligand 
[3H]106 
Ki [nM]a 
[3H]115 
Ki [nM]a 
[3H]NMS 
Ki* or IC50** [nM] 
2 - 2300 ± 260 210 ± 59*b 
7 2.8 ± 0.60 4.6 ± 1.6 0.94 ± 0.19*b 
8 - 29 ± 9.6 2.0 ± 0.21*b 
11 5.2 ± 2.9 6.3 ± 1.3 0.79 ± 0.10*b 
14 - 3500 ± 570 2200 ± 410**c 
15 1800 ± 900 1200 ± 530 460 ± 130**c 
16 - 4900 ± 210 >10000**c 
115 - 0.34 ± 0.15 0.37 ± 0.05*b 
aDetermined by equilibrium competition binding with [3H]106 (c = 2 nM) or [3H]115 (c = 0.3 
nM) at CHO-hM2 cell homogenates; mean values ± SEM from at least three independent 
experiments (performed in triplicate). bDetermined by equilibrium competition binding with 
[3H]NMS (c = 0.2 nM) at live CHO-hM2 cells; mean ± SEM from at least three independent 
experiments (performed in triplicate). cIC50 values obtained from nonlinear four-parameter 
logistic curve analyses of data characterizing the inhibition of [3H]NMS (c = 0.2 nM) 
equilibrium binding at live CHO-hM2 cells; mean ± SEM from at least three independent 
experiments (performed in triplicate). 
 
 
Figure 9. Concentration-dependent effects of MR ligands 8 (A) and 11 (B) on M2R equilibrium binding 
of [3H]115 (c = 0.3 nM, Kd = 0.12 nM) determined at CHO-hM2 cell homogenates at 22 °C, 8 or 11 was 
preincubated with the M2R for 90 min before the addition of [3H]115. Data analyzed by four-parameter 
logistic fits, represent mean values ± SEM from three independent experiments (performed in triplicate). 
A B 
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3.2.7. Schild-like analysis with allosteric modulator 15 at the M2R 
using [3H]115  
 
Competition binding studies with [3H]NMS and 106, and [3H]NMS and 115 at the M2R, as well 
as M2R saturation binding experiments with [3H]106 and [3H]115 (see above) suggested that 
the dibenzodiazepinone-type heterodimeric ligands 106 and 115 bind to the orthosteric site of 
the M2R. Furthermore, competition binding experiments with [3H]106 or [3H]115 at the M2R, 
for instance with the allosteric modulator 15, resulting in sigmoidal curves which reached 0% 
specific binding of the dimeric radioligands, indicated binding of [3H]106 and [3H]115 to the 
allosteric vestibule of the M2R. In order to substantiate the hypothesis of dualsteric binding of 
dibenzodiazepinone-type heterodimeric ligands such as 115 at the M2R, saturation binding 
studies with [3H]115 were performed in the presence of the allosteric modulator 15 (cf. Figure 
10). This kind of experiment is equivalent to the Schild analysis used to investigate the 
inhibiting effect of a receptor antagonist on the response elicited by an agonist and is 
considered the experiment of choice to unveil competitive or non-competitive mechanisms62-
65. For instance, it was used to prove the competitive interplay between the allosteric modulator 
brucine and the pirenzepine derived fluorescent tracer Bo(22)Pz at M1R62. As becomes 
obvious from Figure 10A the presence of 15 led to a parallel rightward shift of the saturation 
isotherms of [3H]115. A plot of log(affinity shift - 1) versus log(concentration of 15) yielded a 
straight line (‘Schild’ regression, cf. Figure 10B) with a slope not different from unity (slope = 
0.97 ± 0.06, P > 0.5), indicating a competitive interaction between [3H]115 and the allosteric 
modulator 15, and thus suggesting again a dualsteric binding of 115 at the M2R. The ‘pA2’ 
value (7.05 ± 0.23) derived from the ‘Schild’ regression was in accordance with the pKi value 
(6.06 ± 0.27) from equilibrium competition binding studies with [3H]115 and 15 as well as with 
reported M2R binding data of 15 (pKA 6.00/6.5335). 
 
Figure 10. Effect of the allosteric modulator 15 on saturation binding of [3H]115 determined at CHO-
hM2 cell homogenates at 22 °C. (A) Saturation isotherm of specific radioligand binding plotted in linear 
and in semi-logarithmic scale. (B) “Schild” regression resulting from the rightward shifts (ΔpKd) of the 
saturation isotherms (log(r-1) plotted vs. log(concentration 15), where r = 10ΔpKd). The presence of 
compound 15 led to a parallel rightward shift of the saturation isotherms of [3H]115. The slope of the 
linear “Schild” regression was not different from unity (P > 0.5, based on the slope mean value ± SEM 
(0.97 ± 0.06) from three sets of independent saturation binding experiments (performed in triplicate)) 
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indicating a competitive interaction between [3H]115 and 15. Data represent mean values ± SEM from 
three independent experiments (each performed in triplicate). 
 
3.3. Conclusion 
 
The present study focused on the synthesis and characterization of a series of 
dibenzodiazepinone-type dimeric MR ligands comprising two homodimeric ligands (‘DIBA-
DIBA’) and nineteen heterodimeric ligands (5 × ‘DIBA-xanomeline’, 5 × ‘DIBA-TBPB’, 2 × 
‘DIBA-77-LH-28-1’, 4 × ‘DIBA-propantheline’ and 3 × ‘DIBA-4-DAMP’). The most interesting 
finding was that all of these DIBA-derived dimeric ligands exhibited high M2R affinities (Ki 
values: 0.08-5.8 nM, cf. Table 1), i.e. variation of the type of the linker (short vs. long, basic vs. 
non-basic, etc.) and the second pharmacophoric group had almost no impact on M2R binding. 
In other words, it was surprising that the bulky ‘side chain’ attached to the dibenzodiazepinone 
moiety did hardly influence or disturb M2R binding. As the monomeric and dimeric reference 
compounds (41, 46, 53-55, 67), devoid of the dibenzodiazepinone moiety, exhibited 
considerably lower M2R affinity compared with the DIBA-derived ligands, the high M2R affinity 
of the heterodimeric dibenzodiazepinone-type ligands is most likely mediated by the 
‘dibenzodiazepinone’ pharmacophore, which presumably binds to the orthosteric site of the 
M2R. The ‘DIBA-xanomeline’ type heterodimeric ligand 97 displayed the highest M2R affinity 
(Ki 0.08 nM) and exhibited the highest M2 subtype preference within the series of presented 
MR ligands. Two tritium-labeled heterodimeric M2R ligands ([3H]106 and [3H]115) were 
prepared and characterized by saturation binding experiments, kinetic studies and equilibrium 
competition binding with various MR ligands. With a Kd value of 0.12 nM and high chemical 
stability, [3H]115 proved to be an interesting new molecular tool for studying muscarinic 
receptors and MR ligands. The results from various M2R binding experiments with [3H]115, in 
particular saturation binding studies in the absence or presence of the allosteric MR ligand 
W84 (15), strongly indicated a simultaneous interaction of 115 with the orthosteric and the 
‘common’ allosteric binding site, i.e a dualsteric binding mode at the M2R. This work suggests 
dibenzodiazepinone-type MR ligands as an interesting compound class to develop highly 
selective M2R ligands according to the dualsteric (bitopic) ligand approach. 
 
3.4. Experimental section 
3.4.1. Chemistry 
3.4.1.1. General experimental conditions 
 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG (Karlsruhe, 
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Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, 
Germany), TCI Europe (Zwijndrecht, Belgium), MP Biomedicals (Eschwege, Germany), 
Absource Diagnostic (Munich, Germany) or Abcam (Cambridge, UK) and used without further 
purification. Technical grade solvents (acetone, ethyl acetate, light petroleum (40-60 °C) and 
dichloromethane) were distilled before use. Deuterated solvents for NMR spectroscopy were 
from Deutero GmbH (Kastellaun, Germany). Acetonitrile for HPLC (gradient grade) was 
obtained from Merck (Darmstadt, Germany). Anhydrous DMF was purchased from Sigma-
Aldrich Chemie GmbH. The radiolabeled MR antagonist [3H]NMS (specific activity = 80 
Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (St. Louis, MO) via 
Hartman Analytics GmbH (Braunschweig, Germany). Millipore water was used throughout for 
the preparation of buffers and HPLC eluents. If moisture-free conditions were required, 
reactions were performed in dried glassware under inert atmosphere (argon). Anhydrous THF 
was obtained by distillation over sodium, and anhydrous CH2Cl2 was prepared by distillation 
over P2O5 after predrying over CaCl2. Reactions were monitored by TLC using aluminum 
plates coated with silica gel (Merck silica gel 60 F254, thickness 0.2 mm). Spots were detected 
by UV light (254 nm or 366 nm) or by staining using a 0.3% solution of ninhydrine in n-butanol 
(amines) or iodine. Flash chromatography was performed in glass columns on silica gel (Merck 
silica gel 60, 40-63 μm). Polypropylene reaction vessels (1.5 or 2 mL) with screw cap (Süd-
Laborbedarf, Gauting, Germany) were used for the synthesis of radioligands ([3H]106 and 
[3H]115), for small scale reactions, for the investigation of chemical stabilities (106, 115) and 
for the preparation and storage of stock solutions. All melting points are uncorrected and were 
measured with a Büchi 530 (Büchi GmbH, Essen, Germany) apparatus. Microwave assisted 
reactions were performed with an Initiator 2.0 synthesizer (Biotage, Uppsala, Sweden). 
NMR spectra were recorded on a Bruker Avance 300 (7.05 T, 1H: 300.1 MHz, 13C: 75.5 MHz), 
Bruker Avance III HD 400 (9.40 T, 1H: 400 MHz, 13C: 100 MHz) or a Bruker Avance III HD 
600 equipped with a cryogenic probe (14.1 T 1H: 600.1 MHz, 13C: 150.9 MHz) (Bruker, 
Karlsruhe, Germany) with TMS as external standard. Abbreviations for the multiplicities of the 
signals: s (singlet), d (doublet), t (triplet), dd (doublet of doublet), q (quartet), m (multiplet), brs 
(broad singlet). For compound 97, 106 and 115, 2D-NMR techniques (1H-COSY, HSQC, 
HMBC) were used to assign 1H and 13C chemical shifts. IR spectra were measured with a 
NICOLET 380 FT-IR spectrophotometer (Thermo Electron Corporation). Low-resolution mass 
spectrometry (MS) was performed on a Finnigan SSQ 710A instrument (CI-MS) (Thermo 
Finnigan, San Jose, CA). High-resolution mass spectrometry (HRMS) analysis was performed 
on an Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa 
Clara, CA) using an ESI source. Preparative HPLC was performed on a system from Knauer 
(Berlin, Germany) consisting of two K-1800 pumps and a K-2001 detector. A Kinetex-XB C18, 
5 μm, 250 mm × 21 mm (Phenomenex, Aschaffenburg, Germany) served as stationary phase 
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at a flow-rate of 15 mL/min using mixtures of acetonitrile and 0.1% aq TFA as mobile phase. 
A detection wavelength of 220 nm was used throughout. Lyophilisation of the collected 
fractions was performed with an Alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, 
Germany) equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, Germany). 
Elemental analysis was performed with a Vario MICRO Cube elemental analyzer (Elementar 
Analysensysteme, Hanau, Germany). Analytical HPLC analysis was performed on a system 
from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-6200-A pump, an AS-
2000A autosampler, a L-4000A UV detector, a D-6000 interface. A Kinetex-XB C18, 5 μm, 250 
mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) was used as stationary phase at a 
flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% aq TFA (B) were used as mobile 
phase (degassed by Helium purging). The following linear gradient was applied: 0-30 min: A/B 
5:95-85:15, 30-32 min: 85:15-95:5, 32-40 min: 95:5. Detection was performed at 220 nm 
throughout. The oven temperature was 30 °C. The HPLC purity of all analyzed compounds 
was >95%.  
Annotation concerning the NMR spectra (1H, 13C) of the dibenzodiazepinone derivatives (92-
102, 105a, 106-108 and 110-120): due to a slow rotation about the exocyclic amide group on 
the NMR time scale, two isomers (ratios provided in the experimental protocols) were evident 
in the 1H- and 13C-NMR spectra. The isolated DIBA-type homodimeric ligand 105b was 
handed to Andrea Pegoli in our research group for further processing. In addition, the number 
of the TFA salts of the piperazine derivatives was identified by elemental analysis (compounds 
97 and 117). 
 
3.4.1.2. Experimental protocols and analytical data 
 
Ethyl 2-(benzylamino)-2-oxoacetate (21)43 
Diethyl oxalate (19) (2.0 g, 13.68 mmol) was mixed in chloroform (100 mL) in a 250-mL three-
necked round bottom flask. A solution of benzylamine (20) (1.3 g, 13.68 mmol) in chloroform 
(50 mL) was added slowly to the reaction mixture. The reaction mixture was refluxed overnight. 
The solid formed during the reaction was removed by filtration and discarded. The combined 
filtrate and washings were concentrated under reduced pressure to give compound 21 as 
yellow oil (1.8 g, 65%). After cooling in the refrigerator (ca. -20 °C) overnight the oil crystallized 
to form a yellow solid, m.p. 45-48 oC (Lit43 m.p. 50-51 oC). Rf = 0.2 (light petroleum/ethyl 
acetate 6:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.38 (t, J 7.1 Hz, 3H), 4.34 (q, J 7.1 Hz, 
2H), 4.52 (d, J 6.0 Hz, 2H), 7.27-7.39 (m, 5H), 7.41 (brs, 1H). 13C-NMR (75 MHz, CDCl3): 14.0, 
43.9, 63.3, 127.9, 128.0, 128.9, 136.8, 156.5, 160.7. HRMS (ESI): m/z [M+H]+ calcd. for 
[C11H14NO3]+ 208.0968, found: 208.0971. C11H13NO3 (207.23). 
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N1-Benzyl-N2-methyloxalamide (22)43 
To a solution of compound 21 (1.0 g, 4.83 mmol) in abs. ethanol (20 mL) was added a 2 M 
solution of methylamine (3.62 mL, 7.24 mmol) in THF. A white solid was formed instantly. After 
8 h, collected the solid by filtration, evaporation of the filtrate provided a second portion of 
product. Combined two portions of product to yield compound 22 as white powder (900 mg, 
97%), m.p. 160-163 oC (Lit43. m.p. 184-185 oC), which was used without further purification. 
Rf = 0.3 (light petroleum/ethyl acetate 3:1 v/v).1H-NMR (300 MHz, CDCl3): δ (ppm) 2.91 (d, J 
6.0 Hz, 3H), 4.49 (d, J 6.0 Hz, 2H), 7.25-7.38 (m, 5H), 7.55 (brs, 1H), 7.83 (brs, 1H). 13C-NMR 
(75 MHz, CDCl3): 26.2, 43.7, 127.8, 127.9, 128.8, 136.8, 159.7, 160.4. HRMS (ESI): m/z 
[M+H]+ calcd. for [C10H13N2O2]+ 193.0972, found: 193.0976. C10H12N2O2 (192.22). 
 
N1-Benzyl-N2-methylethane-1,2-diamine (23)43  
Lithium aluminum hydride (143 mg, 3.77 mmol) was placed in a 50 mL three-necked round 
bottom flask with abs. THF (15 mL) under an atmosphere of argon. The suspension was 
immersed in an ice bath and compound 22 (290 mg, 1.51 mmol) dissolved in abs. THF (10 
mL) was added to the solution dropwise. The reaction mixture was refluxed overnight. The 
flask was immersed in an ice bath for quenching, water (0.15 mL), 15% aq NaOH (0.45 mL) 
and water (0.15 mL) were added dropwise. The suspension was stirred at 0 oC for 30 min. 
Filtered the white solid, washed the white solid with chloroform (3 × 10 mL). The filtrate was 
concentrated under reduced pressure to give the crude product, which was subjected to flash 
column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to provide 
compound 23 as colorless oil (150 mg, 60%). Rf = 0.3 (CH2Cl2/MeOH/25% aq NH3 90:9:1 
v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.91 (s, 2H), 2.39 (s, 3H), 2.64-2.71 (m, 2H), 2.72-
2.74 (m, 2H), 3.77 (s, 2H), 7.18-7.24 (m, 1H), 7.27-7.29 (m, 4H). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 36.3, 48.4, 51.4, 53.9, 126.9, 128.1, 128.4, 140.4. HRMS (ESI): m/z [M+H]+ calcd. for 
[C10H17N2]+ 165.1386, found: 165.1387. C10H16N2 (164.25). 
 
(1- Benzyl-4-methyl-6-nitro-1,4-diazepan-6-yl) methanol (25)  
Compound 23 (4.6 g, 28.04 mmol) and 2-nitroethanol (compound 24) (1985 µL, 27.70 mmol) 
were dissolved in toluene/ethanol (1:1 v/v) (60 mL). Paraformaldehyde (2.5 g, 83.33 mmol) 
was added in small portions under stirring, and the suspension was heated to reflux for 6 h. 
The solvent was evaporated, and the crude product was dissolved in CH2Cl2 (20 mL) and 
washed with H2O (3 x 20 mL). The organic phase was dried over Na2SO4. The product was 
purified by flash column chromatography (eluent: light petroleum/ethyl acetate 4:1 to 2:1 v/v) 
to provide compound 25 as yellow oil (6.9 g, 88%). Rf = 0.3 (light petroleum/ethyl acetate 2:1 
v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 2.45 (s, 3H), 2.53-2.76 (m, 4H), 2.96-3.16 (m, 2H), 
3.42-3.50 (m, 2H), 3.54-3.76 (m, 3H), 3.76-3.88 (m, 2H), 7.22-7.37 (m, 5H). 13C-NMR (75 MHz, 
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CDCl3): δ (ppm) 48.3, 57.9, 59.0, 61.2, 61.6, 63.8, 66.2, 93.9, 127.6, 128.5, 129.1, 138.6. 
HRMS (ESI): m/z [M+H]+ calcd. for [C14H22N3O3]+ 280.1656, found: 280.1661. C14H21N3O3 
(279.34) 
 
1-Benzyl-4-methyl-6-nitro-1,4-diazepane (26)  
Potassium tert-butoxide (2.2 g, 19.61 mmol) was added portionwise to a solution of compound 
25 (3.7 g, 13.25 mmol) in MeOH (50 mL). The mixture was heated at 40 oC for 30 min and 
cooled slowly to room temperature. The solvent was evaporated and the residue dissolved in 
a solution of NH2OH·HCl (1.4 g, 20.15 mmol) in water (100 mL) followed by extraction with 
CH2Cl2 (3 x 20 mL). The combined extracts were washed with brine and dried over Na2SO4. 
The solvent was evaporated at ca 25 oC to afford compound 26 as yellow oil (2.2 g, 67%). Rf 
= 0.7 (CH2Cl2/MeOH/25% aq NH3 95:5:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 2.45 (s, 
3H), 2.54-2.77 (m, 4H), 3.09-3.26 (m, 2H), 3.32-3.42 (m, 2H), 3.67-3.78 (m, 2H), 4.53-4.69 (m, 
1H), 7.21-7.39 (m, 5H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 47.4, 56.7, 56.9, 58.9, 59.9, 62.9, 
84.6, 127.4, 128.5, 128.8, 138.8. HRMS (ESI): m/z [M+H]+ calcd. for [C13H20N3O2]+ 250.1550, 
found: 250.1552. C13H19N3O2 (249.31). 
 
tert-Butyl (1-benzyl-4-methyl-1,4-diazepan-6-yl)carbamate (27) 
A mixture of compound 26 (4.3 g, 17.25 mmol) was dissolved in 95% ethanol (65 mL), Raney 
2800 (slurry in H2O, ca 6 mL) was carefully added to the solution, the suspension was stirred 
in an autoclave (1 L) under an atmosphere of hydrogen at 10 atm at room temperature 
overnight. The catalyst was filtered off and the filtrate was concentrated to afford the 
compound 1-benzyl-4-methyl-1,4-diazepan-6-amine as a brown oily residue (3.7 g, 98%). This 
material (3.7 g, 16.87 mmol) was dissolved in CHCI3 (50 mL) and di-tert-butyl dicarbonate (4.5 
g, 20.64 mmol) in CHCl3 (50 mL) was slowly added to this solution. The mixture was stirred at 
room temperature overnight. H2O (50 mL) was added followed by extraction with CH2Cl2 (3 × 
50 mL). The combined extracts were dried over Na2SO4 and the volatiles were evaporated to 
afford the crude product, which was subjected to flash column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to yield compound 27 as yellow oil (2.9 g, 54%). Rf = 
0.8 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.40 (s, 
9H), 2.35 (s, 3H), 2.39-2.69 (m, 5H), 2.71-2.91 (m, 3H), 3.55 (d, J 13 Hz, 1H), 3.67 (d, J 13 
Hz, 1H), 3.72-3.79 (m, 1H), 5.50 (br. s, 1H), 7.18-7.39 (m, 5H). 13C-NMR (75 MHz, CDCl3): δ 
(ppm) 28.5, 48.2, 48.8, 56.5, 58.9, 59.5, 62.2, 63.5, 78.9, 127.2, 128.4, 128.9, 139.3, 155.4. 
HRMS (ESI): m/z [M+H]+ calcd. for [C18H30N3O2]+ 320.2333, found: 320.2342. C18H29N3O2 
(319.45). 
 
tert-Butyl (1-methyl-1,4-diazepan-6-yl)carbamate (28) 
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Compound 27 (200 mg, 0.626 mmol) was suspended in THF/H2O (1:4 v/v) (5 mL) followed by 
the addition of 10% Pd/C (40 mg). The mixture was stirred in an autoclave (1 L) under an 
atmosphere of hydrogen at 10 atm at room temperature overnight. Filtered the reaction 
mixture through a pad of celite, the filtrate was concentrated under reduced pressure to give 
compound 28 as colorless oil (110 mg, 77%), which was used without further purification. Rf = 
0.2 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 1.36 
(s, 9H), 2.27 (s, 3H), 2.35-2.49 (m, 4H), 2.58-2.69 (m, 2H), 2.59-2.68 (m, 2H), 2.85-2.91 (m, 
1H), 3.49-3.66 (m, 1H), 6.58 (brs, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 28.3, 47.2, 
49.1, 50.7, 52.7, 60.4, 61.3, 77.7, 154.9. HRMS (ESI): m/z [M+H]+ calcd. for [C11H24N3O2]+ 
230.1863, found: 230.1868. C11H23N3O2 (229.32). 
 
tert-Butyl (2-bromoethyl)carbamate (30) 
2-bromoethan-1-amine hydrobromide (compound 29) (3.0 g, 14.63 mmol) and di-tert-butyl 
dicarbonate (3.2 g, 14.67 mmol) were dissolved in CH2Cl2 (80 mL). Triethylamine (2.05 mL, 
14.71 mmol) was added dropwise and the reaction mixture was stirred at room temperature 
overnight. CH2Cl2 (20 mL) was added, the mixture was washed with brine, and the organic 
phase was dried over Na2SO4 followed by removal of the solvent under reduced pressure. The 
product was purified by flash column chromatography (eluent: light petroleum/ethyl acetate 
8:2 v/v) to give compound 30 as yellow oil (2.6 g, 80%). Rf = 0.7 (light petroleum/ethyl acetate 
2:1 v/v). 1H-NMR (400 MHz, CDCl3): δ (ppm) 1.44 (s, 9H), 3.44 (t, J 5.5 Hz, 2H), 3.47-3.57 (m, 
2H), 4.98 (s, 1H). 13C-NMR (100 MHz, CDCl3): 28.4, 32.8, 42.4, 79.8, 155.5. C7H14BrNO2 
(224.10).  
 
tert-Butyl (2-(piperazin-1-yl)ethyl)carbamate (32) 
Compound 30 (1.0 g, 4.46 mmol), piperazine (compound 31) (1.5 g, 17.44 mmol) and K2CO3 
(1.2 g, 8.70 mmol) were added to MeCN (50 mL) and the mixture was kept under reflux for 3 
h. The mixture was filtered and the filtrate was concentrated to afford a yellow oily residue, 
which was dissolved in CH2Cl2 (20 mL) followed by washing with water. The aqueous phase 
was treated with CH2Cl2 (3 × 20 mL) and the organic extracts were collected. All organic 
phases were combined and dried over Na2SO4. Removal of the volatiles under reduced 
pressure gave the crude product, which was subjected to flash column chromatography 
(eluent: CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to yield compound 32 as yellow oil (0.93 g, 
91%). Rf = 0.4 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ 
(ppm)1.45 (s, 9H), 2.42-2.46 (m, 6H), 2.57 (brs, 1H), 2.83-3.01 (m, 4H), 3.19-3.27 (m, 2H), 
4.97 (brs, 1H). 13C-NMR (75 MHz, CDCl3): 28.5, 36.9, 45.7, 53.6, 57.7, 82.6, 160.0. HRMS 
(ESI): m/z [M+H]+ calcd. for [C11H24N3O2]+ 230.1863, found: 230.1869. C11H23N3O2 (229.32). 
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2-Amino-2-(pyridin-3-yl)acetonitrile (34)47  
To a cooled (5 °C) solution of potassium cyanide (10.4 g, 159.7 mmol) in water (100 mL) was 
added 3-pyridinecarbaldehyde (compound 33) (11.4 g, 106.5 mmol) dropwise. Afterwards, 
acetic acid (9.1 mL, 159.7 mmol) was added over a period of 30 min. The mixture was stirred 
at room temperature for 2 h followed by extraction with ethyl acetate (3 × 50 mL). The 
combined organic phases were dried over Na2SO4 and the solvent was removed under 
reduced pressure to give the intermediate 2-hydroxy-2-(pyridin-3-yl)acetonitrile as yellow solid 
(14.0 g, 98%), which was used without further purification. Rf = 0.4 (CH2Cl2/MeOH 10:1 v/v). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 5.65 (s, 1H), 7.38 (dd, J 7.9, 4.9 Hz, 1H), 7.93 (d, J 9.5 
Hz, 1H), 8.45 (dd, J 4.9, 1.3 Hz, 1H), 8.58 (d, J 1.9 Hz, 1H). 13C-NMR (75 MHz, CDCl3) δ (ppm) 
60.7, 118.9, 124.6, 133.2, 135.7, 146.8, 149.4. The intermediate (14.0 g, 104.4 mmol) was 
added to a solution of NH4Cl (33.9 g, 633.7 mmol) in H2O (100 mL) followed by the addition of 
25% aq NH4OH (10 mL). The mixture was stirred at room temperature for 20 h. Extracted the 
mixture with ethyl acetate (10 × 30 mL), the combined organic phases were dried over Na2SO4. 
Removal of the volatiles under reduced pressure gave compound 34 as brown oil (9.3 g, 67%). 
Rf = 0.3 (CH2Cl2/MeOH 10:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 2.09 (brs, 2H), 4.91 (s, 
1H), 7.24-7.34 (m, 1H), 7.78-7.87 (m, 1H), 8.54 (dd, J 4.8, 1.5 Hz, 1H), 8.65-8.77 (m, 1H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 45.2, 120.2, 123.8, 132.2, 134.5, 148.3, 150.3. HRMS (ESI): 
m/z [M+H]+ calcd. for [C7H8N3]+ 134.0713, found: 134.0713. C7H7N3 (133.15). 
 
3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole (35)47  
To a cooled (5-10 °C) solution of S2Cl2 (10.8 mL, 137.2 mmol) in DMF (50 mL) was added a 
solution of compound 34 (9.1 g, 68.34 mmol) in DMF (65 mL) over a period of 1 h. The mixture 
was stirred at 5-10 oC for additional 45 min and ice water (30 mL) was added. The formed 
precipitate was removed by filtration. To the filtrate was added 20% NaOH solution to adjust a 
pH of 8, thereby keeping the temperature below 20 oC. Extracted the mixture with ethyl acetate 
(3 × 20 mL). The combined organic phases were dried over Na2SO4 and the volatiles were 
removed under reduced pressure to give the crude product, which was subjected to flash 
column chromatography (eluent: light petroleum/ethyl acetate 3:2 v/v) to afford compound 35 
as a white solid (9.4 g, 69%), m.p. 40-42 oC (Lit47. m.p. 48-49 oC). Rf = 0.7 (light 
petroleum/acetone 1:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 7.41-7.46 (m, 1H), 8.24-8.28 
(m, 1H), 8.72 (dd, J 4.9, 1.6 Hz, 1H), 9.20 (dd, J 2.2, 0.6 Hz, 1H). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 123.4, 126.9, 135.7, 143.6, 149.4, 150.9, 155.2. HRMS (ESI): m/z [M+H]+ calcd. for 
[C7H5ClN3S]+ 197.9887, found: 197.9893. C7H4ClN3S (197.64). 
 
3-((4-(Pyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)propan-1-ol (37)50 
A suspension of 60% NaH in mineral oil (363 mg, 9.47 mmol) was added to abs. THF (10 mL) 
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under an atmosphere of argon. The mixture was cooled to 0 °C and propane-1,3-diol 
(compound 36) (460 mg, 6.04 mmol) was added under stirring. The mixture was then kept 
under reflux for 1 h. A solution of compound 35 (600 mg, 3.03 mmol) in abs. THF (10 mL) was 
added and reflux was continued for 8 h. The solvent was removed under reduced pressure 
and ice-cold water was added dropwise to the residue. Extracted the mixture with ethyl acetate 
(3 × 20 mL). The combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure to give the crude product, which was subjected to flash column 
chromatography (eluent: light petroleum/acetone 2:1 v/v) to afford compound 37 as yellow oil 
(370 mg, 52%). Rf = 0.3 (light petroleum/acetone 2:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 
2.08-2.20 (m, 2H), 2.19 (brs, 1H), 3.87 (t, J 6.0 Hz, 2H), 4.69 (t, J 6.1 Hz, 2H), 7.36-7.40 (m, 
1H), 8.30-8.54 (m, 1H), 8.62 (dd, J 4.8, 1.6 Hz, 1H), 9.36 (dd, J 2.1, 0.7 Hz, 1H). 13C-NMR (75 
MHz, CDCl3): δ (ppm) 31.9, 59.0, 68.2, 123.6, 127.7, 134.9, 144.8, 148.4, 149.9, 162.7. HRMS 
(ESI): m/z [M+H]+ calcd. for [C10H12N3O2S]+ 238.0645, found: 238.0651. C10H11N3O2S (237.28). 
 
3-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)propan-1-ol 
(38)50  
To a solution of compound 37 (370 mg, 1.56 mmol) in acetone (5 mL) was added methyliodide 
(0.97 mL, 15.6 mmol) and the mixture was stirred at room temperature for 24 h. The formed 
precipitate was collected by filtration and washed with acetone (5 mL). Drying in vacuo gave 
the N-methylated, but non-reduced intermediate as yellow solid (480 mg, 81%). Rf = 0.1 
(CH2Cl2/MeOH 10:1 v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.99-2.06 (m, 2H), 3.59-
3.65 (m, 2H), 4.45 (s, 3H), 4.62 (t, J 6.3 Hz, 2H), 8.28 (dd, J 8.2, 6.2 Hz, 1H), 9.07 (dd, J 12, 
7.3 Hz, 2H), 9.54 (s, 1H). The intermediate (470 mg, 1.24 mmol) was dissolved in MeOH (10 
mL). The solution was cooled to -5 °C and NaBH4 (143 mg, 3.76 mmol) was added carefully. 
The mixture was stirred at room temperature overnight. The solvent was removed under 
reduced pressure. The residue was dissolved in CH2Cl2 (10 mL) followed by washing with 
water. The aqueous phase was treated with CH2Cl2 (3 × 10 mL) and the organic extracts were 
collected. All organic phases were combined and dried over Na2SO4. Removal of the volatiles 
reduced pressure gave the crude product, which was subjected to flash column 
chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v) to afford compound 38 as 
brown oil (130 mg, 41%). Rf = 0.3 (CH2Cl2/MeOH/25% aq NH3 85:15:1 v/v/v). 1H-NMR (300 
MHz, CDCl3): δ (ppm) 2.03-2.11 (m, 2H), 2.38-2.51 (m, 5H), 2.56 (brs, 1H), 2.59 (t, J 5.6 Hz, 
2H), 3.40-3.54 (m, 2H), 3.78 (t, J 6.1 Hz, 2H), 4.59 (t, J 6.1 Hz, 2H), 6.87-7.13 (m, 1H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 26.5, 32.0, 45.9, 51.2, 54.9, 59.3, 67.9, 128.4, 129.2, 146.7, 
162.5. HRMS (ESI): m/z [M+H]+ calcd. for [C11H18N3O2S]+ 256.1114, found: 256.1115. 
C11H17N3O2S (255.34). 
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3-(3-Bromopropoxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole (39)50 
Compound 38 (400 mg, 1.57 mmol) and PPh3 (1.2 g, 4.57 mmol) were dissolved in CH2Cl2 
(30 mL) and the solution was cooled to -5 oC under an atmosphere of argon. A solution of CBr4 
(3.4 g, 10.25 mmol) in CH2Cl2 (20 mL) was slowly dropped into the stirred mixture, thereby 
keeping the temperature of the mixture below 5 oC. After completed addition, stirring was 
continued at room temperature for 24 h. The solvent was removed under reduced pressure to 
give a brown residue, and subjected to flash column chromatography (eluent: light 
petroleum/acetone/25% aq NH3 85:15:1 v/v/v) to afford compound 39 as a brown oil (300 mg, 
50%). Rf = 0.6 (light petroleum/acetone/25% aq NH3 65:35:1 v/v/v). 1H-NMR (300 MHz, CDCl3): 
δ (ppm) 2.26-2.36 (m, 2H), 2.41-2.49 (m, 5H), 2.58 (t, J 5.8 Hz, 2H), 3.45 (dd, J 4.4, 2.5 Hz, 
2H), 3.71 (t, J 6.4 Hz, 2H), 4.61 (t, J 6.0, 2H), 6.91-7.08 (m, 1H). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 26.5, 29.4, 31.8, 45.8, 51.1, 54.9, 68.4, 128.4, 129.1, 146.7, 161.9. HRMS (ESI): m/z 
[M+H]+ calcd. for [C11H17BrN3OS]+ 318.0270, found: 318.0271. C11H16BrN3OS (318.23). 
 
3-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-4-(3-(piperazin-1-yl)propoxy)-1,2,5 
thiadiazole (40) 
Compound 39 (600 mg, 1.89 mmol) and piperazine (1.3 g, 15.09 mmol) were suspended in 
MeCN (12 mL) followed by the addition of potassium carbonate (523 mg, 3.78 mmol). The 
mixture was refluxed for 2 h. Insoluble material was separated by filtration and washed with 
CH2Cl2 (2 × 10 mL). The filtrate and washings were combined and the volatiles were 
evaporated to yield a brown oil-like residue, which was dissolved in CH2Cl2 (20 mL) followed 
by washing with brine. The aqueous phase was treated with CH2Cl2 (3 × 10 mL) and the 
organic extracts were collected. All organic phases were combined and dried over Na2SO4. 
The solvent was removed under reduced pressure to yield the crude product, which was 
subjected to column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 90:6:1 v/v/v) to 
obtain compound 40 as yellow oil (405 mg, 66%). Rf = 0.4 (CH2Cl2/MeOH/25% aq NH3 90:9:1 
v/v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.92-2.13 (m, 2H), 2.30-2.43 (m, 4H), 2.44 (s, 
3H), 2.45-2.52 (m, 4H), 2.55 (t, J 5.7 Hz, 2H), 2.90 (t, J 4.7 Hz, 4H), 3.43 (s, 2H), 4.49 (t, J 6.4 
Hz, 2H), 7.02-7.04 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 26.2, 26.6, 45.90, 45.92, 
51.2, 54.3, 55.0, 55.7, 69.2, 128.3, 129.3, 146.8, 162.4. HRMS (ESI): m/z [M+H]+ calcd. for 
[C15H26N5OS]+ 324.1853, found: 324.1854. C15H25N5OS (323.46).  
 
1-Methyl-4-(3-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)propyl)-1,4-diazepan-6-amine tetrakis(hydrotrifluoroacetate) (41) 
Compound 39 (490 mg, 1.52 mmol) and compound 28 (354 mg, 1.54 mmol) were suspended 
in MeCN (20 mL) followed by the addition of potassium carbonate (427 mg, 3.09 mmol). The 
mixture was stirred at 110 oC under microwave irradiation for 30 min. Solids were separated 
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by filtration and washed with CH2Cl2 (2 × 10 mL). The combined filtrate and washings were 
concentrated under reduced pressure yielding a yellow oily residue, which was dissolved in 
CH2Cl2 (10 mL) followed by washing with brine. The aqueous phase was treated with CH2Cl2 
(3 × 10 mL) and the organic extracts were collected. All organic phases were combined and 
dried over Na2SO4. Removal of the volatiles under reduced pressure yielded the Boc-protected 
intermediate as yellow oily residue, which was dissolved in CH2Cl2/TFA (4:1 v/v) (5 mL). The 
mixture was stirred at room temperature overnight. CH2Cl2 (10 mL) was added, the volatiles 
were evaporated and the residue was subjected to purification by preparative HPLC (column: 
Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-62:38, tR = 
11 min), which afforded compound 41 as white ﬂuffy solid (830 mg, 66%). 1H-NMR (400 MHz, 
[D4]MeOH): δ (ppm) 2.09-2.16 (m, 2H), 2.66-2.86 (m, 2H), 2.93 (t, J 7.3 Hz, 2H), 2.97 (s, 3H), 
2.96-3.02 (m, 1H), 3.05 (s, 3H), 3.09-3.14 (m, 1H), 3.15-3.29 (m, 2H), 3.32-3.39 (m, 1H), 3.47 
(t, J 5.5 Hz, 2H), 3.52-3.68 (m, 3H), 3.83-3.93 (m, 1H), 4.00-4.05 (m, 1H), 4.49-4.54 (m, 1H), 
4.57 (t, J 6.4 Hz, 2H), 7.22 (t, J 4.1 Hz, 1H). 13C-NMR (100 MHz, [D4]MeOH): δ (ppm) 23.8, 
27.1, 43.3, 46.5, 48.7, 50.9, 51.7, 53.1, 55.3, 56.2, 57.8, 58.8, 70.2, 114.6 (TFA), 116.3 (TFA), 
117.4 (TFA), 119.3 (TFA), 125.3, 128.3, 145.6, 162.1 (TFA), 162.4 (TFA), 163.8 (TFA), 163.1 
(TFA), 163.6. RP-HPLC (220 nm): 97% (tR = 10.7 min, k = 2.7). HRMS (ESI): m/z [M+H]+ calcd. 
for [C17H31N6OS]+ 367.2275, found: 367.2273. C17H30N6OS · C8H4F12O8 (366.53 + 456.09). 
 
5-((4-(Pyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)pentan-1-ol (43) 
A suspension of 60% NaH in mineral oil (908 mg, 23.69 mmol) was added to abs. THF (40 
mL) under an atmosphere of argon. The suspension was cooled to 0 °C, 1,5-pentanediol 
(compound 42) (2.0 g, 19.20 mmol) was added under stirring, and the mixture was refluxed 
for 1 h. A solution of compound 35 (1.5 g, 7.58 mmol) in abs. THF (10 mL) was added and 
reflux was continued for 8 h. The solvent was removed under reduced pressure and ice-cold 
water was added dropwise to the residue. Extracted the mixture with ethyl acetate (3 × 30 mL), 
the combined organic phases were dried over Na2SO4 and concentrated under reduced 
pressure to give the crude product, which was subjected to flash column chromatography 
(eluent: light petroleum/acetone 2:1 v/v) to afford compound 43 as colorless oil (960 mg, 48%). 
Rf = 0.3 (light petroleum/acetone 2:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.50-1.76 (m, 
4H), 1.86 (brs, 1H), 1.89-1.98 (m, 2H), 3.69 (t, J 6.2 Hz, 2H), 4.54 (t, J 6.5 Hz, 2H), 7.40 (dd, 
J 8.0, 4.9 Hz, 1H), 8.42 (d, J 8.0 Hz, 1H), 8.64 (d, J 4.8 Hz, 1H), 9.40 (s, 1H). 13C-NMR (75 
MHz, CDCl3): δ (ppm) 21.6, 28.2, 32.6, 62.2, 71.4, 123.4, 127.4, 134.7, 144.5, 147.9, 150.4, 
162.7. HRMS (ESI): m/z [M+H]+ calcd. for [C12H16N3O2S]+ 266.0958, found: 266.0966. 
C12H15N3O2S (265.33). 
 
5-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)pentan-1-ol (44) 
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To a solution of compound 43 (0.96 g, 3.62 mmol) in acetone (15 mL) was added methyliodide 
(2.3 mL, 36.2 mmol) and the mixture was stirred at room temperature for 24 h. The formed 
precipitate was collected by filtration, washed with acetone and dried under vacuum to yield 
the N-methylated, but non-reduced intermediate as yellow solid (1.4 g, 95%). Rf = 0.1 
(CH2Cl2/MeOH 6:1 v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.51-1.73 (m, 4H), 1.87-2.07 
(m, 2H), 3.60 (t, J 5.9 Hz, 2H), 4.52 (s, 3H), 4.65 (t, J 6.5 Hz, 2H), 8.22 (dd, J 8.1, 6.2 Hz, 1H), 
8.96 (d, J 6.1 Hz, 1H), 9.24 (d, J 8.3 Hz, 1H), 9.57 (s, 1H). The intermediate (1.4 g, 3.44 mmol) 
was dissolved in MeOH (20 mL) and the solution was cooled to -5 °C. NaBH4 (519 mg, 13.66 
mmol) was added carefully. The mixture was stirred at room temperature overnight. The 
solvent was removed under reduced pressure. The residue was dissolved in CH2Cl2 (20 mL) 
followed by washing with water. The aqueous phase was treated with CH2Cl2 (3 × 20 mL) and 
the organic extracts were collected. All organic phases were combined and dried over Na2SO4. 
Removal of the volatiles under reduced pressure gave the crude product, which was subjected 
to flash column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 97:3:1 v/v/v) to afford 
compound 44 as brown oil (900 mg, 92%). Rf = 0.3 (CH2Cl2/MeOH/25% aq NH3 85:15:1 v/v/v). 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.47-1.59 (m, 2H), 1.59-1.69 (m, 2H), 1.78-1.98 (m, 2H), 
2.39- 2.49 (m, 5H), 2.57 (t, J 5.6 Hz, 2H), 3.44 (dd, J 4.4, 2.4 Hz, 2H), 3.66 (t, J 6.3 Hz, 2H), 
4.44 (t, J 6.6 Hz, 2H), 7.00-7.09 (m, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 22.3, 26.6, 28.6, 
32.3, 45.9, 51.2, 54.9, 62.6, 70.8, 128.4, 129.2, 146.8, 162.5. HRMS (ESI): m/z [M+H]+ calcd. 
for [C13H22N3O2S]+ 284.1427, found: 284.1430. C13H21N3O2S (283.39). 
 
3-((5-Bromopentyl)oxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole (45) 
Compound 44 (850 mg, 3.0 mmol) and PPh3 (2.4 g, 9.15 mmol) were dissolved in CH2Cl2 (30 
mL) and the solution was cooled to -5 oC under an atmosphere of argon. A solution of CBr4 
(6.5 g, 19.59 mmol) in CH2Cl2 (15 mL) was slowly dropped into the stirred mixture, thereby 
keeping the temperature of the mixture below 5 oC. Stirring was continued at room temperature 
for 24 h. The solvent was removed under reduced pressure and the residue subjected to 
column chromatography (eluent: light petroleum/acetone/25% aq NH3 65:35:1 v/v/v) to afford 
compound 45 as brown oil (740 mg, 71%). Rf = 0.4 (light petroleum/acetone/25% aq NH3 
65:35:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.56-1.71 (m, 2H), 1.81-2.01 (m, 4H), 2.39-
2.50 (m, 5H), 2.57 (t, J 5.5 Hz, 2H), 3.36-3.52 (m, 4H), 4.46 (t, J 6.4 Hz, 2H), 6.97-7.13 (m, 
1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 24.7, 26.7, 28.0, 32.2, 33.5, 45.9, 51.2, 55.0, 70.4, 
128.5, 129.3, 146.8, 162.3. HRMS (ESI): m/z [M+H]+ calcd. for [C13H21BrN3OS]+ 346.0583, 
found: 346.0585. C13H20BrN3OS (346.29). 
 
1,4-Bis(5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)piperazine (46) 
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Compound 45 (730 mg, 2.11 mmol), potassium carbonate (193 mg, 1.39 mmol), and 
piperazine (60 mg, 0.70 mmol) were added to MeCN (5 mL). The mixture was stirred at 110 
oC under microwave irradiation for 30 min, and cooled to room temperature. Insoluble material 
was removed by filtration and the filtrate was concentrated under reduced pressure to give the 
crude product, which was dissolved in CH2Cl2 (10 mL) followed by washing with H2O (3 x 10 
mL). The organic phase was dried over Na2SO4 and the solvent was removed under reduced 
pressure. The product was purified by flash column chromatography (eluent: CH2Cl2/MeOH/25% 
aq NH3 97:3:1 v/v/v) to afford compound 46 as white solid (96 mg, 22%), m.p. 41-42 oC. Rf = 
0.7 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.31-1.61 
(m, 8H), 1.71-1.90 (m, 4H), 2.26-2.33 (m, 5H), 2.34-2.38 (m, 4H), 2.39 (s, 6H), 2.41-2.52 (m, 
11H), 3.38 (dd, J 4.3, 2.4 Hz, 4H), 4.38 (t, J 6.5 Hz, 4H), 6.85-7.15 (m, 2H). 13C-NMR (75 MHz, 
CDCl3): δ (ppm) 24.0, 26.5, 26.6, 28.8, 45.9, 51.1, 53.1, 55.0, 58.5, 70.7, 128.3, 129.3, 146.8, 
162.5. RP-HPLC (220 nm): 97% (tR = 13.9 min, k = 3.8). HRMS (ESI): m/z [M+H]+ calcd. for 
[C30H49N8O2S2]+ 617.3414, found: 617.3407. C30H48N8O2S2 (616.89). 
 
tert-Butyl (5-((4-(pyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)pentyl)carbamate (48) 
To a cooled (0 °C) solution of 5-amino-1-pentanol (1.0 g, 9.67 mmol) and triethylamine (1.2 
mL, 8.89 mmol) in CH2Cl2 (50 mL) was slowly added di-tert-butyl dicarbonate (1.9 g, 8.71 
mmol) in CH2Cl2 (20 mL). The mixture was stirred at 0 oC for 30 min and stirring was continued 
at room temperature for additional 12 h. Saturated aq NH4Cl (20 mL) was added followed by 
extraction with CH2Cl2 (3 x 20 mL). The combined organic extracts was washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to give the intermediate tert-
butyl (5-hydroxypentyl)carbamate (compound 47)66 as colorless oil (1.9 g, 97%) without 
purification. Rf = 0.5 (light petroleum/acetone 2:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 
1.42 (s, 9H), 1.46-1.61 (m, 6H), 1.63 (brs, 1H), 3.12 (t, J 6.9 Hz, 2H), 3.64 (t, J 6.4 Hz, 2H), 
4.53 (brs, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 22.9, 28.4, 29.8, 32.2, 40.4, 62.5, 79.2, 
156.0. HRMS (ESI): m/z [M+H]+ calcd. for [C10H22NO3]+ 204.1594, found: 204.1595. To a 
stirred and cooled (0 °C) solution of compound 47 (307 mg, 1.51 mmol) in abs. THF (5 mL) 
was added the suspension of 60% NaH in mineral oil (73 mg, 1.90 mmol) in portions under an 
atmosphere of argon, followed by the addition of 35 (200 mg, 1.01 mmol) dissolved in abs. 
THF (2 mL). The mixture was stirred at 0 oC for 5 min and slowly warmed up until reflux. Reflux 
was continued for 2 h. The solvent was removed under reduced pressure and ice-cold water 
was added dropwise to the residue. Extracted the mixture with ethyl acetate (3 × 5 mL), the 
combined organic phases were dried over Na2SO4 and concentrated under reduced pressure 
to give the crude product, which was subjected to flash column chromatography (eluent: light 
petroleum/acetone 5:1 v/v) to afford compound 48 as colorless oil (100 mg, 27%). Rf = 0.4 
(light petroleum/acetone 2:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.43 (s, 9H), 1.47-1.67 
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(m, 4H), 1.82-1.99 (m, 2H), 3.12-3.18 (m, 2H), 4.52 (t, J 6.5 Hz, 2H), 4.70 (brs, 1H), 7.33-7.51 
(m, 1H), 8.33-8.51 (m, 1H), 8.65 (dd, J 4.8, 1.5 Hz, 1H), 9.39 (d, J 1.6 Hz, 1H). 13C-NMR (75 
MHz, CDCl3): δ (ppm) 23.3, 28.4, 28.6, 29.8, 40.4, 71.1, 79.1, 123.5, 127.6, 134.7, 144.9, 
148.5, 150.1, 156.0, 162.7. HRMS (ESI): m/z [M+H]+ calcd. for [C17H25N4O3S]+ 365.1642, 
found: 365.1644. C17H24N4O3S (364.46). 
 
tert-Butyl (5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)carbamate (49)  
To a solution of compound 48 (3.3 g, 9.05 mmol) in acetone (10 mL) was added methyliodide 
(5.7 mL, 91.2 mmol) and the mixture was stirred at room temperature for 24 h. The formed 
precipitated was collected, washed with acetone and dried under vacuum to afford the N-
methylated, but non-reduced intermediate as yellow solid (3.3 g, 96%). Rf = 0.1 (CH2Cl2/MeOH 
6:1 v/v). This intermediate (3.0 g, 7.91 mmol) was dissolved in MeOH (50 mL) and the solution 
was cooled to -5 °C followed by the careful addition of NaBH4 (2.1 g, 55.26 mmol). The mixture 
was stirred at room temperature overnight. The solvent was removed under reduced pressure. 
The residue was dissolved in CH2Cl2 (20 mL) followed by washing with brine. The aqueous 
phase was treated with CH2Cl2 (3 × 20 mL) and the organic extracts were collected. All organic 
phases were combined and dried over Na2SO4. Removal of the solvent under reduced 
pressure gave the crude product, which was subjected to flash column chromatography 
(eluent: CH2Cl2/MeOH/25% aq NH3 97:3:1 v/v/v) to afford compound 49 as brown oil (2.4 g, 
79%). Rf = 0.7 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 
1.37 (s, 9H), 1.38-1.62 (m, 4H), 1.76-1.94 (m, 2H), 2.49 (s, 3H), 2.41-2.52 (m, 2H), 2.60 (t, J 
5.6 Hz, 2H), 3.14 (dd, J 13, 6.3 Hz, 2H), 3.46-3.48 (m, 2H), 4.44 (t, J 6.6 Hz, 2H), 4.57 (brs, 
1H), 7.00-7.08 (m, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.3, 26.4, 28.4, 28.5, 29.8, 40.4, 
45.8, 51.2, 54.8, 70.7, 79.1, 128.3, 129.0, 146.6, 156.0, 162.4. HRMS (ESI): m/z [M+H]+ calcd. 
for [C18H31N4O3S]+ 383.2111, found: 383.2103. C18H30N4O3S (382.52). 
 
5-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)pentan-1-amine 
(50) 
Compound 49 (50 mg, 0.13 mmol) was dissolved in CH2Cl2 (4 mL) and TFA (1 mL) was added. 
The mixture was stirred at room temperature overnight and cooled to 0 °C followed by the 
addition of 25% aq NH3 to adjust the pH to 10. The product was extracted with CH2Cl2 (5 × 5 
mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced 
pressure to afford compound 50 as colorless oil (20 mg, 56%), which was used without further 
purification. Rf = 0.3 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ 
(ppm) 1.34-1.55 (m, 4H), 1.73-1.87 (m, 4H), 2.32-2.43 (m, 5H), 2.50 (t, J 5.5 Hz, 2H), 2.66 (t, 
J 6.7 Hz, 2H), 3.36-3.38 (m, 2H), 4.38 (t, J 6.6 Hz, 2H), 6.92-7.05 (m, 1H). 13C-NMR (75 MHz, 
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CDCl3): δ (ppm) 23.3, 26.6, 28.7, 33.1, 41.9, 45.9, 51.2, 55.0, 70.7, 128.4, 129.3, 146.7, 162.3. 
HRMS (ESI): m/z [M+H]+ calcd. for [C13H23N4OS]+ 283.1587, found: 283.1586. C13H22N4OS 
(282.41). 
 
4-Amino-N-(5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)butanamide (52) 
4-aminobutanoic acid (200 mg, 1.93 mmol) was dissolved in H2O/THF (1:1 v/v) (10 mL) and 
di-tert-butyl dicarbonate (507 mg, 2.32 mmol) was slowly added followed by the addition of 
triethylamine (810 μL, 5.82 mmol). The mixture was stirred at room temperature overnight. 
THF was removed under reduced pressure and 0.1 M aq KHSO4 solution was slowly added 
to adjust the pH to 3. The product was extracted with ethyl acetate (3 × 10 mL), the combined 
extracts were dried over Na2SO4 and concentrated under reduced pressure to yield the 
intermediate 4-((tert-butoxycarbonyl)amino)butanoic acid (compound 51) as colorless oil (270 
mg, 69%), which was used without further purification. Rf = 0.8 (CH2Cl2/MeOH/acetic acid 
90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.43 (s, 9H), 1.75-1.86 (m, 2H), 2.38 (t, J 
7.2 Hz, 2H), 3.16 (t, J 6.7 Hz, 2H), 4.75 (brs, 1H), 10.06 (brs, 1H). 13C-NMR (75 MHz, CDCl3): 
δ (ppm) 25.1, 28.4, 31.3, 39.8, 60.5, 171.4, 178.4. HRMS (ESI): m/z [M+H]+ calcd. for 
[C9H16NO4]+ 202.1085, found: 202.1090. To a solution of the intermediate 51 (51 mg, 0.25 
mmol) in DMF (1 mL) were added HOBt (34 mg, 0.25 mmol), TBTU (80 mg, 0.25 mmol) and 
DIPEA (86 μL, 0.49 mmol) and the mixture was stirred at room temperature for 30 min. 
Compound 50 (70 mg, 0.25 mmol) dissolved in DMF (1 mL) was added and the mixture was 
stirred at 60 oC for 3 h. H2O (5 mL) was added, followed by extraction with ethyl acetate (3 × 
5 mL). The combined extracts were dried over Na2SO4 and concentrated under reduced 
pressure to yield the crude product, which was subjected to flash column chromatography 
(eluent: CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to yield the intermediate tert-butyl (4-((5-((4-
(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)pentyl)amino)-4-
oxobutyl)carbamate as yellow oil (80 mg, 67%). Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 
v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.42 (s, 9H), 1.46-1.57 (m, 4H), 1.73-1.80 (m, 2H), 
1.82-1.91 (m, 2H), 2.19 (t, J 6.9 Hz, 2H), 2.49-2.55 (m, 5H), 2.63-2.81 (m, 2H), 3.12-3.18 (m, 
2H), 3.23-3.29 (m, 2H), 3.51-3.73 (m, 2H), 4.45 (t, J 6.4 Hz, 2H), 4.90 (brs, 1H), 6.37 (brs, 1H), 
7.07-7.09 (m, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.4, 26.4, 26.6, 28.4, 28.5, 29.2, 33.6, 
39.3, 39.6, 45.8, 51.1, 54.8, 70.7, 79.3, 128.3, 129.0, 146.6, 156.7, 162.4, 172.7. HRMS (ESI): 
m/z [M+H]+ calcd. for [C22H38N5O4S]+ 468.2639, found: 468.2650. This intermediate (80 mg, 
0.17 mmol) was dissolved in CH2Cl2/TFA (4:1 v/v) (5 mL) and the mixture was stirred at room 
temperature overnight. CH2Cl2 (5 mL) was added followed by the addition of 25% aq NH3 to 
adjust the pH of the aqueous phase to 11. The product was extracted with CH2Cl2 (5 × 10 mL). 
The combined organic phases were dried over Na2SO4 and concentrated under reduced 
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pressure to give compound 52 as yellow oil (55 mg, 89%), which was used without further 
purification. Rf = 0.4 (CH2Cl2/MeOH/25% aq NH3 80:16:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ 
(ppm) 1.38-1.64 (m, 4H), 1.70-1.92 (m, 4H), 1.96 (brs, 2H), 2.22-2.28 (m, 2H), 2.35-2.48 (m, 
5H), 2.52-2.56 (m, 2H), 3.00-3.37 (m, 4H), 3.39-3.42 (m, 2H), 4.41 (t, J 6.5 Hz, 2H), 6.88-7.13 
(m, 1H), 8.56 (brs, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.5, 26.6, 28.5, 29.3, 31.0, 34.1, 
39.3, 41.1, 45.9, 51.2, 55.0, 70.6, 128.4, 129.3, 146.8, 162.4, 172.8. HRMS (ESI): m/z [M+H]+ 
calcd. for [C17H30N5O2S]+ 368.2115, found: 368.2116. C17H29N5O2S (367.51) 
 
N1,N8-Bis(5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl) 
oxy)pentyl)octanediamide (53)  
To a cooled (0 °C) solution of compound 50 (300 mg, 1.06 mmol) and triethylamine (322 mg, 
3.18 mmol) in abs. THF (2 mL) was added dropwise octanedioyl dichloride (76 μL, 0.43 mmol) 
dissolved in abs. THF (1 mL) under an atmosphere of argon. The mixture was stirred at room 
temperature overnight. The solvent was evaporated. The residue was dissolved in ethyl 
acetate (5 mL) followed by washing with water. The aqueous phase was treated with ethyl 
acetate (3 × 10 mL) and the organic extracts were collected. All organic phases were combined 
and dried over Na2SO4. Removal of the solvent under reduced pressure gave the crude 
product, which was subjected to flash column chromatography (eluent: CH2Cl2/MeOH/25% aq 
NH3 97:3:1 v/v/v) to afford compound 53 as white solid (118 mg, 39%), m.p. 55-57 oC. Rf = 0.6 
(CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.26-1.37 (m, 
4H), 1.48-1.65 (m, 10H), 1.78-1.96 (m, 6H), 2.14 (t, J 7.5 Hz, 4H), 2.40-2.50 (m, 10H), 2.57-
2.61 (m, 4H), 3.23-3.29 (m, 4H), 3.42-3.49 (m, 4H), 4.44 (t, J 6.5 Hz, 4H), 5.58 (brs, 2H), 7.02-
7.05 (m, 2H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.4, 25.8, 26.6, 28.5, 28.7, 29.4, 36.6, 39.3, 
45.9, 51.2, 55.0, 70.6, 128.4, 129.3, 146.8, 162.4, 173.0. RP-HPLC (220 nm): 96% (tR = 18.1 
min, k = 5.3). HRMS (ESI): m/z [M+H]+ calcd. for [C34H55N8O4S2]+ 703.3782, found: 703.3786. 
C34H54N8O4S2 (702.98). 
 
N1,N10-Bis(5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)decanediamide (54) 
To a cooled (0 °C) solution of compound 50 (400 mg, 1.42 mmol) and triethylamine (430 mg, 
4.25 mmol) in abs. THF (5 mL) was added dropwise decanedioyl dichloride (92 μL, 0.57 mmol) 
dissolved in abs. THF (1 mL) under an atmosphere of argon. The mixture was stirred at room 
temperature overnight. The solvent was evaporated. The residue was dissolved in ethyl 
acetate (5 mL) followed by washing with brine. The aqueous phase was treated with ethyl 
acetate (3 × 10 mL) and the organic extracts were collected. All organic phases were combined 
and dried over Na2SO4. Removal of the solvent under reduced pressure gave the crude 
product, which was subjected to flash column chromatography (eluent: CH2Cl2/MeOH/25% aq 
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NH3 97:3:1 v/v/v) to afford compound 54 as white solid (270 mg, 65%), m.p. 45-49 oC. Rf = 0.5 
(CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.25-1.33 (m, 
8H), 1.41-1.63 (m, 10H), 1.81-1.94 (m, 4H), 2.06 -2.23 (m, 4H), 2.12-2.17 (m, 4H), 2.46-2.53 
(m, 8H), 2.63-2.67 (m, 4H), 3.27 (dd, J 13, 6.8 Hz, 4H), 3.49-3.54 (m, 4H), 4.44 (t, J 6.5 Hz, 
4H), 5.54 (brs, 2H), 7.03-7.07 (m, 2H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.4, 25.7, 26.6, 
28.5, 29.1, 29.2, 29.4, 36.8, 39.3, 45.9, 51.2, 55.0, 70.6, 128.4, 129.3, 146.8, 162.4, 173.1. 
RP-HPLC (220 nm): 98% (tR = 19.5 min, k = 5.8). HRMS (ESI): m/z [M+H]+ calcd. for 
[C36H59N8O4S2]+ 731.4095, found: 731.4097. C36H58N8O4S2 (731.0320). 
 
N1,N4-Bis(5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)terephthalamide (55) 
To a solution of terephthalic acid (117 mg, 0.71 mmol) in DMF (3 mL) were added EDC (271 
mg, 1.41 mmol), HOBt (216 mg, 1.41 mmol) and DIPEA (183 mg, 1.42 mmol) and the mixture 
was stirred at room temperature for 30 min. Compound 50 (400 mg, 1.42 mmol) in DMF (2 
mL) was added and stirring was continued at room temperature overnight. H2O (10 mL) was 
added followed by extraction with ethyl acetate (3 × 10 mL). The combined extracts were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give the 
crude product, which was subjected to flash column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 95:5:1 v/v/v) to afford compound 55 as white solid (130 mg, 26%), 
m.p. 50-53 oC. Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 95:5:1 v/v/v). 1H-NMR (300 MHz, CDCl3): 
δ (ppm) 1.52-1.61 (m, 4H), 1.67-1.78 (m, 4H), 1.83-1.96 (m, 4H), 2.42-2.52 (m, 4H), 2.62 (s, 
6H), 2.78 (t, J 5.8 Hz, 4H), 3.46-3.54 (m, 4H), 3.65-3.70 (m, 4H), 4.47 (t, J 6.2 Hz, 4H), 6.94 
(brs, 2H), 7.01-7.09 (m, 2H), 7.85 (s, 4H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 23.6, 25.0, 28.5, 
29.3, 39.9, 44.9, 50.7, 53.8, 70.9, 127.0, 127.3, 127.8, 137.2, 145.7, 162.4, 166.9. RP-HPLC 
(220 nm): 96% (tR = 18.3 min, k = 5.4). HRMS (ESI): m/z [M+H]+ calcd. for [C34H47N8O4S2]+ 
695.3156, found: 695.3158. C34H46N8O4S2 (694.91). 
 
Ethyl 4-((2-nitrophenyl)amino)piperidine-1-carboxylate (58)67 
Ethyl 4-aminopiperidine-1-carboxylate (compound 57) (244 mg, 1.42 mmol) and potassium 
carbonate (587 mg, 4.25 mmol) were added to a stirred solution of 1-fluoro-2-nitrobenzene 
(compound 56) (200 mg, 1.42 mmol) in DMF (1.5 mL) followed by the addition of sodium iodide 
(106 mg, 0.71 mmol). The mixture was stirred at 180 oC under microwave irradiation for 10 
min, cooled to room temperature and diluted with water (50 mL). The product was extracted 
with ethyl acetate (3 × 10 mL). The combined extracts were washed with brine and dried over 
Na2SO4. Removal of the volatiles under reduced pressure gave compound 58 as yellow solid 
(300 mg, 72%), which was used without further purification. Rf = 0.2 (light petroleum/ethyl 
acetate 5:1 v/v), m.p. 80-82 oC. 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.28 (t, J 7.1 Hz, 3H), 
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1.51-1.63 (m, 2H), 1.70 (brs, 1H), 2.05-2.11 (m, 2H), 3.04-3.20 (m, 2H), 3.66-3.74 (m, 1H), 
4.05-4.19 (m, 4H), 6.63-6.68 (m, 1H), 6.87 (d, J 8.4 Hz, 1H), 7.37-7.50 (m, 1H), 8.19 (dd, J 
8.6, 1.6 Hz, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 14.7, 31.7, 42.2, 49.1, 61.6, 113.9, 115.5, 
127.3, 132.0, 136.3, 144.3, 155.5. HRMS (ESI): m/z [M+H]+ calcd. for [C14H20N3O4]+ 294.1448, 
found: 294.1453. C14H19N3O4 (293.32). 
 
Ethyl 4-((2-aminophenyl)amino)piperidine-1-carboxylate (59) 
A mixture of compound 58 (200 mg, 0.68 mmol), 10% Pd/C (20 mg) and MeOH (10 mL) was 
stirred in an autoclave (1 L) under an atmosphere of hydrogen at 10 atm at room temperature 
overnight. The catalyst was removed by filtation through a pad of celite, which was washed 
with MeOH (2 × 5 mL). The combined filtrates were concentrated under reduced pressure to 
give compound 59 as purple solid (160 mg, 89%), which was used without further purification. 
Rf = 0.4 (light petroleum/acetone = 4:1), m.p. 138-140 oC. 1H-NMR (300 MHz, CDCl3): δ (ppm) 
1.27 (t, J 7.1 Hz, 3H), 1.35-1.48 (m, 2H), 1.98-2.12 (m, 2H), 2.90-3.09 (m, 3H), 3.20 (brs, 1H), 
3.34-3.51 (m, 2H), 4.07 (brs, 2H), 4.15 (q, J 12 Hz, 2H), 6.64-6.89 (m, 4H). 13C-NMR (75 MHz, 
CDCl3): δ (ppm) 14.7, 32.3, 42.6, 50.3, 61.4, 113.9, 117.1, 119.6, 120.6, 135.2, 135.3, 155.6. 
HRMS (ESI): m/z [M+H]+ calcd. for [C14H22N3O2]+ 264.1707, found: 264.1718. C14H21N3O2 
(263.34). 
 
Ethyl 4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate (60) 
A solution of triphosgene (85 mg, 0.28 mmol) in anhydrous CH2Cl2 (5 mL) was added dropwise 
over 10 min to a stirred and cooled (0 °C) mixture of compound 59 (50 mg, 0.19 mmol), sodium 
bicarbonate (24 mg, 0.28 mmol) in CH2Cl2 (10 mL). The mixture was slowly warmed up to 
room temperature and stirred for additional 2 h. Water (5 mL) was added slowly and the 
organic phase was separated followed by additional extraction with CH2Cl2 (2 x 10 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and evaporated under 
reduced pressure to give the crude product, which was subjected to column chromatography 
(eluent: light petroleum/acetone 2:1 v/v) to give compound 60 as white solid (40 mg, 73%). Rf 
= 0.3 (light petroleum/ethyl acetate 1:1 v/v), m.p. 173-176 oC. 1H-NMR (300 MHz, CDCl3): δ 
(ppm) 1.30 (t, J 7.1 Hz, 3H), 1.84-1.95 (m, 2H), 2.30-2.41 (m, 2H), 2.89-2.98 (m, 2H), 4.19 (q, 
J 7.1 Hz, 2H), 4.37-4.41 (m, 2H), 4.46-4.57 (m, 1H), 7.05-7.16 (m, 4H), 10.25 (brs, 1H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 14.7, 30.9, 43.6, 50.8, 61.6, 109.4, 110.0, 121.2, 121.5, 128.1, 
128.9, 155.5, 206.9. HRMS (ESI): m/z [M+H]+ calcd. for [C15H20N3O3]+ 290.1499, found: 
290.1515. C15H19N3O3 (289.34). 
 
1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (61) 
Compound 60 (200 mg, 0.69 mmol) was suspended in 10% aq NaOH (16 mL), the mixture 
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was kept under reflux for 5 h, and cooled to room temperature and acidified by the addition of 
10% HCl solution until the evolution of gas had ceased (pH around 2). Afterwards, the pH was 
carefully adjusted to 9 using 15% NaOH solution, followed by extraction with CH2Cl2 (4 x 10 
mL). The combined extracts were dried over Na2SO4 and the solvent was evaporated under 
reduced pressure to give compound 61 as white solid (120 mg, 81%), m.p. 112-115 oC, which 
was used without further purification. Rf = 0.4 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-
NMR (300 MHz, [D6]DMSO): δ (ppm) 1.56-1.60 (m, 2H), 2.08-2.30 (m, 2H), 2.53-2.61 (m, 2H), 
3.04-3.08 (m, 2H), 3.29 (brs, 1H), 4.17-4.28 (m, 1H), 6.92-7.03 (m, 3H), 7.28 (dd, J 7.1, 2.4 
Hz, 1H), 10.83 (brs, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 29.8, 45.6, 50.1, 108.7, 
108.8, 120.1, 120.3, 128.2, 129.0, 153.5. HRMS (ESI): m/z [M+H]+ calcd. for [C12H16N3O]+ 
218.1288, found: 218.1289. C12H15N3O (217.27). 
 
1-([1,4'-Bipiperidin]-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (63) 
4-piperidine hydrochloride (5.0 g, 32.55 mmol) and sodium bicarbonate (5.5 g, 65.49 mmol) 
were added to THF/H2O (1:1 v/v) (150 mL) followed by the slow addition of di-tert-butyl 
dicarbonate (5.7 g, 26.12 mmol) in THF (20 mL). The mixture was stirred at room temperature 
overnight. THF was evaporated and the product was extracted with CH2Cl2 (3 x 50 mL). The 
combined extracts were washed with brine and dried over Na2SO4. The solvent was removed 
under reduced pressure and the product was purified by column chromatography (eluent: light 
petroleum/ethyl acetate 7:1 v/v) to yield the intermediate tert-butyl 4-oxopiperidine-1-
carboxylate (compound 62) as white solid (6.4 g, 98%). Rf = 0.8 (CH2Cl2/MeOH 30:1 v/v). 1H-
NMR (300 MHz, CDCl3): δ (ppm) 1.49 (s, 9H), 2.43 (t, J 6.0 Hz, 4H), 3.73 (t, J 6.0 Hz, 4H). 
13C-NMR (75 MHz, CDCl3): δ (ppm) 28.4, 41.2, 43.1, 80.5, 154.6, 208.1. HRMS (ESI): m/z 
[M+H]+ calcd. for [C10H18NO3]+ 200.1281, found: 200.1279. The intermediate 62 (1.6 g, 8.03 
mmol) and acetic acid (0.16 mL, 2.74 mmol) were added to a stirred and cooled (0 °C) solution 
of compound 61 (1.2 g, 5.53 mmol) in MeOH (50 mL) and the mixture was stirred at 0 °C for 
15 min. Sodium cyanoborohydride (688 mg, 10.95 mmol) was added and the stirred mixture 
was allowed to warm up to room temperature, followed by stirring overnight. 5% aq KHCO3 
(16 mL) was added prior to extraction with CH2Cl2 (3 x 20 mL). The combined organic phases 
were washed with brine and dried over Na2SO4. The volatiles were removed under reduced 
pressure and the product was purified by flash column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 97:2:1 to 95:4:1 v/v/v) to yield the intermediate tert-butyl 4-(2-oxo-
2,3-dihydro-1H-benzo[d]imidazol-1-yl)-[1,4'-bipiperidine]-1'-carboxylate (1.15 g, 52%) as 
white solid. Rf = 0.7 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). The Boc-protected intermediate 
(1.1 g, 2.75 mmol) was dissolved in TFA/CH2Cl2 (1:4 v/v) (15 mL) and the mixture was stirred 
at room temperature overnight. The pH was carefully adjusted to 11 by adding 25% aq NH3. 
The two phases were separated and the aqueous phase was treated with CH2Cl2 (5 x 20 mL). 
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The combined organic phases were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The product was purified by flash column chromatography with (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v) to afford compound 63 as white solid (620 mg, 75%), 
m.p. 180-182 oC. Rf = 0.4 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 1.63-1.88 (m, 4H), 2.05-2.09 (m, 2H), 2.36-2.58 (m, 4H), 2.65-2.74 (m, 
1H), 2.84-3.02 (m, 2H), 3.12-3.15 (m, 2H), 3.34-3.42 (m, 2H), 4.24-4.33 (m, 1H), 6.95-7.17 (m, 
3H), 7.33-7.39 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 27.1, 29.9, 45.1, 49.9, 52.0, 
60.7, 110.5, 110.6, 122.2, 122.5, 129.6, 130.3, 156.2. HRMS (ESI): m/z [M+H]+ calcd. for 
[C17H25N4O]+ 301.2023, found: 301.2025. C17H24N4O (300.41). 
 
1-(1'-(2-Aminoethyl)-[1,4'-bipiperidin]-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (64) 
Compound 63 (570 mg, 1.89 mmol), tert-butyl (2-bromoethyl) carbamate (compound 30) (508 
mg, 2.27 mmol) and potassium carbonate (525 mg, 3.80 mmol) were added to MeCN (60 mL) 
and the mixture was stirred under reflux overnight. Insoluble material was removed by filtration. 
The filtrate was concentrated under reduced pressure to yield a yellow oily residue, which was 
dissolved in CH2Cl2 (10 mL) followed by washing with water. The aqueous phase was treated 
with CH2Cl2 (3 × 10 mL) and the organic extracts were collected. All organic phases were 
combined and dried over Na2SO4. Removal of the solvent under reduced pressure yielded a 
yellow oil, which was subjected to flash column chromatography (eluent: CH2Cl2/MeOH/25% 
aq NH3 90:3:1 to 90:9:1 v/v/v) to afford the Boc-protected intermediate as colorless oil (350 
mg, 42%). Rf = 0.6 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, [D4]MeOH): 
δ (ppm) 1.43 (s, 9H), 1.54-1.67 (m, 2H), 1.72-1.84 (m, 2H), 1.87-1.91 (m, 2H), 2.01-2.10 (m, 
2H), 2.27-2.60 (m, 7H), 3.01-3.05 (m, 2H), 3.08-3.24 (m, 4H), 4.20-4.43 (m, 1H), 6.89-7.16 (m, 
3H), 7.24-7.57 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 28.8, 28.9, 29.9, 38.7, 50.1, 
52.0, 54.4, 58.7, 63.1, 80.2, 110.7, 110.9, 122.3, 122.6, 129.7, 130.3, 156.3, 158.4. HRMS 
(ESI): m/z [M+H]+ calcd. for [C24H38N5O3]+ 444.2969, found: 444.2966. The intermediate (150 
mg, 0.34 mmol) was dissolved in CH2Cl2/TFA (4:1 v/v) (5 mL) and the mixture was stirred at 
room temperature overnight. 25% aq NH3 was added to adjust the pH to 11 followed by 
extraction with CH2Cl2/MeOH (9:1 v/v) (5 × 10 mL). Removal of the volatiles from the combined 
extracts in vacuo gave compound 64 as colorless oil (100 mg, 86%), which was used without 
further purification. Rf = 0.1 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 1.50-1.71 (m, 2H), 1.76-1.79 (m, 2H), 1.89-1.94 (m, 2H), 2.00-2.11 (m, 
2H), 2.32-2.52 (m, 7H), 2.74-2.78 (m, 1H), 3.00-3.17 (m, 4H), 3.39-3.45 (m, 1H), 4.18-4.44 (m, 
1H), 6.95-7.16 (m, 3H), 7.34-7.52 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 28.9, 29.8, 
39.3, 50.2, 52.1, 54.5, 61.2, 63.2, 110.6, 110.9, 122.3, 122.6, 129.7, 130.3, 156.3. HRMS (ESI): 
m/z [M+H]+ calcd. for [C19H30N5O]+ 344.2445, found: 344.2443. C19H29N5O (343.48). 
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1-(1'-(2-Bromoacetyl)-[1,4'-bipiperidin]-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (66) 
To a solution of compound 63 (630 mg, 2.09 mmol) in CHCl3 (50 mL) was added pyridine (762 
μL, 9.45 mmol) and the mixture was cooled in an ice bath. 2-Bromoacetyl bromide (compound 
65) (820 μL, 9.45 mmol) was added dropwise and stirring was continued at room temperature 
overnight. H2O (10 mL) was added and the phases were separated. The organic phase was 
washed with brine, dried over Na2SO4 and the solvent was evaporated to obtain the crude 
product, which was subjected to flash column chromatography (eluent: CH2Cl2/MeOH/25% aq 
NH3 90:3:1 v/v/v) to yield compound 66 as colorless oil (800 mg, 91%). Rf = 0.7 
(CH2Cl2/MeOH/25% aq NH3 95:5:1 v/v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.35-1.73 
(m, 2H), 1.78-1.92 (m, 2H), 2.01 (t, J 11 Hz, 2H), 2.36-2.61 (m, 4H), 2.72 (t, J 13 Hz, 2H), 3.14-
3.22 (m, 3H), 3.99-4.10 (m, 3H), 4.26-4.33 (m, 1H), 4.55-4.57 (m, 1H), 7.02-7.09 (m, 3H), 
7.33-7.48 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 28.8, 29.5, 29.9, 42.9, 47.4, 52.0, 
62.7, 110.6, 110.8, 122.2, 122.6, 129.7, 130.4, 156.3, 167.7. HRMS (ESI): m/z [M+H]+ calcd. 
for [C19H26BrN4O2]+ 421.1234, found: found: 421.1244. C19H25BrN4O2 (421.34). 
 
1-(1'-(2-(6-Amino-4-methyl-1,4-diazepan-1-yl)acetyl)-[1,4'-bipiperidin]-4-yl)-1,3-dihydro-
2H-benzo[d]imidazol-2-one tetrakis(hydrotrifluoroacetate) (67)  
Potassium carbonate (53 mg, 0.38 mmol) was added to a suspension of compound 66 (80 
mg, 0.19 mmol) and compound 28 (48 mg, 0.21 mmol) in MeCN (2 mL). The mixture was 
stirred at 110 oC under microwave irradiation for 30 min and cooled to room temperature. 
Insoluble material was separated by filtration and washed with CH2Cl2 (2 × 10 mL). The 
combined filtrate and washings were concentrated under reduced pressure yielding a yellow 
residue, which was dissolved in CH2Cl2 (5 mL) followed by washing with water. The aqueous 
phase was treated with CH2Cl2 (3 × 10 mL) and the organic extracts were collected. All organic 
phases were combined and dried over Na2SO4. Removal of the volatiles under reduced 
pressure gave the Boc-protected intermediate (50 mg, 46%), which was dissolved in 
CH2Cl2/TFA (4:1 v/v) (5 mL). The mixture was stirred at room temperature for 8 h. CH2Cl2 (10 
mL) was added and the volatiles were evaporated. Purification by preparative HPLC (column: 
Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-62:38, tR = 
12 min) afforded compound 67 as white ﬂuffy solid (35 mg, 43%). 1H-NMR (600 MHz, 
[D4]MeOH): δ (ppm) 1.63-1.90 (m, 2H), 2.09-2.11 (m, 2H), 2.21-2.22 (m, 2H), 2.68-2.72 (m, 
1H), 2.82-2.91 (m, 2H), 3.02 (s, 3H), 3.05-3.21 (m, 4H), 3.25-3.29 (m, 1H), 3.32-3.37 (m, 2H), 
3.47-3.58 (m, 3H), 3.59-3.66 (m, 2H), 3.65-3.74 (m, 4H), 3.77-3.82 (m, 1H), 3.96-3.97 (m, 1H), 
4.57-4.63 (m, 1H), 4.72-4.75 (m, 1H), 7.03-7.09 (m, 3H), 7.32 (d, J 3.4 Hz, 1H). 13C-NMR (150 
MHz, [D4]MeOH): δ (ppm) 27.3, 27.5, 27.9, 41.6, 43.9, 46.7, 50.2, 50.4, 51.9, 58.5, 58.6, 60.6, 
64.7, 110.0, 110.7, 115.1 (TFA), 117.0 (TFA), 118.9 (TFA), 120.9 (TFA), 122.4, 122.9, 129.7, 
130.1, 156.1, 162.3 (TFA), 162.6 (TFA), 162.8 (TFA), 163.0 (TFA), 170.8. RP-HPLC (220 nm): 
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98% (tR = 11.6 min, k = 3.0). HRMS (ESI): m/z [M+H]+ calcd. for [C25H40N7O2]+ 470.3238, found: 
470.3241. C25H39N7O2 · C8H4F12O8 (469.63 + 456.09). 
 
tert-Butyl 4-(2,2-diphenylacetoxy)piperidine-1-carboxylate (70) 
Di-tert-butyl dicarbonate (5.6 g, 25.68 mmol) in THF (20 mL) was slowly added to a solution 
of piperidin-4-ol (2.0 g, 19.77 mmol) and triethylamine (3.6 mL, 25.70 mmol) in THF/H2O (1:7 
v/v) (200 mL) and the mixture was stirred at room temperature overnight. THF was removed 
by evaporation followed by extraction with CH2Cl2 (3 × 50 mL). The combined extracts were 
dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected to 
column chromatography (eluent: CH2Cl2/MeOH 30:1 to 15:1 v/v) to yield the Boc-protected 
intermediate (compound 69) as white solid (3.7 g, 93%). Compound 69 (2.9 g, 14.41 mmol) 
and 2,2-diphenylacetic acid (compound 68) (2.7 g, 12.74 mmol) were dissolved in CH2Cl2 (100 
mL) and the solution was cooled to 0 °C. DMAP (173 mg, 1.42 mmol) was added and the 
mixture was allowed to clear up before the slow addition of N,N'-dicyclohexylcarbodiimide (3.2 
g, 15.51 mmol) under stirring at 0 oC. The mixture was slowly warmed up to room temperature 
and kept under stirring overnight. H2O (50 mL) was added, the phases were separated and 
the aqueous phase was treated with CH2Cl2 (3 × 20 mL). The combined organic phases were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give the 
crude product, which was subjected to column chromatography (eluent: light 
petroleum/acetone 3:1 v/v) to afford compound 70 as yellow oil (4.9 g, 97%). Rf = 0.8 (light 
petroleum/acetone 3:1 v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.40 (s, 9H), 1.49-1.59 (m, 
2H), 1.72-1.82 (m, 2H), 3.15-3.24 (m, 2H), 3.15-3.24 (m, 2H), 4.93-5.00 (m, 2H), 7.18-7.29 (m, 
10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.4, 30.3, 57.3, 65.9, 70.4, 79.7, 127.3, 128.5, 
128.6, 138.6, 154.7, 171.8. HRMS (ESI): m/z [M+Na]+ calcd. for [C24H29NNaO4]+ 418.1989, 
found: 418.1988. C24H29NO4 (395.50). 
 
Piperidin-4-yl 2, 2-diphenylacetate (71) 
Compound 70 (860 mg, 2.17 mmol) was dissolved in CH2Cl2 (40 mL) and the solution was 
cooled to 0 °C. TFA (10 mL) was added dropwise, the mixture was allowed to warm up to room 
temperature and stirring was continued for 8 h. Ice water (10 mL) was added followed by the 
slow addition of 25% aq NH3 to adjust the pH value to 11. The product was extracted with 
CH2Cl2 (3 × 15 mL), the combined organic phases were dried over Na2SO4 and concentrated 
under reduced pressure to give compound 71 as white solid (360 mg, 56%), m.p. 75-77 oC. 
Rf = 0.6 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v/). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.45-
1.65 (m, 2H), 1.82 (brs, 1H), 1.84-1.93 (m, 2H), 2.64-2.73 (m, 2H), 2.89-3.03 (m, 2H), 4.90-
4.99 (m, 1H), 5.01 (s, 1H), 7.21-7.35 (m, 10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 31.9, 43.9, 
57.4, 71.4, 127.3, 128.6, 128.7, 138.9, 171.9. HRMS (ESI): m/z [M+H]+ calcd. for [C19H22NO2]+ 
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296.1645, found: 296.1666. C19H21NO2 (295.38). 
 
1-(2-((tert-Butoxycarbonyl)amino)ethyl)piperidin-4-yl 2,2-diphenylacetate (72) 
Compound 71 (150 mg, 0.51 mmol), tert-butyl (2-bromoethyl) carbamate (compound 30) (136 
mg, 0.61 mmol) and potassium carbonate (140 mg, 1.01 mmol) were added to MeCN (50 mL) 
and the mixture was refluxed for 3 h. Insoluble material was separated by filtration and washed 
with CH2Cl2 (2 × 5 mL). The combined filtrate and washings were concentrated under reduced 
pressure to yield a brown residue, which was dissolved in CH2Cl2 (10 mL) followed by washing 
with water. The aqueous phase was treated with CH2Cl2 (3 × 5 mL) and the organic extracts 
were collected. All organic phases were combined and dried over Na2SO4. Removal of the 
solvent under reduced pressure gave the crude product, which was subjected to flash column 
chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to yield compound 72 as 
colorless oil (150 mg, 67%). Rf = 0.6 (CH2Cl2/MeOH/25% aq NH3 90:10:1 v/v/v). 1H-NMR (300 
MHz, CDCl3): δ (ppm) 1.40 (s, 9H), 1.58-1.70 (m, 2H), 1.81-1.95 (m, 2H), 2.21-2.30 (m, 2H), 
2.39 (t, J 12 Hz, 2H), 2.49-2.59 (m, 2H), 3.16-3.18 (m, 2H), 4.82-4.89 (m, 1H), 4.96 (s, 1H), 
5.03 (brs, 1H), 7.18-7.28 (m, 10H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.5, 30.2, 37.1, 50.2, 
57.1, 57.3, 70.3, 79.3, 127.3, 128.59, 128.60, 138.7, 155.9, 171.8. HRMS (ESI): m/z [M+H]+ 
calcd. for [C26H35N2O4]+ 439.2591, found: 439.2619. C26H34N2O4 (438.57). 
 
1-(2-Aminoethyl)piperidin-4-yl 2,2-diphenylacetate (73)  
Compound 72 (500 mg, 1.14 mmol) was dissolved in CH2Cl2 (4 mL), TFA (1 mL) was added 
slowly and the mixture was stirred at room temperature for 8 h. 25% aq NH3 was added slowly 
to adjust the pH to 11, followed by extraction with CH2Cl2/MeOH (9:1 v/v) (5 × 10 mL). The 
combined extracts were dried over Na2SO4 and the volatiles were evaporated to afford 
compound 73 as colorless oil (320 mg, 83%), which was used without further purification. Rf 
= 0.3 (CH2Cl2/MeOH/25% aq NH3 90:10:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.59-
1.77 (m, 2H), 1.84-1.93 (m, 2H), 2.26 (t, J 8.5 Hz, 2H), 2.38-2.47 (m, 2H), 2.55 (brs, 2H), 2.79 
(t, J 6.0 Hz, 4H), 4.84-4.92 (m, 1H), 5.00 (s, 1H), 7.23-7.26 (m, 2H), 7.28-7.37 (m, 8H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 30.6, 38.5, 50.5, 57.3, 59.5, 70.7, 127.2, 128.57, 128.62, 
138.7, 171.9. HRMS (ESI): m/z [M+H]+ calcd. for [C21H27N2O2]+ 339.2067, found: 339.2072. 
C21H26N2O2 (338.45). 
 
2-Bromoethyl 9H-xanthene-9-carboxylate (75)  
9H-xanthene-9-carboxylic acid (compound 74) (1.0 g, 4.42 mmol) and 2-bromoethan-1-ol (1.1 
g, 8.87 mmol) were dissolved in CH2Cl2 (30 mL) and the solution was cooled to 0 °C. N,N'-
Dicyclohexylcarbodiimide (1.1 g, 5.34 mmol) dissolved in CH2Cl2 (5 mL) was added dropwise 
followed by the addition of DMAP (270 mg, 2.21 mmol). The mixture was allowed to warm up 
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to room temperature and stirring was continued overnight. H2O (50 mL) was added, the 
phases were separated and the aqueous phase was treated with CH2Cl2 (3 × 30 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. Purification by column chromatography (eluent: light petroleum/acetone 7:1 
v/v) afforded compound 75 as colorless oil (1.0 g, 68%). Rf = 0.7 (light petroleum/acetone 3:1 
v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 3.40 (t, J 6.1 Hz, 2H), 4.35 (t, J 6.1 Hz, 2H), 5.06 (s, 
1H), 7.06-7.19 (m, 4H), 7.27-7.36 (m, 4H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.3, 45.2, 
64.5, 117.1, 117.9, 123.4, 129.1, 129.3, 151.4, 171.4. HRMS (ESI): m/z [M+H]+ calcd. for 
[C16H14BrO3]+ 333.0121, found: 333.0124. C16H13BrO3 (333.18). 
 
4-Bromobutyl 9H-xanthene-9-carboxylate (76) 
9H-Xanthene-9-carboxylic acid (compound 74) (2.0 g, 8.84 mmol) and 4-bromobutan-1-ol (1.6 
g, 10.61 mmol) were dissolved in CH2Cl2 (30 mL) and the mixture was cooled to 0 °C. A 
solution of N, N'-dicyclohexylcarbodiimide (2.2 g, 10.61 mmol) in CH2Cl2 (5 mL) was added 
dropwise followed by the addition of DMAP (270 mg, 2.21 mmol). The mixture was allowed to 
warm up to room temperature and stirring was continued overnight. H2O (20 mL) was added, 
the phases were separated and the aqueous phase was treated with CH2Cl2 (3 × 15 mL). The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated under 
reduced pressure. Purification by column chromatography (eluent: light petroleum/acetone 7:1 
v/v) yielded compound 76 as colorless oil (1.8 g, 56%). Rf = 0.7 (light petroleum/acetone 4:1 
v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.59-1.74 (m, 4H), 3.23 (t, J 9.0 Hz, 2H), 4.06 (t, J 
6.0 Hz, 2H), 4.99 (s, 1H), 7.04-7.18 (m, 4H), 7.26-7.34 (m, 4H). 13C-NMR (75 MHz, CDCl3): δ 
(ppm) 27.1, 29.0, 33.0, 45.7, 64.5, 117.1, 118.5, 123.4, 128.9, 129.3, 151.4, 171.9. HRMS 
(ESI): m/z [M+H]+ calcd. for [C18H18BrO3]+ 361.0434, found: 361.0435. C18H17BrO3 (361.24). 
 
2-(Piperazin-1-yl)ethyl 9H-xanthene-9-carboxylate (77) 
Compound 75 (500 mg, 1.50 mmol), piperazine (1.04 g, 12.08 mmol) and potassium 
carbonate (416 mg, 3.01 mmol) were added to MeCN (18 mL) and the mixture was refluxed 
overnight. Insoluble material was separated by filtration and washed with CH2Cl2 (2 × 10 mL). 
The combined filtrate and washings were concentrated under reduced pressure yielding a 
yellow oil, which was dissolved in CH2Cl2 (10 mL) followed by washing with brine. The aqueous 
phase was treated with CH2Cl2 (3 × 15 mL) and the organic extracts were collected. All organic 
phases were combined and dried over Na2SO4. Removal of the solvent under reduced 
pressure gave the crude product, which was subjected to column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 96:3:1 v/v/v) to yield compound 77 as yellow solid (300 mg, 59%). 
Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v), m.p. 77-79 oC. 1H-NMR (300 MHz, CDCl3): 
δ (ppm) 2.36-2.54 (m, 6H), 2.82-2.92 (m, 4H), 4.61 (brs, 1H), 4.13 (t, J 10 Hz, 2H), 5.00 (s, 
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1H), 7.05-7.17 (m, 4H), 7.27-7.35 (m, 4H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 44.2, 45.6, 
50.9, 56.3, 62.7, 117.0, 118.4, 123.3, 128.9, 129.2, 151.4, 171.5. HRMS (ESI): m/z [M+H]+ 
calcd. for [C20H23N2O3]+ 339.1703, found: 339.1707. C20H22N2O3 (338.41). 
 
4-(Piperazin-1-yl)butyl 9H-xanthene-9-carboxylate (78) 
Compound 76 (1.0 g, 2.77 mmol), piperazine (1.9 g, 22.07 mmol) and potassium carbonate 
(1.2 g, 8.70 mmol) were added to MeCN (50 mL) and the stirred mixture was kept under reflux 
for 1.5 h. Insoluble material was separated by filtration and washed with CH2Cl2 (2 × 20 mL). 
The combined filtrate and washings were concentrated under reduced pressure to give a 
yellow oil, which was dissolved in CH2Cl2 (20 mL) followed by washing with water. The 
aqueous phase was treated with CH2Cl2 (3 × 30 mL) and the organic extracts were collected. 
All organic phases were combined and dried over Na2SO4. Removal of the volatiles under 
reduced pressure gave the crude product, which was subjected to column chromatography 
(eluent: CH2Cl2/MeOH/25% aq NH3 94:5:1 v/v/v) to afford compound 78 as colorless oil (470 
mg, 46%). Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ 
(ppm) 1.19-1.42 (m, 2H), 1.43-1.60 (m, 2H), 2.12-2.26 (m, 4H), 2.26-2.32 (m, 2H), 2.36 (brs, 
1H), 2.81-2.94 (m, 4H), 4.04 (t, J 6.3 Hz, 2H), 4.98 (s, 1H), 7.00-7.17 (m, 4H), 7.23-7.35 (m, 
4H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 22.6, 26.5, 45.6, 45.8, 54.1, 58.4, 65.3, 116.9, 118.5, 
123.3, 128.9, 129.1, 151.3, 171.9. HRMS (ESI): m/z [M+H]+ calcd. for [C22H27N2O3]+ 367.2016, 
found: 367.2027. C22H26N2O3 (366.46). 
 
2-(4-(2-((tert-Butoxycarbonyl)amino)ethyl)piperazin-1-yl)ethyl-9H-xanthene-9-
carboxylate (79) 
Compound 77 (1.27 g, 3.76 mmol), tert-butyl (2-bromoethyl) carbamate (compound 30) (921 
mg, 4.13 mmol) and potassium carbonate (1.3 g, 9.41 mmol) were added to MeCN (30 mL) 
and the mixture was kept under reflux for 2 h. Insoluble material was separated by filtration 
and washed with CH2Cl2 (2 × 10 mL). The filtrate and washings were combined and the 
volatiles were removed under reduced pressure yielding a yellow oily residue, which was 
dissolved in CH2Cl2 (20 mL) followed by washing with water. The aqueous phase was treated 
with CH2Cl2 (3 × 20 mL) and the organic extracts were collected. All organic phases were 
combined and dried over Na2SO4. Removal of the solvent under reduced pressure gave the 
crude product, which was subjected to column chromatography (eluent: CH2Cl2/MeOH/25% 
aq NH3 90:3:1 v/v/v) to afford compound 79 as yellow oil (1.03 g, 57%). Rf = 0.5 
(CH2Cl2/MeOH/25% aq NH3 90:10:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.45 (d, J 5.3 
Hz, 9H), 2.13-2.38 (m, 8H), 2.42 (t, J 5.9 Hz, 2H), 2.45-2.55 (m, 2H), 3.19-3.27 (m, 2H), 4.08-
4.19 (m, 2H), 4.99 (s, 1H), 5.04 (brs, 1H), 7.04-7.11 (m, 2H), 7.04-7.13 (m, 2H), 7.23-7.31 (m, 
4H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 28.5, 37.0, 45.5, 52.8, 53.5, 56.3, 57.0, 63.3, 79.2, 
82                                          Chapter 3 
116.9, 118.4, 123.3, 129.0, 129.1, 151.3, 155.9, 171.6. HRMS (ESI): m/z [M+H]+ calcd. for 
[C27H36N3O5]+ 482.2649, found: 482.2645. C27H35N3O5 (481.59). 
 
2-(4-(2-Aminoethyl)piperazin-1-yl)ethyl 9H-xanthene-9-carboxylate (80) 
Compound 79 (1.0 g, 2.08 mmol) was dissolved in CH2Cl2 (8 mL), TFA (2 mL) was added 
slowly, and the mixture was stirred at room temperature overnight. 25% aq NH3 was added to 
adjust the pH to 11, followed by extraction with CH2Cl2/MeOH (9:1 v/v) (5 × 15 mL). The 
combined extracts were dried over Na2SO4. Removal of the solvent in vacuo gave compound 
80 as colorless oil (700 mg, 88%), which was used without further purification. Rf = 0.2 
(CH2Cl2/MeOH/25% aq NH3 90:10:1 v/v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 2.20-2.42 
(m, 8H), 2.41-2.61 (m, 4H), 2.67-2.79 (m, 2H), 4.05-4.23 (m, 2H), 4.90 (s, 1H), 7.01-7.21 (m, 
4H), 7.23-7.44 (m, 4H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 38.9, 46.1, 53.9, 54.0, 57.4, 
60.9, 64.4, 117.8, 119.9, 124.6, 130.32, 130.34, 152.9, 173.2. HRMS (ESI): m/z [M+H]+ calcd. 
for [C22H28N3O3]+ 382.2125, found: 382.2123. C22H27N3O3 (381.48). 
 
1-(3-Chloropropyl)-3,4-dihydroquinolin-2(1H)-one (83)53 
3,4-dihydroquinolin-2(1H)-one (compound 81) (1.0 g, 6.80 mmol), 1-chloro-3-iodopropane 
(compound 82) (1.7 mg, 8.32 mmol) and caesium carbonate (4.4 g, 13.51 mmol) were added 
to MeCN (50 mL) and the mixture was stirred and heated to 50 oC for 12 h. Insoluble material 
was separated by filtration and washed with CH2Cl2 (2 × 20 mL). The filtrate and washings 
were combined and the volatiles were removed under reduced pressure yielding a yellow solid, 
which was dissolved in CH2Cl2 (20 mL). This solution was washed with brine, the phases were 
separated and the aqueous phase was treated with CH2Cl2 (3 × 20 mL). The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure to yield a yellow 
oil, which was subjected to column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 
90:3:1 v/v/v) to afford compound 83 as yellow oil (1.05 g, 69%). Rf = 0.7 (CH2Cl2/MeOH/25% 
aq NH3 90:3:1). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 2.07-2.21 (m, 2H), 2.59-2.70 (m, 2H), 
2.81-2.98 (m, 2H), 3.56-3.71 (m, 2H), 4.00-4.20 (m, 2H), 6.97-7.10 (m, 2H), 7.15-7.31 (m, 2H). 
13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 25.5, 30.2, 31.8, 40.1, 42.8, 114.6, 122.9, 126.5, 127.6, 
128.1, 139.4, 170.4. HRMS (ESI): m/z [M+H]+ calcd. for [C12H15ClNO]+ 224.0837, found: 
224.0846. C12H14ClNO (223.70). 
 
1-(3-(4-(4-Hydroxybutyl)piperidin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one (85) 
4-(Piperidin-4-yl)butanoic acid hydrochloride (1.0 g, 4.81 mmol) was suspended in anhydrous 
THF (20 mL) under an atmosphere of argon. The suspension was immersed in an ice bath 
and lithium aluminium hydride (456 mg, 12.01 mmol) was added in portions under stirring. The 
mixture was slowly warmed up to room temperature, then kept under reflux overnight, and 
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cooled in an ice bath. For quenching, water (5 mL), 15% NaOH solution (10 mL) and water 
(10 mL) were added dropwise to reaction mixture. Insoluble material was separated by 
filtration and washed with chloroform (3 × 20 mL). The combined filtrate and washings were 
dried over Na2SO4 and concentrated under reduced pressure to give the intermediate 4-
(piperidin-4-yl)butan-1-ol68 (compound 84) as colorless oil-like residue (510 mg, 68%), which 
was used without further purification. Rf = 0.1 (CH2Cl2/MeOH/25% aq NH3 66:33:1 v/v/v). 1H-
NMR (300 MHz, [D4]MeOH): δ (ppm) 1.04-1.18 (m, 2H), 1.20-1.31 (m, 2H), 1.31-1.44 (m, 3H), 
1.47-1.57 (m, 2H), 1.70 (d, J 12 Hz, 2H), 2.55-2.57 (m, 2H), 2.99-3.01 (m, 2H), 3.54 (t, J 6.5 
Hz, 2H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 23.9, 33.8, 33.9, 37.2, 38.2, 47.1, 62.9. 
HRMS (ESI): m/z [M+H]+ calcd. for [C9H20NO]+ 158.1539, found: 158.1541. The intermediate 
84 (867 mg, 5.52 mmol) and compound 83 (1.1 g, 4.92 mmol) were dissolved in MeCN (30 
mL), followed by the addition of potassium carbonate (1.4 g, 10.14 mmol) and sodium iodide 
(376 mg, 2.51 mmol). The mixture was kept at 50 oC for 24 h. Insoluble material was separated 
by filtration and washed with CH2Cl2 (2 × 10 mL). The filtrate and washings were combined 
and the solvent was removed under reduced pressure to yield a yellow residue, which was 
dissolved in CH2Cl2 (20 mL) followed by washing with water. The aqueous phase was treated 
with CH2Cl2 (3 × 20 mL) and the organic extracts were collected. All organic phases were 
combined and dried over Na2SO4. Removal of the solvent under reduced pressure gave crude 
product, which was subjected to column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 
90:9:1 v/v/v) to afford compound 85 as colorless oil (900 mg, 53%). Rf = 0.4 (CH2Cl2/MeOH/25% 
aq NH3 90:10:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.26-1.42 (m, 7H), 1.45-1.59 (m, 
2H), 1.68 (brs, 1H), 1.68-1.72 (m, 2H), 1.84-2.12 (m, 4H), 2.45-2.56 (m, 2H), 2.59-2.65 (m, 
2H), 2.77-2.94 (m, 2H), 2.99-3.03 (m, 2H), 3.62 (t, J 6.4 Hz, 2H), 3.90-4.00 (m, 2H), 6.96-7.01 
(m, 1H), 7.07 (d, J 7.7 Hz, 1H), 7.13-7.16 (m, 1H), 7.20-7.26 (m, 1H). 13C NMR (75 MHz, 
CDCl3): δ (ppm) 18.4, 22.9, 24.4, 25.4, 31.8, 32.9, 36.0, 40.5, 50.8, 53.9, 55.9, 62.8, 114.9, 
122.9, 126.4, 127.6, 128.0, 139.4, 170.4. HRMS (ESI): m/z [M+H]+ calcd. for [C21H33N2O2]+ 
345.2537, found: 345.2565. C21H32N2O2 (344.50). 
 
1-(3-(4-(4-Bromobutyl)piperidin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one (86)  
Compound 85 (900 mg, 2.61 mmol) and PPh3 (2.06 g, 7.86 mmol) were dissolved in 
anhydrous CH2Cl2 (30 mL) and the solution was cooled to -5 oC. A solution of CBr4 (3.03 g, 
9.14 mmol) in anhydrous CH2Cl2 (15 mL) was slowly dropped into the stirred mixture, thereby 
keeping the temperature of the mixture below 5 oC. Stirring was continued at room temperature 
overnight. The solvent was evaporated yielding a yellow residue, which was subjected to 
column chromatography (eluent: light petroleum/acetone/25% aq NH3 80:20:1 v/v/v) to yield 
compound 86 as colorless oil (330 mg, 31%). Rf = 0.3 (light petroleum/acetone/25% aq NH3 
80:20:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.26-1.31 (m, 5H), 1.35-1.52 (m, 2H), 1.68 
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(d, J 9.3 Hz, 2H), 1.76-2.03 (m, 6H), 2.42 (t, J 6.1 Hz, 2H), 2.60-2.65 (m, 2H), 2.80-3.01 (m, 
4H), 3.40 (t, J 6.8 Hz, 2H), 3.96 (t, J 7.5Hz, 2H), 6.96-7.01 (m, 1H), 7.08 (d, J 8.1 Hz, 1H), 
7.15 (dd, J 7.3, 1.1 Hz, 1H), 7.22 (dd, J 11, 4.6 Hz, 1H). 13C-NMR (75 MHz, CDCl3): δ (ppm) 
24.8, 25.5, 25.7, 32.0, 32.2, 33.0, 34.1, 35.6, 35.7, 40.7, 54.1, 56.1, 115.1, 122.9, 126.6, 127.6, 
128.1, 139.7, 170.4. HRMS (ESI): m/z [M+H]+ calcd. for [C21H32BrN2O]+ 407.1693, found: 
407.1695. C21H31BrN2O (407.40). 
 
tert-Butyl (2-(4-(4-(1-(3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)carbamate (87) 
Compound 86 (1.21 g, 2.97 mmol), tert-butyl (2-(piperazin-1-yl) ethyl)carbamate (compound 
32) (1.5 g, 6.55 mmol) and potassium carbonate (1.24 g, 8.99 mmol) were added to MeCN 
(60 mL) and the stirred mixture was kept under reflux for 2 h. Insoluble material was removed 
by filtration and the filtrate was concentrated under reduced pressure yielding a yellow oily 
residue, which was dissolved in CH2Cl2 (20 mL) followed by washing with water. The aqueous 
phase was treated with CH2Cl2 (3 × 30 mL) and the organic extracts were collected. All organic 
phases were combined and dried over Na2SO4. Removal of the solvent under reduced 
pressure gave the crude product, which was subjected to column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to afford compound 87 as yellow oil (1.02 g, 62%). Rf 
= 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.13-1.18 
(m, 7H), 1.38 (s, 9H), 1.39-1.44 (m, 2H), 1.53-1.62 (m, 2H), 1.71-1.94 (m, 4H), 2.19-2.29 (m, 
2H), 2.30-2.51 (m, 10H), 2.54-2.59 (m, 3H), 2.74-2.94 (m, 4H), 3.08-3.21 (m, 2H), 3.90 (t, J 
6.0 Hz, 2H), 6.89-6.95 (m, 1H), 7.02-7.09 (m, 2H), 7.05-7.11 (m, 1H), 7.12-7.20 (m, 1H). 13C-
NMR (75 MHz, CDCl3): δ (ppm) 24.7, 25.6, 27.1, 28.5, 31.9, 32.2, 35.6, 36.4, 37.1, 40.5, 52.9, 
53.2, 54.1, 56.1, 57.1, 58.8, 65.9, 79.1, 114.9, 122.7, 126.5, 127.5, 127.9, 139.6, 155.9, 170.2. 
HRMS (ESI): m/z [M+H]+ calcd. for [C32H54N5O3]+ 556.4221, found: 556.4227. C32H53N5O3 
(555.81) 
 
1-(3-(4-(4-(4-(2-Aminoethyl)piperazin-1-yl)butyl)piperidin-1-yl)propyl)-3,4-
dihydroquinolin-2(1H)-one (88)  
Compound 87 (300 mg, 0.54 mmol) was dissolved in CH2Cl2/TFA (4:1 v/v) (5 mL) and the 
mixture was stirred at room temperature for 8 h. 25% aq NH3 was added to adjust the pH to 
11, followed by extraction with CH2Cl2/MeOH (9:1 v/v) (5 × 10 mL). The combined extracts 
were dried over Na2SO4. Removal of the volatiles in vacuo yielded compound 88 as yellow oil 
(240 mg, 97%), which was used without further purification. Rf = 0.1 (CH2Cl2/MeOH/25% aq 
NH3 90:9:1 v/v/v). 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.16-1.32 (m, 7H), 1.44-1.54 (m, 
2H), 1.62-1.70 (m, 2H), 1.76-1.86 (m, 2H), 1.89-1.98 (m, 2H), 2.32-2.40 (m, 6H), 2.42-2.67 (m, 
10H), 2.78-2.82 (m, 2H), 2.81-2.98 (m, 4H), 3.86-4.09 (m, 2H), 6.89-7.08 (m, 1H), 7.08-7.31(m, 
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3H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 25.5, 25.8, 26.3, 27.7, 32.8, 33.0, 36.8, 37.6, 
38.7, 41.3, 53.9, 55.1, 55.0, 57.1, 59.8, 60.1, 116.5, 124.4, 128.3, 128.7, 129.2, 140.4, 170.5. 
HRMS (ESI): m/z [M+H]+ calcd. for [C27H46N5O]+ 456.3697, found: 456.3700. C27H45N5O 
(455.69). 
 
5,10-Dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (91)54 
A mixture of 2-chlorobenzoic acid (compound 89) (20 g, 127.7 mmol), 1,2-benzenediamine 
(compound 90) (13.8 g, 127.6 mmol) and copper powder (8.1 g, 127.5 mmol) in chlorobenzene 
(300 mL) was kept under reflux in a round bottom flask, equipped with a Dean-stark apparatus, 
for 6 h. The hot mixture was filtered and the solid was washed with a small amount of 
chlorobenzene. The combined filtrates were concentrated under reduced pressure to reach a 
volume of approx. 400 mL. After storage at -20 °C for 12 h the crystalline product was collected 
and recrystallized from ethanol/ethyl acetate (1:1 v/v) to yield 91 as yellow-green crystals (3.5 
g, 13%). Rf = 0.6 (light petroleum/ethyl acetate 1:1 v/v), m.p. 247-249 oC (Lit54. m.p. 256-257 
oC). 1H-NMR (300 MHz, [D6]DMSO): (ppm) 6.85-7.02 (m, 6H), 7.26-7.40 (m, 1H), 7.67 (dd, J 
7.9, 1.6 Hz, 1H), 7.85 (s, 1H), 9.85 (s, 1H). 13C-NMR (75 MHz, [D6]DMSO): δ (ppm) 118.9, 
119.7, 120.6, 121.2, 122.6, 122.7, 124.4, 129.7, 131.9, 133.1, 139.9, 150.3, 167.8. HRMS 
(ESI): m/z [M+H]+ calcd. for [C13H11N2O]+ 211.0866, found: 211.0862. C13H10N2O (210.24). 
 
5-(2-Chloroacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (92)69 
Under an atmosphere of argon compound 91 (3.5 g, 16.65 mmol), N,N-dimethylaniline (1.61 
g, 13.28 mmol) and 2-chloroacetyl chloride (6.59 g, 58.35 mmol) were added to abs. THF (50 
mL) and the mixture was kept under reflux overnight. 5% aq KHCO3 (40 mL) was added slowly, 
resulting in the formation of a greyish solid, which was collected by filtration. The filtrate was 
concentrated under reduced pressure yielding a white-pink solid, which was washed with light 
petroleum/ethyl acetate (1:1 v/v) until the color of the solid turned to grey. The grey solids were 
combined and dried under vacuum (4.02 g, 84%). Rf = 0.4 (light petroleum/ethyl acetate 1:1 
v/v), m.p. 231-233 oC (Lit69. m.p. 241-242 oC). Ratio of configurational isomers evident in the 
NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, [D6]DMSO) δ (ppm) 4.10 (d, J 14 Hz, 0.6H), 4.19 
(d, J 13 Hz, 0.4H), 4.40 (d, J 12 Hz, 1H), 7.17-7.33 (m, 2H), 7.34-7.61 (m, 3H), 7.61-7.89 (m, 
3H), 10.70 (s, 0.4 H), 10.76 (s, 0.6H). 13C-NMR (75 MHz, [D6]DMSO) δ (ppm) 41.7, 121.3, 
121.6, 124.3, 124.9, 126.3, 126.9, 127.2, 127.8, 127.9, 128.1, 128.7, 129.1, 129.3, 130.3, 
130.6, 132.4, 132.7, 133.1, 134.3, 135.3, 141.3, 164.9, 165.5, 165.7. HRMS (ESI): m/z [M+H]+ 
calcd. for [C15H12ClN2O2]+ 287.0582, found: 287.0581. C15H11ClN2O2 (286.72). 
 
5-(2-(4-(4-Hydroxybutyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (93) 
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4-(Piperidin-4-yl)butan-1-ol (compound 84) (1.81 g, 11.53 mmol), compound 92 (3.0 g, 10.46 
mmol) and potassium carbonate (5.8 g, 42.03 mmol) were added to MeCN (80 mL) and the 
mixture was kept under reflux for 8 h. Insoluble material was separated by filtration and 
washed with CH2Cl2 (2 × 20 mL). The filtrate and washings were combined and the volatiles 
were removed under reduced pressure yielding a yellow oil, which was dissolved in CH2Cl2 
(20 mL) followed by washing with brine. The aqueous phase was treated with CH2Cl2 (3 × 20 
mL) and the organic extracts were collected. All organic phases were combined and dried over 
Na2SO4. Removal of the volatiles under reduced pressure gave the crude product, which was 
subjected to column chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 96:3:1 v/v/v) to 
afford compound 93 as white solid (2.9 g, 62%), m.p. 143-145 oC. Rf = 0.8 (CH2Cl2/MeOH/25% 
aq NH3 90:9:1 v/v/v). Ratio of configurational isomers evident in the NMR spectra: ca 1.2:1. 
1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 0.86-1.13 (m, 2H), 1.13-1.21 (m, 3H), 1.27-1.38 (m, 
2H), 1.40-1.64 (m, 4H), 1.78-2.04 (m, 2H), 2.48-2.65 (m, 1H), 2.74-2.85 (m, 1H), 3.02 (d, J 15 
Hz, 0.55H), 3.11-3.16 (m, 1H), 3.22 (d, J 15 Hz, 0.45H), 3.51 (t, J 6.5 Hz, 2H), 7.18-7.30 (m, 
2H), 7.30-7.39 (m, 1H), 7.40-7.56 (m, 3H), 7.61-7.66 (m, 1H), 7.80-7.94 (m, 1H). 13C-NMR (75 
MHz, [D4]MeOH): δ (ppm) 24.0, 32.7, 32.9, 33.9, 36.4, 37.4, 54.8, 54.9, 62.9, 123.0, 123.1, 
126.6, 127.0, 127.8, 128.9, 129.0, 129.5, 129.9, 130.6, 131.1, 132.1, 132.3, 134.3, 134.7, 
135.9, 136.9, 143.7, 169.2, 169.4, 171.2, 171.5. HRMS (ESI): m/z [M+H]+ calcd. for 
[C24H30N3O3]+ 408.2282, found: 408.2299. C24H29N3O3 (407.22). 
 
5-(2-(4-(4-Bromobutyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one (94) 
Under an atmosphere of argon compound 93 (200 mg, 0.49 mmol) and PPh3 (386 mg, 1.47 
mmol) were dissolved in CH2Cl2 (5 mL) in a three-necked round bottom flask and the solution 
was cooled to -5 oC. A solution of CBr4 (1.06 g, 3.20 mmol) in CH2Cl2 (10 mL) was added 
dropwise, thereby keeping the temperature of the mixture below 5 oC. Stirring was continued 
at room temperature overnight. The solvent was evaporated and the residue subjected to 
column chromatography to column chromatography (eluent: light petroleum/acetone/25% aq 
NH3 83:16:1 v/v/v) to afford compound 94 as white solid (180 mg, 78%). Rf = 0.5 (light 
petroleum/acetone/25% aq NH3 66:33:1 v/v/v), m.p. 68-70 oC. Ratio of configurational isomers 
evident in the NMR spectra: ca 1.2:1. 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.03-1.27 (m, 
5H), 1.31-1.46 (m, 2H), 1.46-1.62 (m, 2H), 1.73-1.82 (m, 2H), 1.82-2.03 (m, 2H), 2.47-2.64 (m, 
1H), 2.77-2.85 (m, 1H), 3.01 (d, J 18 Hz, 0.55H), 3.10-3.18 (m, 1H), 3.21 (d, J 18 Hz, 0.45H), 
3.41 (t, J 6.7 Hz, 2H), 7.17-7.40 (m, 3H), 7.40-7.59 (m, 3H), 7.61-7.66 (m, 1H), 7.84-7.90 (m, 
1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 26.3, 32.8, 34.1, 34.4, 36.3, 36.6, 54.8, 54.9, 
61.0, 122.9, 126.6, 126.9, 127.8, 128.9, 129.0, 129.5, 129.9, 130.1, 130.6, 133.0, 132.1, 134.3, 
134.7, 135.9, 143.9, 169.3, 171.4. HRMS (ESI): m/z [M+H]+ calcd. for [C24H29BrN3O2]+ 
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470.1438, found: 470.1437. C24H28BrN3O2 (470.41). 
 
5-(2-(4-(4-(6-Amino-4-methyl-1,4-diazepan-1-yl)butyl)piperidin-1-yl)acetyl)-5,10-
dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one tetrakis(hydrotrifluoroacetate) (95) 
Potassium carbonate (70 mg, 0.51 mmol) was added to a solution of compound 94 (120 mg, 
0.26 mmol) and compound 28 (65 mg, 0.28 mmol) in MeCN (5 mL), and the mixture was kept 
under reflux for 3 h. Insoluble material was removed by filtration. The filtrate was concentrated 
under reduced pressure to yield a yellow oil, which was dissolved in CH2Cl2 (5 mL) followed 
by washing with brine. The aqueous phase was treated with CH2Cl2 (3 × 10 mL) and the 
organic extracts were collected. All organic phases were combined and dried over Na2SO4. 
Removal of the solvent under reduced pressure gave the Boc-protected intermediate as yellow 
oil (110 mg, 69%), which was dissolved in CH2Cl2/TFA/H2O (10:10:1 v/v/v) (5 mL). The mixture 
was stirred at room temperature for 2 h. CH2Cl2 (10 mL) was added and the volatiles were 
evaporated. Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; 
gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-62:38, tR = 14 min) afforded compound 95 as 
white ﬂuffy solid (30 mg, 17%). Ratio of configurational isomers evident in the NMR spectra: 
ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.27-1.37 (m, 4H), 1.40-1.55 (m, 3H), 1.56-
1.66 (m, 2H), 1.87-1.95 (m, 2H), 2.83 (s, 3H), 2.88 (t, J 7.9 Hz, 2H), 2.90-2.96 (m, 1H), 3.01-
3.05 (m, 1H), 3.08-3.15 (m, 1H), 3.21-3.24 (m, 1H), 3.26-3.28 (m, 2H), 3.32-3.39 (m, 3H), 
3.43-3.48 (m, 2H), 3.69-3.79 (m, 2H), 3.82-3.86 (m, 1H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 
Hz, 0.4H), 7.23-7.29 (m, 1H), 7.31-7.40 (m, 2H), 7.45-7.52 (m, 2H), 7.60-7.75 (m, 2H), 7.89 
(d, J 8.0 Hz, 0.6H), 7.96 (d, J 8.0 Hz, 0.4H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 24.8, 
26.7, 30.4, 34.3, 36.4, 46.5, 52.7, 54.9, 55.3, 55.6, 56.4, 57.9, 58.0, 58.2, 59.6, 123.1, 123.7, 
126.9, 127.5, 127.9, 128.5, 128.9, 129.4, 130.1, 130.5, 130.9, 131.2, 131.7, 131.9, 132.3, 
132.9, 133.4, 134.6, 134.9, 135.5, 135.7, 136.9, 140.9, 142.7, 164.9, 165.5, 168.9, 168.8. RP-
HPLC (220 nm): 99% (tR = 13.7 min, k = 3.8). HRMS (ESI): m/z [M+H]+ calcd. for [C30H43N6O2]+ 
519.3442, found: 519.3441. C30H42N6O2 · C8H4F12O8 (518.71 + 456.09). 
 
5-(2-(4-(4-(4-(2-Aminoethyl)piperazin-1-yl)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one tetrakis(hydrotrifluoroacetate) (96) 
Compound 94 (280 mg, 0.60 mmol), tert-butyl (2-(piperazin-1-yl)ethyl)carbamate (32) (164 mg, 
0.72 mmol) and potassium carbonate (247 mg, 1.79 mmol) were added to MeCN (20 mL) and 
the mixture was kept under reflux for 3 h. Insoluble material was separated by filtration and 
washed with CH2Cl2 (2 × 5 mL). The filtrate and washings were combined and the solvent was 
evaporated. The residue was dissolved in CH2Cl2 (10 mL) followed by washing with brine. The 
aqueous phase was treated with CH2Cl2 (3 × 10 mL) and the organic extracts were collected. 
All organic phases were combined and dried over Na2SO4. The volatiles were removed under 
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reduced pressure and the residue was subjected to flash column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) to afford the Boc-protected intermediate as white 
solid (270 mg, 73%). Rf = 0.6 (CH2Cl2/MeOH/25% aq NH3 90:10:1 v/v/v). The intermediate 
(270mg, 0.436 mmol) was dissolved in CH2Cl2 (5mL), TFA (1 mL) was added slowly, and the 
mixture was stirred at room temperature for 8 h. CH2Cl2 (10 mL) was added and the volatiles 
were evaporated. Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 
mm; gradient: 0-30 min: MeCN/0.1% aq TFA 20:80-64:36, tR = 8 min) afforded compound 96 
as white fluffy solid (280 mg, 66%). Ratio of configurational isomers evident in the NMR 
spectra: ca 1.8:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.29-1.42 (m, 4H), 1.42-1.60 (m, 
3H), 1.69-1.74 (m, 2H), 1.83 -2.04 (m, 2H), 2.51 (s, 2H), 2.69 (t, J 5.7 Hz, 2H), 2.84-2.99 (m, 
1H), 3.00-3.24 (m, 9H), 3.38-3.60 (m, 3H), 3.70-3.80 (m, 2H), 4.39 (d, J 17 Hz, 0.65H), 4.44 
(d, J 17 Hz, 0.35H), 7.24-7.29 (m, 1H), 7.31-7.38 (m, 2H), 7.45-7.52 (m, 2H), 7.60-7.75 (m, 
2H), 7.89 (d, J 7.8 Hz, 0.65H), 7.96 (d, J 7.8 Hz, 0.35H). 13C-NMR (150 MHz, [D4]MeOH): δ 
(ppm) 24.5, 24.9, 30.4, 34.3, 36.1, 37.3, 50.6, 53.0, 54.6, 54.9, 55.3, 57.7, 58.0, 123.1, 123.6, 
126.8, 127.5, 127.9, 128.5, 128.9, 129.5, 130.1, 130.5, 130.9, 131.2, 131.7, 131.9, 132.3, 
132.9, 133.4, 134.6, 134.9, 135.5, 135.7, 137.0, 141.0, 142.7, 164.9, 165.4, 168.6, 168.8. RP-
HPLC (220 nm): 99% (tR = 13.4 min, k = 3.7). HRMS (ESI): m/z [M+H]+ calcd. for [C30H43N6O2]+ 
519.3442, found: 519.3447. C30H42N6O2 · C8H4F12O8 (518.71 + 456.09). 
 
5-(2-(4-(4-(4-(3-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)propyl)piperazin-1-yl)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one tetrakis(hydrotrifluoroacetate) (97) 
Compound 94 (100 mg, 0.21 mmol), compound 40 (76 mg, 0.23 mmol) and potassium 
carbonate (88 mg, 0.64 mmol) were added to MeCN (5 mL) and the mixture was refluxed for 
6 h. Insoluble material was separated by filtration and washed with CH2Cl2 (2 × 10 mL). The 
filtrate and washings were combined and the solvent was evaporated yielding a yellow oil, 
which was dissolved in CH2Cl2 (5 mL) followed by washing with brine. The aqueous phase 
was treated with CH2Cl2 (3 × 10 mL) and the organic extracts were collected. All organic 
phases were combined, dried over Na2SO4, and the volatiles were removed under reduced 
pressure. Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; 
gradient: 0-30 min: MeCN/0.1% aq TFA 20:80-62:38, tR = 8 min) afforded 97 as white ﬂuffy 
solid (100 mg, 41%). Anal. calcd. for C39H52N8O3S · C8H4F12O8 · H13O6.5: C 43.89, H 5.41, N 
8.71, S 2.49; found: C 43.77, H 4.63, N 8.27, S 2.35. Ratio of configurational isomers evident 
in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.29-1.36 (m, 2H), 1.38-
1.43 (m, 2H), 1.44-1.59 (m, 3H), 1.69-1.75 (m, 2H), 1.89-1.97 (m, 2H), 2.20-2.28 (m, 2H), 
2.68-2.78 (m, 2H), 2.92-2.96 (m, 1H), 3.06 (s, 3H), 2.98-3.09 (m, 3H), 3.09-3.14 (m, 2H), 3.17-
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3.30 (m, 5H), 3.42-3.45 (m, 5H), 3.63 (brs, 1H), 3.71-3.81 (m, 2H), 4.04 (d, J 14.3 Hz, 1H), 
4.40 (d, J 17 Hz, 0.6H), 4.44 (d, J 17 Hz, 0.4H), 4.48-4.58 (m, 1H), 4.61 (t, J 6.2 Hz, 2H), 7.22-
7.24 (m, 1H), 7.26-7.32 (m, 1H), 7.34-7.39 (m, 1H), 7.46-7.51 (m, 1H), 7.52-7.54 (m, 1H), 
7.62-7.77 (m, 3H), 7.89-7.91 (m, 0.6H), 7.95-8.00 (m, 0.4H). 13C-NMR (150 MHz, [D4]MeOH): 
δ (ppm) 23.9, 24.5, 25.1, 25.8, 30.4, 34.3, 36.1, 43.3, 50.6, 50.9, 51.4, 53.1, 54.9, 55.3, 57.8, 
57.9, 58.0, 69.7, 115.1, 116.9, 123.1, 123.6, 125.3, 126.9, 127.5, 127.9, 128.4, 128.5, 128.9, 
129.4, 130.1, 130.5, 130.9, 131.2, 131.9, 132.3, 132.9, 133.4, 134.6, 134.9, 135.5, 135.7, 
137.0, 142.7, 145.6, 158.8, 159.1, 163.4, 164.9, 165.4. RP-HPLC (220 nm): 99% (tR = 14.2 
min, k = 3.9). HRMS (ESI): m/z [M+H]+ calcd. for [C39H53N8O3S]+ 713.3956, found: 713.3951. 
C39H52N8O3S · C8H4F12O8 (712.96 + 456.09). 
 
5-(2-(4-(4-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-[1,4'-bipiperidin]-1'-
yl)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 
tris(hydrotrifluoroacetate) (98) 
Compound 98 was prepared from 94 (80 mg, 0.17 mmol), potassium carbonate (71 mg, 0.51 
mmol) and 63 (56 mg, 0.19 mmol) according to the procedure for the synthesis of 97, but the 
reflux period was 3 h instead of 6 h. Purification by preparative HPLC (column: Kinetex XB-
C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 20:80-62:38, tR = 11 min) 
afforded 98 as white ﬂuffy solid (100 mg, 57%). Ratio of configurational isomers evident in the 
NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.24-1.45 (m, 6H), 1.44-1.58 
(m, 4H), 1.69-1.77 (m, 2H), 1.88-1.98 (m, 3H), 2.09-2.26 (m, 3H), 2.44-2.48 (m, 1H), 2.80-
2.99 (m, 3H), 3.02-3.14 (m, 4H), 3.34-3.48 (m, 2H), 3.54 (t, J 6.3 Hz, 1H), 3.62-3.82 (m, 6H), 
4.38-4.40 (m, 0.4H), 4.42-4.45 (m, 0.6H), 4.58-4.67(m, 1H), 7.02-7.07 (m, 2H), 7.24-7.34 (m, 
2H), 7.34-7.38 (m, 1H), 7.44-7.55 (m, 3H), 7.60-7.78 (m, 3H), 7.89-7.91 (m, 0.6H), 7.96-7.98 
(m, 0.4H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 25.8, 27.8, 28.5, 29.8, 32.9, 36.4, 37.4, 
52.0, 54.1, 54.9, 59.5, 61.0, 61.3, 62.8, 68.8, 110.6, 110.8, 122.2, 122.5, 123.0, 126.6, 127.0, 
127.7, 128.9, 129.0, 129.4, 129.6, 129.9, 130.2, 130.5, 131.1, 132.1, 132.2, 134.3, 134.7, 
136.0, 136.9, 143.7, 143.8, 156.2, 169.1, 169.3, 171.2, 171.4. RP-HPLC (220 nm): 99% (tR = 
14.9 min, k = 4.2). HRMS (ESI): m/z [M+H]+ calcd. for [C41H52N7O3]+ 690.4126, found: 
690.4128. C41H51N7O3 · C6H3F9O6 (689.91 + 342.07). 
 
1-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperidin-4-yl 2,2-diphenylacetate (99) 
Compound 99 was prepared from 94 (100 mg, 0.21 mmol) and 71 (69 mg, 0.23 mmol) 
according to the procedure for the synthesis of 97, but the reflux period was 5 h instead of 6 
h. Potassium carbonate: 88 mg, 0.64 mmol. Purification by column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) afforded compound 99 as white solid (40 mg, 27%), 
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m. p. 47-49 oC. Rf = 0.6 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). Ratio of configurational 
isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 0.97-
1.31 (m, 8H), 1.39-1.42 (m, 2H), 1.48-1.58 (m, 1H), 1.61-1.71 (m, 2H), 1.79-2.01 (m, 4H), 
2.20-2.36 (m, 4H), 2.36-2.51 (m, 2H), 2.55-2.70 (m, 1H), 2.78-2.85 (m, 1H), 2.99-3.04 (m, 
0.6H), 3.11-3.26 (m, 1.4H), 4.84-4.87 (m, 1H), 5.07 (s, 1H), 7.21-7.25 (m, 3H), 7.28-7.32 (m, 
9H), 7.36-7.40 (m, 1H), 7.41-7.51 (m, 2H), 7.53-7.56 (m, 1H), 7.61-7.66 (m, 1H), 7.84-7.90 (m, 
1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 25.8, 27.7, 31.0, 32.9, 33.0, 36.4, 37.4, 51.2, 
54.8, 55.0, 58.4, 59.6, 71.5, 123.0, 126.6, 126.9, 127.8, 128.3, 128.9, 129.0, 129.6, 129.7, 
129.9, 130.6, 132.0, 132.2, 134.3, 134.7, 136.0, 136.9, 140.3, 143.8, 143.9, 169.4, 171.2, 
171.5, 173.5. RP-HPLC (220 nm): 99% (tR = 21.1 min, k = 6.4). HRMS (ESI): m/z [M+H]+ calcd. 
for [C43H49N4O4]+ 685.3748, found: 685.3752. C43H48N4O4 (684.88). 
 
2-(4-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl 9H-xanthene-9-carboxylate 
tris(hydrotrifluoroacetate) (100) 
Compound 100 was prepared from 94 (80 mg, 0.17 mmol) and 77 (58 mg, 0.17 mmol) 
according to the procedure for the synthesis of 97, but the reflux period was 3 h instead of 6 
h. Potassium carbonate: 94 mg, 0.68 mmol. Purification by preparative HPLC (column: Kinetex 
XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 20:80-64:36, tR = 16 min) 
afforded compound 100 as white ﬂuffy solid (93 mg, 51%). Ratio of configurational isomers 
evident in the NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 1.25-1.42 (m, 
4H), 1.44-1.56 (m, 3H), 1.63-1.70 (m, 2H), 1.87-2.04 (m, 2H), 2.57-2.75 (m, 5H), 2.86-3.19 (m, 
8H), 3.33-3.61 (m, 2H), 3.71-3.84 (m, 2H), 4.20 (t, J 5.1 Hz, 2H), 4.41 (d, J 12 Hz, 0.6H), 4.47 
(d, J 12 Hz, 0.4H), 5.10 (s, 1H), 7.07-7.17 (m, 4H), 7/25-7.46 (m, 7H), 7.47-7.55 (m, 2H), 7.61-
7.79 (m, 2H), 7.89-7.92 (m, 0.6 H), 7.96-7.98 (m, 0.4H). 13C-NMR (75 MHz, [D4]MeOH): δ 
(ppm) 19.1, 24.6, 25.1, 30.5, 34.4, 36.2, 46.6, 50.9, 42.7, 55.3, 56.7, 57.7, 58.1, 63.3, 117.9, 
120.2, 122.2, 123.7, 124.6, 126.9, 127.6, 127.9, 128.6, 128.9, 130.2, 130.4, 130.5, 130.9, 
131.8, 132.4, 133.5, 134.6, 136.5, 137.1, 152.9, 162.8, 165.0, 165.5, 172.9. RP-HPLC (220 
nm): 99% (tR = 20.3 min, k = 6.1). HRMS (ESI): m/z [M+H]+ calcd. for [C44H50N5O5]+ 728.3806, 
found: 728.3805. C44H49N5O5 · C6H3F9O6 (727.91 + 342.07). 
 
4-(4-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)butyl 9H-xanthene-9-carboxylate (101) 
Compound 101 was prepared from 94 (50 mg, 0.11 mmol) and 78 (39 mg, 0.11 mmol) 
according to the procedure for the synthesis of 97, but the reflux period was 5 h instead of 6 
h. Potassium carbonate: 59 mg, 0.43 mmol. Purification by column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) yielded compound 101 as white solid (32 mg, 38%), 
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m.p. 43-45 oC. Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). Ratio of configurational 
isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, [D4]MeOH): δ (ppm) 0.98-
1.11 (m, 2H), 1.24-1.37 (m, 8H), 1.41-1.64 (m, 6H), 1.84-2.00 (m, 2H), 2.15-2.25 (m, 3H), 2.26-
2.38 (m, 4H), 2.38-2.51 (m, 4H), 2.61-2.65 (m, 1H), 2.78-2.85 (m, 1H), 2.99-3.04 (m, 0.6H), 
3.12-3.26 (m, 1.4H), 4.04 (t, J 6.0 Hz, 2H), 5.05 (s, 1H), 7.07-7.13 (m, 4H), 7.19-7.26 (m, 2H), 
7.27 (d, J 1.5 Hz, 1H), 7.30-7.38 (m, 4H), 7.41-7.49 (m, 1.6H), 7.50-7.58 (m, 1.4H), 7.62-7.67 
(m, 1H), 7.84-7.91 (m, 1H). 13C-NMR (75 MHz, [D4]MeOH): δ (ppm) 23.6, 25.8, 27.6, 32.9, 
33.1, 36.5, 37.5, 46.7, 53.7, 53.8, 54.9, 55.0, 58.9, 59.8, 61.1, 66.2, 117.9, 120.2, 123.1, 124.6, 
126.6, 127.0, 127.8, 129.0, 129.5, 129.9, 130.2, 130.3, 132.1, 134.3, 134.7, 136.0, 136.9, 
143.8, 152.8, 169.2, 169.4, 171.3, 171.5, 173.4. RP-HPLC (220 nm): 95% (tR = 19.4 min, k = 
5.8). HRMS (ESI): m/z [M+H]+ calcd. for [C46H54N5O5]+ 756.4119, found: 756.4117. C46H53N5O5 
(755.96). 
 
5-(2-(4-(4-((4-(1-(3-(2-Oxo-3,4-dihydroquinolin-1(2H)-yl)propyl)piperidin-4-
yl)butyl)amino)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
11-one (102) 
Compound 86 (50 mg, 0.12 mmol), compound 10 (50 mg, 0.12 mmol), potassium carbonate 
(71 mg, 0.51 mmol) and sodium iodide (9 mg, 0.06 mmol) were added to MeCN (5 mL) and 
the mixture was kept under reflux for 3 h. Insoluble material was separated by filtration and 
washed with CH2Cl2 (2 × 10 mL). The filtrate and washings were combined and the solvent 
was removed under reduced pressure yielding a yellow oily residue, which was dissolved in 
CH2Cl2 (5 mL) followed by washing with brine. The aqueous phase was treated with CH2Cl2 
(3 × 10 mL) and the organic extracts were collected. All organic phases were combined, dried 
over Na2SO4, and the volatiles were removed under reduced pressure. Purification by column 
chromatography (eluent: CH2Cl2/MeOH/25% aq NH3 90:3:1 v/v/v) afforded compound 102 as 
yellow solid (46 mg, 52%), m.p. 141-143 oC. Rf = 0.5 (CH2Cl2/MeOH/25% aq NH3 90:9:1 v/v/v). 
Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (300 MHz, 
[D4]MeOH): δ (ppm) 0.98-1.17 (m, 3H), 1.17-1.35 (m, 12H), 1.42-1.51 (m, 5H), 1.55-1.58 (m, 
1H), 1.63-1.69 (m, 2H), 1.78-1.86 (m, 2H), 1.87-2.02 (m, 4H), 2.32-2.43 (m, 2H), 2.48-2.58 (m, 
5H), 2.58-2.66 (m, 2H), 2.78-2.81 (m, 0.6H), 2.83-2.95 (m, 4H), 2.99-3.04 (m, 0.4H), 3.10-3.25 
(m, 1H), 3.99 (t, J 7.3 Hz, 2H), 7.00-7.05 (m, 1H), 7.13-7.28 (m, 5H), 7.28-7.38 (m, 1H), 7.39-
7.51 (m, 2H), 7.54-7.57 (m, 1H), 7.62-7.67 (m, 1H), 7.84-7.90 (m, 1H). 13C-NMR (75 MHz, 
[D4]MeOH): δ (ppm) 25.1, 25.4, 25.5, 26.2, 30.4, 30.7, 32.7, 32.8, 32.9, 33.0, 34.0, 36.4, 36.8, 
37.4, 37.5, 41.3, 50.5, 50.6, 54.8, 55.0, 57.1, 116.4, 123.0, 124.4, 126.6, 127.0, 127.8, 128.2, 
128.6, 129.0, 129.1, 129.5, 129.9, 130.6, 131.1, 131.9, 132.0, 132.2, 134.3, 135.9, 140.2, 
143.8, 144.9, 169.1, 169.3, 171.2, 171.4, 172.7. RP-HPLC (220 nm): 95% (tR = 16.7 min, k = 
4.8). HRMS (ESI): m/z [M+H]+ calcd. for [C45H61N6O3]+ 733.4800, found: 733.4805. C45H60N6O3 
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(733.01). 
 
5-(2-(4-(4-(6-Amino-4-(3-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)propyl)-1,4-diazepan-1-yl)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one pentakis(hydrotrifluoroacetate) (105a) 
Compound 94 (196 mg, 0.42 mmol), tert-butyl (1,4-diazepan-6-yl)carbamate (compound 103) 
(90 mg, 0.42 mmol) and compound 39 (134 mg, 0.42 mmol) were added to MeCN (10 mL), 
followed by the addition of potassium carbonate (116 mg, 0.84 mmol). The mixture was stirred 
under reflux overnight. Insoluble material was separated by filtration and washed with CH2Cl2 
(2 × 10 mL). The filtrate and washings were combined and the solvent was evaporated to yield 
a yellow residue, which was dissolved in CH2Cl2 (5 mL) followed by washing with brine. The 
aqueous phase was treated with CH2Cl2 (3 × 10 mL) and the organic extracts were collected. 
All organic phases were combined, dried over Na2SO4, and the volatiles were removed under 
reduced pressure. The residue was subjected to column chromatography (eluent: 
CH2Cl2/MeOH/25% aq NH3 90:3:1) to afford the Boc-protected intermediate as colorless oil, 
which was dissolved in CH2Cl2/TFA/H2O (10:10:1 v/v/v) (5 mL). The mixture was stirred at 
room temperature for 2 h. CH2Cl2 (10 mL) was added and the volatiles were evaporated. 
Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-
30 min: MeCN/0.1% aq TFA 5:95-62:48, tR = 15 min) afforded compound 105a as white ﬂuffy 
solid (92 mg, 17%). Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-
NMR (600 MHz, [D4]MeOH): δ (ppm) 1.27-1.41 (m, 4H), 1.41-1.47 (m, 1H), 1.49-1.58 (m, 2H), 
1.65-1.79 (m, 2H), 1.84-2.01 (m, 2H), 2.07-2.20 (m, 2H), 2.64-2.85 (m, 2H), 2.92 (t, J 7.4 Hz, 
3H), 3.05 (s, 3H), 2.98-3.09 (m, 3H), 3.14 (t, J 16 Hz, 2H), 3.17-3.19 (m, 1H), 3.23-3.28 (m, 
1H), 3.31-3.33 (m, 1H), 3.34-3.40 (m, 1H), 3.40-3.48 (m, 2H), 3.48-3.56 (m, 2H), 3.59-3.66 (m, 
1H), 3.69-3.80 (m, 2H), 3.82-3.89 (m, 1H), 3.97-4.09 (m, 1H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, 
J 17 Hz, 0.4H), 4.46-4.54 (m, 1H), 4.57 (t, J 6.5 Hz, 2H), 7.20-7.23 (m, 1H), 7.23-7.30 (m, 1H), 
7.29-7.42 (m, 2H), 7.44-7.56 (m, 2H), 7.61-7.76 (m, 2H), 7.89-7.90 (m, 0.6H), 7.96-7.97 (m, 
0.4H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 23.9, 24.6, 25.5, 27.1, 30.4, 34.3, 36.2, 43.3, 
49.6, 50.9, 52.1, 53.1, 54.9, 55.3, 55.6, 56.2, 56.5, 57.9, 58.0, 59.9, 70.3, 117.0 (TFA), 118.9 
(TFA), 123.1, 123.6, 125.4, 126.8, 127.5, 127.9, 128.3, 128.5, 128.9, 129.4, 130.1, 130.6, 
130.9, 131.2, 131.7, 131.9, 132.4, 133.0, 133.4, 134.6, 134.9, 135.5, 135.7, 137.0, 141.0, 
142.7, 145.6, 162.4 (TFA), 162.6 (TFA), 163.6, 164.9, 165.4, 168.6, 168.8. RP-HPLC (220 
nm): 98% (tR = 14.3 min, k = 4.0). HRMS (ESI): m/z [M+H]+ calcd. for [C40H56N9O3S]+ 742.4221, 
found: 742.42210. C40H55N9O3S · C10H5F15O10 (742.00 + 570.12). 
 
N-(1-(3-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-yl)oxy)propyl)-4-
(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-
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4-yl)butyl)-1,4-diazepan-6-yl)propionamide tetrakis(hydrotrifluoroacetate) (106) 
Compound 105 (12.5 mg, 9.53 μmol) was dissolved in DMF (100 μL) in a 1.5-mL 
polypropylene reaction vessel, followed by the addition of DIPEA (17 μL, 98 μmol) and a 
solution of succinimidyl propionate (compound 104) (2.5 mg, 14.6 μmol) in DMF (20 μL). 
Stirring of the mixture was continued at room temperature for 2 h. 10% aq TFA (100 µL) was 
added. Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; 
gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-62:48, tR = 16 min) afforded compound 106 as 
white ﬂuffy solid (11.4 mg, 95%). IR (KBr): 3430, 3050, 2605, 1680, 1455, 1365, 1210, 1135, 
840, 725. Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 
MHz, [D4]MeOH): δ (ppm) 1.10 (t, J 7.6 Hz, 3H), 1.26-1.42 (m, 4H), 1.43-1.59 (m, 3H), 1.64-
1.76 (m, 2H), 1.88-1.96 (m, 2H), 2.13-2.17 (m, 2H), 2.23 (q, J 7.6 Hz, 2H), 2.65-2.83 (m, 2H), 
2.89-2.95 (m, 1H), 3.05 (s, 3H), 2.98-3.08 (m, 3H), 3.12-3.15 (m, 2H), 3.16-3.28 (m, 5H), 3.41-
3.44 (m, 5H), 3.63 (d, J 4.5 Hz, 1H), 3.70-3.74 (m, 1.5H), 3.79 (d, J 17 Hz, 0.5H), 4.03 (d, J 
15 Hz, 1H), 4.25- 4.32(m, 1H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 4.46-4.55 (m, 
1H), 4.60 (t, J 6.4 Hz, 2H), 7.21-7.23 (m, 1H), 7.24-7.30 (m, 1H), 7.30-7.39 (m, 2H), 7.46-7.49 
(m, 1H), 7.51-7.53 (m, 1H), 7.60-7.76 (m, 2H), 7.88-7.92 (m, 0.6H), 7.96-7.97 (m, 0.4H). 13C-
NMR (150 MHz, [D4]MeOH): δ (ppm) 10.1, 23.9, 24.5, 25.6, 26.9, 29.9, 30.4, 34.3, 36.2, 43.2, 
46.9, 49.6, 50.9, 52.4, 53.1, 54.9, 55.2, 56.2, 57.5, 58.0, 58.4, 59.2, 70.1, 116.9, 123.1, 123.6, 
125.4, 126.9, 127.5, 127.9, 128.4, 128.5, 128.9, 129.4, 130.1, 130.6, 130.9, 131.2, 131.7, 
132.4, 133.0, 133.4, 134.6, 134.9, 135.5, 135.7, 137.1, 141.0, 142.7, 145.6, 162.1 (TFA), 
162.3 (TFA), 163.6, 164.9, 165.4, 168.6, 168.8, 176.9. RP-HPLC (220 nm): 98% (tR = 14.8 
min, k = 4.2). HRMS (ESI): m/z [M+H]+ calcd. for [C43H60N9O4S]+ 798.4483, found: 798.4487. 
C43H59N9O4S · C8H4F12O8 (798.06 + 456.09). 
 
5-(2-(4-(4-(6-Amino-4-(2-oxo-2-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-[1,4'-
bipiperidin]-1'-yl)ethyl)-1,4-diazepan-1-yl)butyl)piperidin-1-yl)acetyl)-5,10-dihydro-11H-
dibenzo[b,e][1,4]diazepin-11-one pentakis(hydrotrifluoroacetate) (107) 
Potassium carbonate (44 mg, 0.32 mmol) was added to a mixture of compound 66 (45 mg, 
0.11 mmol), compound 94 (50 mg, 0.11 mmol), tert-butyl (1,4-diazepan-6-yl)carbamate 
(compound 103) (23 mg, 0.11 mmol) in MeCN (2 mL). The mixture was stirred at 110 oC under 
microwave irradiation for 30 min, and cooled to room temperature. Insoluble material was 
separated by filtration and washed with CH2Cl2 (2 × 5 mL). The filtrate and the washings were 
combined and the solvent was evaporated. The residue was dissolved in CH2Cl2 (5 mL) 
followed by washing with brine. The aqueous phase was treated with CH2Cl2 (3 × 5 mL) and 
the organic extracts were collected. All organic phases were combined and dried over Na2SO4. 
Removal of the volatiles under reduced pressure gave the Boc-protected intermediate, which 
was dissolved in CH2Cl2/TFA/H2O (10:10:1 v/v/v) (4 mL). The mixture was stirred at room 
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temperature for 2 h. CH2Cl2 (10 mL) was added and the volatiles were evaporated. Purification 
by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: 
MeCN/0.1% aq TFA 5:95-62:38, tR = 16 min) afforded compound 107 as white ﬂuffy solid (19 
mg, 12%). 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.36-1.42 (m, 4H), 1.42-1.59 (m, 3H), 1.64-
1.72 (m, 1H), 1.73-1.87 (m, 3H), 1.89-1.97 (m, 2H), 2.09-2.22 (m, 4H), 2.69 (t, J 13 Hz, 1H), 
2.80-2.89 (m, 2H), 2.91-2.97 (m, 1H), 3.00-3.07 (m, 2H), 3.07-3.22 (m, 4H), 3.24-3.27 (m, 3H), 
3.33-3.41 (m, 1H), 3.41-3.49 (m, 2H), 3.50-3.68 (m, 4H), 3.69-3.76 (m, 5H), 3.76-3.83 (m, 2H), 
3.96-3.98 (m, 1H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 4.57-4.62 (m, 1H), 4.72-
4.74 (m, 1H), 7.04-7.07 (m, 3H), 7.22-7.30 (m, 1H), 7.29-7.38 (m, 3H), 7.46-7.49 (m, 1H), 
7.50-7.54 (m, 1H), 7.61-7.64 (m, 1H), 7.66-7.76 (m, 1H), 7.89 (d, J 7.7 Hz 0.6H), 7.96 (d, J 
7.7 Hz, 0.4H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 24.5, 25.0, 27.3, 27.5, 27.8, 27.9, 30.4, 
34.3, 36.1, 41.6, 43.9, 50.2, 50.4, 51.8, 54.9, 55.3, 56.1, 58.0, 58.5, 59.9, 64.7, 109.9, 110.7, 
115.0 (TFA), 116.9 (TFA), 118.9 (TFA), 120.9 (TFA), 122.4, 122.9, 123.1, 123.6, 126.8, 127.5, 
127.9, 128.5, 128.9, 129.4, 129.7, 130.1, 130.5, 130.9, 131.2, 131.7, 131.9, 132.3, 133.0, 
133.4, 134.6, 134.9, 135.5, 135.7, 137.0, 141.0, 142.7, 156.1, 162.3 (TFA), 162.5 (TFA), 162.8 
(TFA), 162.9 (TFA), 164.9, 165.4, 168.6, 168.8, 170.8. RP-HPLC (220 nm): 99% (tR = 14.9 
min, k = 4.2). HRMS (ESI): m/z [M+2H]2+ calcd. for [C48H66N10O4]2+ 423.2629, found: 423.2613. 
C48H64N10O4 · C10H5F15O10 (845.11 + 570.12). 
 
N-(1-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)-4-(2-oxo-2-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)-[1,4'-bipiperidin]-1'-yl)ethyl)-1,4-diazepan-6-yl)propionamide 
tetrakis(hydrotrifluoroacetate) (108) 
Compound 108 was prepared from 107 (7.6 mg, 5.37 μmol) and 104 (1.4 mg, 8.18 μmol) 
according to the procedure for the synthesis of 106. DIPEA: 10 μL, 58 μmol. Purification by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% 
aq TFA 5:95-62:48, tR = 16 min) yielded compound 108 as hygroscopic white fluffy solid (7 mg, 
96%). Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): 
δ (ppm) 1.14 (t, J 7.6 Hz, 3H), 1.32-1.45 (m, 4H), 1.45-1.59 (m, 3H), 1.60-1.80 (m, 4H), 1.80-
1.89 (m, 1H), 1.91-1.99 (m, 2H), 2.09-2.12 (m, 2H), 2.19-2.24 (m, 2H), 2.27 (q, J 12 Hz, 2H), 
2.68-2.76 (m, 1H), 2.81-2.89 (m, 2H), 2.89-3.00 (m, 2H), 3.03-3.17 (m, 4H), 3.16-3.23 (m, 3H), 
3.33-3.51 (m, 5H), 3.51-3.60 (m, 2H), 3.69-3.85 (m, 6H), 3.98-4.06 (m, 1H), 4.12-4.19 (m, 1H), 
4.41 (d, J 17 Hz, 0.6H), 4.45 (d, J 17 Hz, 0.4H), 4.58-4.62 (m, 1H), 4.74-4.76 (m, 1H), 7.05-
7.08 (m, 3H), 7.19-7.40 (m, 4H), 7.47-7.51 (m, 1H), 7.51-7.53 (m, 1H), 7.63 (dd, J 15, 7.1 Hz, 
1H), 7.66-7.76 (m, 1H), 7.90 (d, J 8.0 Hz, 0.6H), 7.97 (d, J 8.0 Hz, 0.4H). 13C-NMR (150 MHz, 
[D4]MeOH): δ (ppm) 10.2, 24.5, 25.4, 27.3, 27.5, 27.9, 30.1, 30.4, 34.3, 36.2, 41.7, 44.1, 50.2, 
50.4, 54.9, 55.3, 56.7, 57.2, 58.0, 59.2, 59.6, 61.0, 64.8, 109.9, 110.7, 116.9 (TFA), 118.9 
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(TFA), 122.4, 122.9, 123.1, 123.6, 126.9, 127.5, 127.9, 128.5, 128.9, 129.4, 129.7, 130.1, 
130.6, 130.9, 131.2, 131.7, 131.9, 132.4, 133.0, 133.4, 134.6, 134.9, 135.5, 135.7, 137.0, 
141.0, 142.7, 156.1, 162.6 (TFA), 162.8 (TFA), 164.9, 165.5, 168.6, 168.8, 177.1. RP-HPLC 
(220 nm): 99% (tR = 15.6 min, k = 4.4). HRMS (ESI): m/z [M+2H]2+ calcd. for [C51H70N10O5]2+ 
451.2760, found: 451.2764. C51H68N10O5 · C8H4F12O8 (901.17 + 456.09). 
 
5-(Aminomethyl)-N1-(4-((5-((4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-
3-yl)oxy)pentyl)amino)-4-oxobutyl)-N3-(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)isophthalamide pentakis(hydrotrifluoroacetate) (110)  
and 5-(Aminomethyl)-N1,N3-bis(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)isophthalamide heptakis(hydrotrifluoroacetate)  (112) 
TBTU (244 mg, 0.76 mmol) and DIPEA (131 μL, 0.76 mmol) were added to a solution of 109 
(113 mg, 0.38 mmol) and HOBt (103 mg, 0.76 mmol) in DMF (2 mL) and the mixture was 
stirred at room temperature for 20 min. A solution of 52 (140 mg, 0.38 mmol), 96 (370 mg, 
0.38 mmol) and DIPEA (131 μL, 0.76 mmol) in DMF (2 mL) was added dropwise and stirring 
was continued at 60 oC for 3 h. H2O (10 mL) was added followed by extraction with ethyl 
acetate (3 × 5 mL). The combined extracts were dried over Na2SO4 and concentrated under 
reduced pressure to yield the Boc-protected intermediate as yellow oil, which was dissolved 
in CH2Cl2/TFA/H2O (10:10:1 v/v/v) (5 mL). The mixture was stirred at room temperature for 2 
h. CH2Cl2 (10 mL) was added and the volatiles were evaporated. Purification by preparative 
HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% aq TFA 
12:88-64:36, tR (112) = 11 min, tR (110) = 12 min) afforded compound 110 (101 mg, 14%) and 
compound 112 (60 mg, 8%) as white ﬂuffy solids. 110: ratio of isomers evident in the NMR 
spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.23-1.43 (m, 5H), 1.43-1.54 (m, 
5H), 1.54-1.63 (m, 3H), 1.68-1.73 (m, 2H), 1.82-2.01 (m, 7H), 2.28 (t, J 7.5 Hz, 2H), 2.69-2.81 
(m, 2H), 2.89-2.95 (m, 4H), 3.02-3.05 (m, 1H), 3.05 (s, 3H), 3.06-3.11 (m, 3H), 3.15-3.22 (m, 
3H), 3.31-3.39 (m, 3H), 3.39-3.47 (m, 4H), 3.58-3.68 (m, 3H), 3.70-3.73 (m, 1.5H), 3.78 (d, J 
18 Hz, 0.5H), 4.02-4.05 (m, 1H), 4.23 (s, 2H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 
4.51 (t, J 6.5 Hz, 2H), 7.23-7.26 (m, 1H), 7.27-7.39 (m, 2H), 7.46-7.53 (m, 2H), 7.59-7.76 (m, 
3H), 7.89-7.90 (m, 0.6 H), 7.95-7.96 (m, 0.4H), 8.04-8.10 (m, 2H), 8.29-8.30 (m, 1H). 13C-NMR 
(150 MHz, [D4]MeOH): δ (ppm) 22.5, 23.0, 23.1, 23.8, 25.4, 28.1, 28.7, 29.0, 32.9, 33.2, 34.7, 
36.1, 38.8, 39.3, 41.9, 42.4, 48.2, 49.6, 50.9, 51.8, 53.5, 53.9, 55.7, 56.3, 56.6, 70.9, 121.7, 
122.2, 124.1, 125.5, 126.1, 126.3, 126.5, 126.8, 127.1, 127.5, 127.5, 128.0, 128.7, 129.2, 
129.5, 129.8, 130.3, 130.6, 130.9, 131.6, 132.0, 133.2, 133.5, 134.1, 134.2, 134.3, 135.4, 
135.6, 135.8, 139.5, 139.6, 141.3, 144.2, 160.2 (TFA), 160.4 (TFA), 160.6 (TFA), 160.8 (TFA), 
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162.4, 163.6, 164.0, 167.1, 167.2, 167.4, 167.6, 174.0. RP-HPLC (220 nm): 96% (tR = 14.9 
min, k = 4.2). HRMS (ESI): m/z [M+H]+ calcd. for [C56H77N12O6S]+ 1045.5810, found: 
1045.5803. C56H76N12O6S · C10H5F15O10 (1045.36 + 570.12).  
112: Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ 
(ppm) 1.29-1.42 (m, 8H), 1.41-1.60 (m, 6H), 1.63-1.77 (m, 4H), 1.88-1.96 (m, 4H), 2.83-2.97 
(m, 2H), 2.98-3.10 (m, 6H), 3.11-3.14 (m, 4H), 3.16-3.28 (m, 4H), 3.30-3.36 (m, 4H), 3.26-3.60 
(m, 10H), 3.69-3.72 (m, 6H), 3.77-3.89 (m, 2H), 4.23 (s, 2H), 4.40 (d, J 17 Hz, 1.2H), 4.44 (d, 
J 17 Hz, 0.8H), 7.21-7.35 (m, 4H), 7.36-7.38 (m, 1H), 7.44-7.54 (m, 4H), 7.58-7.71 (m, 4H), 
7.55-7.73 (m, 1H), 7.86-7.91 (m, 1.2H), 7.95-7.96 (m, 0.8H), 8.10 (s, 2H), 8.34 (s, 1H). 13C-
NMR (150 MHz, [D4]MeOH): δ (ppm) 23.1, 23.7, 29.0, 32.9, 34.7, 35.6, 42.4, 49.3, 50.1, 53.5, 
53.9, 56.0, 56.3, 56.6, 113.7 (TFA), 115.6 (TFA), 117.6 (TFA), 119.5 (TFA), 121.7, 122.3, 125.5, 
126.1, 126.5, 127.1, 127.5, 128.1, 128.7, 129.1, 129.5, 129.8, 130.3, 130.6, 130.8, 130.9, 
131.6, 132.0, 133.2, 133.5, 134.1, 134.3, 135.2, 135.6, 139.6, 141.3, 161.0 (TFA), 161.4 (TFA), 
163.6, 164.1, 167.2, 167.4, 167.7. RP-HPLC (220 nm): 98% (tR = 14.4 min, k = 4.1). HRMS 
(ESI): m/z [M+H]+ calcd. for [C69H91N13O6]2+ 589.8602, found: 589.8601. 
C69H89N13O6 · C14H7F21O14 (1196.56 + 798.16). 
 
N1-(4-((5-((4-(1-Methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazol-3-
yl)oxy)pentyl)amino)-4-oxobutyl)-N3-(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)-5-
(propionamidomethyl)isophthalamide tetrakis(hydrotrifluoroacetate) (111) 
Compound 111 was prepared from 110 (16 mg, 8.7 μmol) and 104 (2.3 mg, 13 μmol) according 
to the procedure for the synthesis of 106. DIPEA: 17 μL, 98 μmol. Purification by preparative 
HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% aq TFA 
20:80-95:5, tR = 9 min), yielded compound 111 as white fluffy solid (12 mg, 89%). Ratio of 
isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.14 
(t, J 7.6 Hz, 3H), 1.31-1.43 (m, 6H), 1.43-1.61 (m, 7H), 1.64-1.79 (m, 2H), 1.84-1.94 (m, 6H), 
1.92-1.99 (m, 1H), 2.24-2.30 (m, 4H), 2.61-2.68 (m, 1H), 2.69-2.83 (m, 3H), 2.85-2.97 (m, 4H), 
2.99-3.14 (m, 9H), 3.18 (t, J 6.6 Hz, 2H), 3.39-3.41 (m, 3H), 3.42-3.53 (m, 1H), 3.61 (t, J 6.2 
Hz, 3H), 3.70-3.80 (m, 2H), 4.03 (d, J 15 Hz, 1H), 4.39 (d, J 17 Hz, 0.6H), 4.41 (d, J 17 Hz, 
0.4H), 4.44 (d, J 4.5 Hz, 2H), 4.50 (t, J 6.5 Hz, 2H), 7.23-7.24 (m, 1H), 7.26-7.40 (m, 2H), 7.46-
7.48 (m, 1H), 7.50-7.53 (m, 1H), 7.59-7.68 (m, 2H), 7.68-7.76 (m, 1H), 7.88 (s, 2H), 7.89-7.90 
(m, 0.6H), 7.96-7.97 (m, 0.4H), 8.14-8.15 (m, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 
10.4, 23.9, 24.4, 24.5, 25.2, 26.5, 26.8, 29.5, 30.0, 30.1, 30.4, 34.3, 34.6, 36.1, 37.5, 40.2, 
40.6, 43.3, 43.7, 51.0, 52.3, 53.2, 54.9, 55.3, 57.4, 57.8, 58.0, 72.4, 115.1 (TFA), 116.4 (TFA), 
117.0 (TFA), 118.9 (TFA), 123.1, 123.6, 125.4, 126.1, 126.9, 127.5, 127.9, 128.2, 128.5, 128.9, 
129.4, 130.1, 130.3, 130.6, 130.9, 131.2, 131.7, 132.3, 133.0, 133.4, 134.6, 134.9, 135.5, 
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136.7, 136.2, 136.5, 137.0, 141.0, 141.5, 142.7, 145.6, 163.8, 164.9, 165.4, 168.6, 168.8, 
169.2, 169.6, 171.1, 171.9, 175.4, 177.1. RP-HPLC (220 nm): 98% (tR = 15.9 min, k = 4.5). 
HRMS (ESI): m/z [M+H]+ calcd. for [C59H81N12O7S]+ 1101.6072, found: 1101.6066. 
C59H80N12O7S · C8H4F12O8 (1101.43 + 456.09). 
 
N1,N3-Bis(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)-5-
(propionamidomethyl)isophthalamide hexakis(hydrotrifluoroacetate) (113) 
Compound 113 was prepared from 112 (17 mg, 8.52 μmol) and 104 (2.3 mg, 13 μmol) 
according to the procedure for the synthesis of 106. DIPEA: 16 μL, 93 μmol. Purification by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% 
aq TFA 20:80-64:36, tR = 11 min), yielded compound 113 as white fluffy solid (13 mg, 79%). 
Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 
1.14 (t, J 7.6 Hz, 3H), 1.30-1.48 (m, 10H), 1.48-1.61 (m, 4H), 1.68-1.79 (m, 4H), 1.85-2.01 (m, 
4H), 2.28 (q, J 7.6 Hz, 2H), 2.81-2.99 (m, 4H), 2.99-3.08 (m, 6H), 3.08-3.17 (m, 6H), 3.17-3.26 
(m, 4H), 3.34-3.48 (m, 8H), 3.48-3.65 (m, 4H), 3.38-3.83 (m, 6H), 4.36-4.51 (m, 4H), 7.20-
7.31 (m, 2H), 7.32-7.35 (m, 2H), 7.36-7.39 (m, 1H), 7.44-7.51 (m, 2H), 7.51-7.53 (m, 2H), 
7.61-7.69 (m, 4H), 7.72-7.78 (m, 1H), 7.89 (d, J 7.7 Hz, 1.2H), 7.93 (s, 2H), 7.96 (d, J 7.7 Hz, 
0.8H), 8.25 (s, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 10.4, 24.5, 25.1, 30.1, 30.4, 34.2, 
36.1, 37.2, 43.5, 50.8, 52.0, 54.9, 55.3, 57.5, 57.8, 58.1, 116.9 (TFA), 118.9 (TFA), 123.1, 
123.7, 126.3, 126.9, 127.5, 127.9, 128.5, 128.9, 129.5, 130.1, 130.5, 130.7, 130.9, 131.2, 
131.7, 131.9, 132.3, 133.0, 133.4, 134.6, 134.9, 135.5, 135.7, 136.0, 137.0, 141.0, 141.6, 
142.7, 162.4 (TFA), 162.6 (TFA), 165.0, 165.5, 168.6, 168.8, 169.6, 177.1. RP-HPLC (220 
nm): 95% (tR = 15.3 min, k = 4.3). HRMS (ESI): m/z [M+H]+ calcd. for [C72H94N13O7]+ 1252.7394, 
found: 1252.7375. C72H93N13O7 · C12H6F18O12 (1252.62 + 684.14). 
 
5-(Aminomethyl)-N1-(2-(4-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-[1,4'-
bipiperidin]-1'-yl)ethyl)-N3-(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)isophthalamide hexakis(hydrotrifluoroacetate) (114) 
Compound 114 was prepared from 109 (80 mg, 0.27 mmol), 96 (263 mg, 0.27 mmol) and 64 
(93 mg, 0.27 mmol) according to the procedure for the synthesis of 110 and 112. TBTU: 173 
mg, 0.54 mmol; HOBt: 73 mg, 0.54 mmol; DIPEA: 189 + 189 μL, 1.1 + 1.1 mmol. Purification 
by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: 
MeCN/0.1% aq TFA 15:85-64:36, tR (112) = 10 min, tR (114) = 12 min) yielded compounds 112 
(25 mg, 5%) and 114 (45 mg, 10%) as white fluffy solids. 114: ratio of isomers evident in the 
NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH) δ (ppm) 1.31-1.42 (m, 4H), 1.43-1.59 
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(m, 3H), 1.66-1.77 (m, 2H), 1.84-1.99 (m, 2H), 2.11 (d, J 12 Hz, 2H), 2.22-2.28 (m, 2H), 2.49 
(d, J 13 Hz, 2H), 2.80-2.96 (m, 3H), 2.98-3.07 (m, 3H), 3.09-3.14 (m, 3H), 3.15-3.28 (m, 5H), 
3.31-3.38 (m, 3H), 3.40-3.50 (m, 6H), 3.64-3.81 (m, 7H), 3.85 (t, J 5.8 Hz, 2H), 3.98 (d, J 12 
Hz, 2H), 4.24 (s, 2H), 4.40 (d, J 18 Hz, 0.4H), 4.43 (d, J 18 Hz, 0.6H), 4.58-4.67 (m, 1H), 7.02-
7.09 (m, 3H), 7.24-7.29 (m, 1H), 7.32-7.88 (m, 2H), 7.45-7.48 (m, 1H), 7.49-7.52 (m, 1H), 
7.60-7.76 (m, 3H), 7.88-7.90 (m, 0.6H), 7.95-7.97 (m, 0.4H), 8.13 (d, J 15 Hz, 2H), 8.37 (s, 
1H). 13C-NMR (150 MHz, [D4]MeOH) δ (ppm) 24.2, 24.5, 25.1, 27.4, 30.4, 34.3, 36.0, 36.1, 
37.2, 43.8, 49.6, 50.5, 50.8, 51.7, 52.3, 54.9, 55.3, 57.4, 57.7, 57.9, 58.0, 61.6, 110.1, 110.7, 
115.1 (TFA), 117.0 (TFA), 118.9 (TFA), 120.9 (TFA), 122.4, 122.9, 123.1, 123.6, 126.9, 127.5, 
127.8, 127.9, 128.5, 128.8, 129.4, 129.7, 130.0, 130.1, 130.5, 130.9, 131.2, 132.7, 131.9, 
132.3, 132.4, 132.9, 133.4, 134.6, 134.9, 135.4, 135.5, 135.7, 136.1, 136.7, 137.0, 140.9, 
142.7, 156.1, 162.3 (TFA), 162.6 (TFA), 162.8 (TFA), 163.0 (TFA), 164.9, 165.5, 168.6, 168.8, 
168.9, 169.4. RP-HPLC (220 nm): 98% (tR = 14.6 min, k = 4.1). HRMS (ESI): m/z [M+H]+ calcd. 
for [C58H77N12O5]+ 1021.6140, found: 1021.6134. C58H76N12O5 · C12H6F18O12 (1021.33 + 
684.14). 
 
N1-(2-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)-[1,4'-bipiperidin]-1'-yl)ethyl)-N3-
(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)-5-
(propionamidomethyl)isophthalamide pentakis(hydrotrifluoroacetate) (115) 
Compound 115 was prepared from 114 (20 mg, 11.7 μmol) and 104 (3.2 mg, 18.7 μmol) 
according to the procedure for the synthesis of 106. DIPEA: 22 μL, 130 μmol. Purification by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% 
aq TFA 20:80-64:36, tR = 9 min), yielded compound 115 as white fluffy solid (17 mg, 88%). IR 
(KBr): 3400, 3070, 2690, 1675, 1545, 1505, 1485, 1460, 1430, 1365, 1200, 1135, 835, 800, 
720. Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D6]DMSO) δ 
(ppm) 1.02 (t, J 7.6 Hz, 3H), 1.15-1.29 (m, 4H), 1.31-1.47 (m, 3H), 1.53-1.66 (m, 2H), 1.73-
1.80 (m, 2H), 1.87-2.05 (m, 4H), 2.16 (q, J 7.6 Hz, 2H), 2.34-2.38 (m, 2H), 2.60-2.72 (m, 2H), 
2.75-3.97 (m, 4H), 2.97-3.05 (m, 4H), 3.05-3.21 (m, 4H), 3.22-3.31 (m, 4H), 3.31-3.45 (m, 3H), 
3.46-3.55 (m, 4H), 3.55-3.62 (m, 4H), 3.65-3.70 (m, 2H), 3.73-3.97 (m, 3H), 4.33 (d, J 5.9 Hz, 
2H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 4.60 (t, J 12 Hz, 1H), 6.93-7.02 (m, 3H), 
7.22-7.30 (m, 2H), 7.33-7.35 (m, 1H), 7.42-7.47 (m, 1H), 7.50-7.60 (m, 1H), 7.68-7.77 (m, 2H), 
7.80-7.82 (m, 0.6H), 7.86-7.88 (m, 0.4H), 7.88 (s, 2H), 8.21 (s, 1H), 8.41-8.43 (m, 1H), 8.75 
(brs, 1H), 8.91 (brs, 1H), 9.61 (brs, 0.6H), 10.66 (Brs, 0.4H), 10.73 (s, 0.4H), 10.78 (s, 0.6H), 
10.94 (s, 1H). 13C-NMR (150 MHz, [D6]DMSO) δ (ppm) 9.9, 23.0, 23.5, 23.7, 23.8, 25.4, 25.8, 
28.5, 28.6, 32.7, 34.4, 34.8, 35.5, 40.1, 41.8, 46.5, 48.4, 49.0, 50.4, 52.7, 53.2, 54.9, 55.9, 
59.5, 108.5, 109.1, 113.6, 115.6, 117.6, 119.5, 120.5, 120.9, 122.3, 124.7, 124.9, 125.5, 127.3, 
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127.7, 128.3, 128.4, 128.7, 128.9, 129.0, 129.7, 130.0, 130.4, 131.0, 131.6, 133.0, 133.1, 
133.8, 134.1, 134.4, 134.7, 135.8, 139.5, 140.4, 141.0, 153.6, 158.2 (TFA), 158.4 (TFA), 158.6 
(TFA), 158.8 (TFA), 164.2, 165.7, 166.1, 166.4, 170.3, 173.1. RP-HPLC (220 nm): 99% (tR = 
15.0 min, k = 4.2). HRMS (ESI): m/z [M+H]+ calcd. for [C61H81N12O6]+ 1077.6397, found: 
1077.6392. C61H80N12O6 · C10H5F15O10 (1077.39 + 570.12). 
 
1-(2-(3-(Aminomethyl)-5-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)carbamoyl)benzamido)ethyl)piperidin-4-yl 2,2-diphenylacetate 
pentakis(hydrotrifluoroacetate) (116) 
Compound 116 was prepared from 109 (80 mg, 0.27 mmol), 96 (262 mg, 0.27 mmol) and 73 
(92 mg, 0.27 mmol) according to the procedure for the synthesis of 110 and 112. TBTU: 173 
mg, 0.54 mmol; HOBt: 73 mg, 0.54 mmol; DIPEA: 95 + 95 μL, 0.54 + 0.54 mmol. Purification 
by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: 
MeCN/0.1% aq TFA 20:80-95:5, tR (112) = 9 min, tR (116) = 11 min) afforded compounds 112 
(30 mg, 6%) and 116 (120 mg, 28%) as white ﬂuffy solids. 116: ratio of configurational isomers 
evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.26-1.40 (m, 
4H), 1.40-1.58 (m, 3H), 1.68-1.73 (m, 2H), 1.81-1.99 (m, 3H), 2.05-2.14 (m, 2H), 2.25-2.26 (m, 
1H), 2.78-2.96 (m, 2H), 2.99 (t, J 6.7 Hz, 2H), 3.03-3.05 (m, 1H), 3.06-3.10 (m, 2H), 3.11-3.22 
(m, 3H), 3.23-3.26 (m, 2H), 3.39-3.46 (m, 6H), 3.55-3.57 (m, 2H), 3.66 (t, J 6.2 Hz, 2H), 3.69-
3.88 (m, 5H), 4.23 (s, 2H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 17 Hz, 0.4H), 5.04-5.09 (m, 1H), 
5.18 (d, J 18 Hz, 1H), 7.25-7.28 (m, 4H), 7.31-7.38 (m, 8H), 7.45-7.49 (m, 1H), 7,51 (d, J 7.8 
Hz, 1H), 7.56-7.81 (m, 3H), 7.88-7.90 (m, 0.6H), 7.95-7.96 (M, 0.4H), 8.11-8.13 (m, 2H), 8.36 
(s, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 24.5, 25.1, 28.1, 28.9, 30.4, 34.3, 35.8, 36.1, 
37.3, 43.8, 49.6, 50.9, 51.9, 54.9, 55.3, 57.4, 57.8, 58.0, 58.1, 66.0, 115.1, 116.9, 117.1 (TFA), 
118.9 (TFA), 123.1, 123.7, 126.9, 127.5, 127.8, 127.9, 128.5, 128.9, 129.5, 129.7, 130.1, 130.5, 
130.9, 131.2, 131.7, 131.9, 132.2, 132.3, 132.4, 133.0, 133.4, 134.6, 134.9, 135.4, 135.7, 
136.1, 136.7, 137.0, 140.0, 141.0, 142.7, 158.8, 159.1, 162.4 (TFA), 162.6 (TFA), 162.8 (TFA), 
163.1 (TFA), 164.9, 165.4, 168.6, 168.8, 168.9, 169.4. RP-HPLC (220 nm): 99% (tR = 17.9 
min, k = 5.2). HRMS (ESI): m/z [M+H]+ calcd. for [C60H74N9O6]+ 1016.5757, found: 1016.5750. 
C60H73N9O6 · C10H5F15O10 (1016.30 + 570.12). 
 
1-(2-(3-((2-(4-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)carbamoyl)-5-
(propionamidomethyl)benzamido)ethyl)piperidin-4-yl 2,2-diphenylacetate 
tetrakis(hydrotrifluoroacetate) (117) 
Compound 117 was prepared from 116 (15 mg, 9.5 μmol) and 104 (2.9 mg, 16.9 μmol) 
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according to the procedure for the synthesis of 106. DIPEA: 16 μL, 92 μmol. Purification by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% 
aq TFA 20:80-95:5, tR = 11 min), afforded compound 117 as hygroscopic white fluffy solid (12.1 
mg, 83%). Anal. calcd. for C63H77N9O7 · C8H4F12O8 · H14O7: C 51.54, H 5.79, N 7.62; found: C 
51.61, H 5.27, N 7.26. Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 
MHz, [D4]MeOH): δ (ppm) 1.14 (t, J 7.6 Hz, 3H), 1.30-1.41 (m, 4H), 1.43-1.57 (m, 3H), 1.68-
1.73 (m, 2H), 1.83-1.96 (m, 3H), 2.03-2.13 (m, 2H), 2.27 (q, J 7.6 Hz, 2H), 2.80-2.89 (m, 2H), 
2.90-2.94 (m, 3H), 2.98-3.02 (m, 2H), 3.05-3.11 (m, 3H), 3.12-3.19 (m, 2H), 3.23-3.26 (m, 2H), 
3.34-3.37 (m, 4H), 3.40-3.48 (m, 2H), 3.55-3.57 (m, 1H), 3.63 (t, J 6.2 Hz, 2H), 3.67-3.85 (m, 
5H), 4.36-4.42 (m, 1H), 4.44 (s, 2H), 5.04-5.19 (m, 2H), 7.24-7.28 (m, 3H), 7.29-7.39 (m, 10H), 
7.46-7.53 (m, 2H), 7.61-7.64 (m, 1H), 7.65-7.76 (m, 1H), 7.89-7.90 (m, 0.6H), 7.92 (d, J 9.3 
Hz, 2H), 7.96-7.97 (m, 0.4H), 8.21 (s, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 10.4, 24.5, 
25.2, 28.2, 29.0, 30.1, 30.4, 34.3, 35.9, 36.1, 37.4, 43.7, 49.6, 50.9, 52.1, 54.9, 55.3, 57.5, 
57.8, 58.1, 65.9, 116.9 (TFA), 118.9 (TFA), 123.1, 123.6, 126.4, 126.9, 127.5, 127.9, 128.5, 
128.9, 129.4, 129.7, 130.1, 130.5, 130.6, 130.8, 130.9, 131.9, 132.4, 133.0, 133.4, 134.6, 
134.9, 135.5, 135.7, 136.2, 137.0, 140.0, 141.0, 141.7, 142.7, 162.0 (TFA), 162.3 (TFA), 162.5 
(TFA), 162.8 (TFA), 164.9, 165.4, 168.6, 168.8, 169.5, 170.1, 177.1. RP-HPLC (220 nm): 98% 
(tR = 18.9 min, k = 5.6). HRMS (ESI): m/z [M+H]+ calcd. for [C63H78N9O7]+ 1072.6024, found: 
1072.6013. C63H77N9O7 · C8H4F12O8 (1072.37 + 456.09). 
 
2-(4-(2-(3-(Aminomethyl)-5-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)carbamoyl)benzamido)ethyl)piperazin-1-yl)ethyl 9H-xanthene-9-carboxylate 
hexakis(hydrotrifluoroacetate) (118) 
Compound 118 was prepared from 109 (80 mg, 0.27 mmol), 96 (262 mg, 0.27 mmol) and 80 
(102 mg, 0.27 mmol) according to the procedure for the synthesis of 110 and 112. TBTU: 172 
mg, 0.54 mmol; HOBt: 73 mg, 0.54 mmol; DIPEA: 95 + 95 μL, 0.55 + 0.55 mmol. Purification 
by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: 
MeCN/0.1% aq TFA 20:80-95:5, tR (112) = 9 min, tR (118) = 11 min) afforded compounds 112 
(20 mg, 4%) and 118 (70 mg, 15%) as white ﬂuffy solids. 118: ratio of isomers evident in the 
NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.29-1.39 (m, 5H), 1.41-1.60 
(m, 3H), 1.67-1.72 (m, 2H), 1.83-2.00 (m, 2H), 2.78 (t, J 4.8 Hz, 2H), 2.69-2.72 (m, 4H), 2.97 
(t, J 6.2 Hz, 2H), 3.03-3.12 (m, 6H), 3.15-3.25 (m, 4H), 3.30-3.51 (m, 8H), 3.66 (t, J 6.3 Hz, 
2H), 3.68-3.82 (m, 4H), 4.20-4.24 (m, 2H), 4.25 (brs, 2H), 4.39 (d, J 17 Hz, 0.6H), 4.43 (d, J 
17 Hz, 0.4H), 5.10 (s, 1H), 7.07-7.17 (m, 4H), 7.23-7.30 (m, 1H), 7.31-7.39 (m, 6H), , 7.46-
7.53 (m, 2H), 7.61-7.65 (m, 1H), 7.66-7.71 (m, 0.6H), 7.73-7.76 (m, 0.4H), 7.89-7.90 (m, 0.6H), 
7.94-7.99 (m, 0.4H), 8.10-8.18 (m, 2H), 8.38-8.39 (m, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ 
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(ppm) 23.1, 23.8, 29.0, 32.9, 34.7, 35.0, 35.9, 42.4, 45.2, 49.5, 50.1, 50.6, 51.3, 53.5, 53.9, 
55.1, 55.9, 56.0, 56.4, 56.6, 61.7, 113.5 (TFA), 115.5 (TFA), 116.4, 117.4 (TFA), 118.7, 119.3 
(TFA), 121.7, 122.2, 123.3, 125.5, 126.1, 126.4, 126.5, 127.1, 127.5, 128.0, 128.7, 129.0, 
129.1, 129.5, 129.8, 130.3, 130.6, 130.8, 130.9, 131.0, 131.6, 132.0, 133.2, 133.5, 134.1, 
134.2, 134.3, 135.0, 135.4, 135.6, 139.6, 141.3, 151.5, 160.8 (TFA), 161.0 (TFA), 161.3 (TFA), 
163.5, 164.0, 167.2, 167.4, 167.5, 167.8, 171.3. RP-HPLC (220 nm): 96% (tR = 17.9 min, k = 
5.2). HRMS (ESI): m/z [M+H]+ calcd. for [C61H75N10O7]+ 1059.5815, found: 1059.5796. 
C61H74N10O7 · C12H6F18O12 (1059.33 + 684.14). 
 
2-(4-(2-(3-((2-(4-(4-(1-(2-Oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-
yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)carbamoyl)-5-
(propionamidomethyl)benzamido)ethyl)piperazin-1-yl)ethyl 9H-xanthene-9-carboxylate 
pentakis(hydrotrifluoroacetate) (119) 
Compound 119 was prepared from 118 (16 mg, 9.18 μmol) and 104 (2.3 mg, 13.4 μmol) 
according to the procedure for the synthesis of 106. DIPEA: 16 μL, 92 μmol. Purification by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-25 min: MeCN/0.1% 
aq TFA 20:80-95:5, tR = 10 min), yielded compound 118 as hygroscopic white fluffy solid (13.3 
mg, 86%). Ratio of isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, 
[D4]MeOH): δ (ppm) 1.14 (t, J 7.6 Hz, 3H), 1.27-1.41 (m, 5H), 1.41-1.57 (m, 3H), 1.67-1.72 (m, 
2H), 1.88-1.95 (m, 2H), 2.28 (q, J 7.6 Hz, 2H), 2.65-2.71 (m, 4H), 2.78-2.83 (m, 2H), 2.81-2.97 
(m, 2H), 2.96-2.98 (m, 3H), 3.01-3.09 (m, 6H), 3.12-3.25 (m, 5H), 3.35-3.45 (m, 4H), 3.65 (t, 
J 6.6 Hz, 2H), 3.69-3.72 (m, 3H), 3.73-3.81 (m, 1H), 4.18-4.25 (m, 2H), 4.39 (d, J 17 Hz, 0.6H), 
4.43 (d, J 17 Hz, 0.4H), 4.46 (s, 2H), 5.10 (s, 1H), 7.10-7.14 (m, 4H), 7.24-7.30 (m, 1H), 7.30-
7.34 (m, 3H), 7.34-7.41 (m, 3H), 7.45-7.50 (m, 1H), 7.49-7.53 (m, 1H), 7.59-7.66 (m, 1H), 
7.66-7.71 (m, 0.6H), 7.73-7.76 (m, 0.4H), 7.89 (m, 0.6H), 7.93-7.97 (m, 2.4H), 8.23-8.24 (m, 
1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 10.4, 24.5, 25.1, 30.1, 30.4, 34.3, 36.1, 36.4, 
37.3, 43.7, 46.6, 50.9, 51.5, 52.0, 52.7, 54.9, 55.3, 56.5, 57.4, 57.5, 57.8, 58.0, 63.1, 116.9 
(TFA), 117.9, 118.8 (TFA), 120.1, 123.1, 123.6, 124.6, 126.4, 126.9, 127.5, 127.9, 128.5, 128.9, 
129.4, 130.1, 130.4, 130.5, 130.6, 130.7, 130.9, 131.2, 131.7, 132.0, 132.4, 133.0, 133.4, 
134.6, 134.9, 135.5, 135.7, 136.1, 137.0, 141.0, 141.7, 142.7, 152.9, 162.1 (TFA), 162.4 (TFA), 
162.6 (TFA), 164.9, 165.4, 168.6, 168.8, 169.6, 169.9, 172.7, 177.2. RP-HPLC (220 nm): 96% 
(tR = 18.9 min, k = 5.6). HRMS (ESI): m/z [M+H]+ calcd. for [C64H79N10O8]+ 1115.6082, found: 
1115.6076. C64H78N10O8 · C10H5F15O10 (1115.39 + 570.12). 
 
5-(Aminomethyl)-N1-(2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)-N3-(2-(4-
(4-(1-(3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl)piperidin-4-yl)butyl)piperazin-1-
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yl)ethyl)isophthalamide heptakis(hydrotrifluoroacetate) (120) 
Compound 120 was prepared from 109 (80 mg, 0.27 mmol), 96 (263 mg, 0.27 mmol) and 88 
(123 mg, 0.27 mmol) according to the procedure for the synthesis of 110 and 112. TBTU: 172 
mg, 0.54 mmol; HOBt: 73 mg, 0.54 mmol; DIPEA: 94 + 94 μL, 0.54 + 0.54 mmol. Purification 
by preparative HPLC (Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-20 min: MeCN/0.1% 
aq TFA 10:90-35:65, tR (112) = 18.5 min, tR (120) = 19.1 min) afforded compounds 112 (15 mg, 
3%) and 120 (22 mg, 4%) as white ﬂuffy solids. 120: ratio of isomers evident in the NMR 
spectra: ca 1.5:1. 1H-NMR (600 MHz, [D4]MeOH): δ (ppm) 1.30-1.41(m, 10H), 1.48-1.62 (m, 
4H), 1.69-1.79 (m, 4H), 1.89-1.92 (m, 1H), 1.93-1.98 (m, 2H), 2.06-2.14 (m, 2H), 2.59-2.69 (m, 
2H), 2.89-2.95 (m, 5H), 3.00-3.09 (m, 6H), 3.14-3.18 (m, 7H), 3.20-3.27 (m, 5H), 3.37-3.49 (m, 
8H), 3.54-3.59 (m, 4H), 3.68-3.80 (m, 7H), 4.06 (t, J 6.3 Hz, 2H), 4.24 (s, 2H), 4.39-4.46 (m, 
1H), 7.04-7.06 (m, 1H), 7.17-7.23 (m, 2H), 7.24-7.39 (m, 4H), 7.46-7.49 (m, 1H), 7.50-7.53 (m, 
1H), 7.61-7.64 (m, 1H), 7.67-7.76 (m, 1H), 7.89 (d, J 7.5 Hz, 0.6H), 7.96 (d, J 7.6 Hz, 0.4H), 
8.12 (s, 2H), 8.38 (s, 1H). 13C-NMR (150 MHz, [D4]MeOH): δ (ppm) 23.7, 24.5, 25.1, 26.1, 
30.4, 30.7, 32.6, 34.3, 34.5, 36.0, 36.1, 36.2, 37.1, 37.2, 40.2, 43.8, 49.6, 50.8, 51.7, 51.8, 
54.1, 54.9, 55.0, 55.3, 55.7, 57.4, 57.8, 57.9, 58.1, 61.0, 116.1, 116.9 (TFA), 118.1 (TFA), 118.9 
(TFA), 123.1, 123.7, 124.8, 126.9, 127.5, 127.9, 128.2, 128.5, 128.8, 128.9, 129.3, 129.5, 
130.1, 130.5, 130.9, 131.2, 131.7, 131.9, 132.2, 132.3, 133.0, 133.4, 134.6, 134.9, 135.4, 
135.5, 135.7, 136.6, 137.0, 139.6, 141.0, 142.7, 162.0 (TFA), 162.3 (TFA), 162.6 (TFA), 164.9, 
165.5, 168.6, 168.8, 168.9, 173.3. RP-HPLC (220 nm): 98% (tR = 15.4 min, k = 4.4). HRMS 
(ESI): m/z [M+H]+ calcd. for [C66H93N12O5]+ 1133.7392, found: 1133.7386. 
C66H92N12O5 · C14H7F21O14 (1133.54 + 798.16). 
 
3.4.2. Synthesis of the radioligands [3H]106 and [3H]115  
 
The tritiated heterodimeric ligands [3H]106 and [3H]115 were prepared by [3H]propionylation of 
the precursor amines 105a and 114, respectively. A solution of succinimidyl [2,3-3H]-
proprionate (specific activity: 80 Ci/mmol, purchased from American Radiolabeled Chemicals, 
St. Louis, MO, via Hartman Analytics, Braunschweig, Germany) (2.5 mCi, 5.5 μg, 31.25 nmol 
(each)) in hexane/EtOAc (9:1) was transferred from the delivered ampoule to a 1.5-mL 
reaction vessel with screw cap, and the solvent was removed in a vacuum concentrator (ca 
30 min at about 30 °C). A solution of the precursor molecule (105a: 0.53 mg, 403 nmol; 114: 
0.52 mg, 305 nmol) in anhydrous DMF/DIPEA (50:1 v/v) (60 μL) was added, and the vessel 
was vigorously shaken at rt for 1.5 h. 2% aq TFA (40 μL) and MeCN/H2O (10:90 v/v) (300 μL) 
were added and the radioligands were purified using an analytical HPLC system (Waters, 
Eschborn, Germany) consisting of two 510 pumps, a pump control module, a 486 UV/vis 
detector, and a Flow-one Beta series A-500 radiodetector (Packard, Meriden, CT). A Luna C18 
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(3 μm, 150 mm × 4.6 mm, Phenomenex, Aschaffenburg, Germany) was used as stationary 
phase at a flow rate of 0.8 mL/min. Mixtures of 0.05% aq TFA (A) and acetonitrile containing 
0.04% TFA (B) were used as mobile phase. The following linear gradient was applied: 0-20 
min: A/B 90:10-79:21, 20-25 min: 79:21 (isocratic), 25-27 min: 79:21-5:95, 27-35 min: 5:95. 
For the purification of each radioligand three HPLC runs were performed (UV detection: 220 
nm; no radiometric detection). Each radioligand was collected in a 2-mL reaction vessel with 
screw cap (tR ([3H]106) = 25.0 min, tR ([3H]115) = 25.2 min). The volume of the combined 
eluates was reduced in a vacuum concentrator to approx. 400 μL and approx. 300 µL, 
respectively and ethanol (400 and 300 µL, respectively) was added. The solutions were 
transferred into 3-mL borosilicate glass vials with conical bottom (Wheaton NextGen 3-mL V-
vials). The reaction vessels were rinsed twice with EtOH/water (50:50 v/v) (200 and 300 µL, 
respectively) and the washings were transferred to the 3-mL glass vials to obtain tentative 
stocks with volumes of 1200 μL. For the quantification of the radioligands, a four-point 
calibration was performed with the corresponding ‘cold’ forms 106 (0.1, 0.2, 0.5, and 0.8 μM) 
and 115 (0.1, 0.2, 0.5, and 1 μM) using the following HPLC conditions: HPLC system, 
stationary phase, eluents and flow rate as above; linear gradient for [3H]106: 0-20 min: A/B 
90:10-69:31, 20-22 min: 69:31-5:95, 22-29 min: 5:95; linear gradient for [3H]115: 0-20 min: A/B 
90:10-72:28, 20-22 min: 72:28-5:95, 22-29 min: 5:95; injection volume: 100 μL; UV detection: 
220 nm. A 2-µL aliquot of each tentative radioligand stock solutions was added to 128 μL of 
acetonitrile/0.05% aq TFA (10:90 v/v), 100 μL of this solution were analyzed by HPLC, and 
five times 2 μL were counted in 3 mL of scintillator (Rotiszint eco plus; Carl Roth, Karlsruhe, 
Germany) with a LS 6500 liquid scintillation counter (Beckmann-Coulter, Munich, Germany). 
These analyses were performed twice. The molarities of the tentative stock solutions of 
[3H]106 and [3H]115 were calculated from the mean of the peak areas and the linear calibration 
curves obtained from the peak areas of the standards. To determine the radiochemical purities 
and to prove the chemical identities, solutions (100 µL) of [3H]106 (0.18 μM) and [3H]115 (0.23 
µM) spiked with 106 (3 μM) and 115 (3 μM), respectively, were analyzed by RP-HPLC using 
the system, column, eluents, flow rate, injection volume and UV detection as for the 
quantification and additionally radiometric detection (flow rate of the liquid scintillator (Rotiscint 
eco plus/acetonitrile (90:10 v/v)): 4.0 mL/min) The following linear gradient was used: 0-20 
min: A/B 90:10-69:31, 20-30 min: 69:31-5:95, 30-38 min: 5:95). The radiochemical purities 
amounted to 98% and 99%, respectively. The analyses were repeated after storage at -20 °C 
for 10 months and revealed radiochemical purities of 88% and 98%, respectively. Calculated 
specific activities: [3H]106, 2.420 TBq/mmol (65.40 Ci/mmol), [3H]115, 1.815 TBq/mmol (49.06 
Ci/mmol). The final activity concentrations were adjusted to 18.50 MBq/mL by the addition of 
EtOH/water (50:50 v/v), resulting in molarities of 7.64 μM ([3H]106) and 10.2 μM ([3H]115). 
Radiochemical yields: [3H]106, 33.64 MBq, 36%; [3H]115, 32.56 MBq, 35%. 
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3.4.3. Investigation of the chemical stability  
 
The chemical stability of 106 and 115 was investigated in PBS (pH = 7.4) at 22 ± 1 °C. The 
incubation was started by addition of a 10 mM solution of the compounds in DMSO (1 μL) to 
PBS (99 μL) to give a final concentration of 100 μM. After 0, 12, and 48 h, an aliquot (20 μL) 
was taken and added to acetonitrile/0.04% aq TFA (1:9 v/v) (20 μL). An aliquot (20 μL) of the 
resulting solution was analyzed by RP-HPLC using a system from Agilent Technologies 
(composed of a 1290 Infinity binary pump equipped with a degasser, a 1290 Infinity 
autosampler, a 1290 Infinity thermostated column compartment, a 1260 Infinity diode array 
detector, and a 1260 Infinity fluorescence detector). A Kinetex-XB C18 2.6 μm, 100 × 3 mm 
(Phenomenex) served as stationary phase at a flow rate of 0.5 mL/min. The following linear 
gradient was applied: 0-20 min: 0.04% aq TFA/acetonitrile 10:90-68:32, 20-22 min: 68:32-95:5, 
22-28 min: 95:5. The detection wavelength was set to 220 nm. 
 
3.4.4. Cell culture and preparation of cell homogenates  
 
CHO-K9 cell lines stably transfected with the human M1-M5 muscarinic receptors were 
obtained from Missouri S&T cDNA Resource Center (Rolla, MO). Cells were cultured in HAM’s 
F12 medium supplemented with fetal calf serum (Biochrom, Berlin, Germany) (10%) and G418 
(Biochrom) (750 µg/mL). CHO-hM2 cell homogenates were prepared according to a reported 
procedure with minor modifications70: the harvest buffer (50 mM TRIS, 1 mM EDTA) was 
supplemented with protease inhibitor (SIGMAFAST, Sigma-Aldrich)). Aliquots of 200 µL were 
transferred to 2-mL cups and stored at -80°C. 
 
3.4.5. MR radioligand binding experiments  
 
All radioligand binding experiments were performed at 22 ± 1 °C. Leibovitz L-15 medium 
(Gibco, Life Technologies GmbH, Darmstadt, Germany) supplemented with 1% BSA (Serva, 
Heidelberg, Germany) (in the following referred to as L15 medium) was used as binding buffer 
throughout. The effects of various MR ligands on the equilibrium binding of [3H]NMS 
(equilibrium competition binding assay) were determined at intact adherent CHO-hMxR cells 
(x = 1-5) in white 96-well plates with clear bottom (Corning Life Sciences, Tewksbury, MA; 
Corning cat. no. 3610) using the protocol of previously described MR binding studies with 
[3H]NMS55 with the following modification: the total volume of L15 medium per well was 200 
µL instead of 188 µL, i.e. the cells were covered with L15 medium (160 µL) followed by the 
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addition of L15 medium (20 µL), neat or containing atropine 10-fold concentrated, and L15 
medium (20 µL) containing the radioligand 10-fold concentrated. The concentration of 
[3H]NMS was 0.2 nM (M1, M2, M3), 0.1 nM (M4) or 0.3 nM (M5) and the incubation time was 3 
h throughout.  
Saturation binding experiments with [3H]106 and [3H]115 at live adherent CHO-hM2 cells were 
also performed as previously described binding studies with [3H]NMS55. The incubation period 
was 2 h. Nonspecific binding was determined in the presence of atropine (7) (500-fold excess 
to the radioligand).  
Saturation binding experiments with [3H]106 and [3H]115 at CHO-hM2 cell homogenates and 
the investigation of the effects of various MR ligands on equilibrium binding of [3H]106 and 
[3H]115 (equilibrium competition binding assay), investigated at CHO-hM2 cell homogenates, 
too, were performed in Primaria 96-well plates (Corning Life Sciences) using a final volume of 
100 µL per well. On the day of the experiment, CHO-hM2 cell homogenates were thawed and 
re-suspended using a 1-mL syringe (Henke-Sass Wolf GmBh, Tuttlingen, Germany) equipped 
with a needle (0.90 × 40 mm, B. Braun, Melsungen, Germany) followed by centrifugation at 
500 g at 4°C for 5 min. The supernatant was discarded and the pellets were re-suspended in 
L15 medium using a 1-mL syringe equipped with a needle (0.45 × 25 mm, B. Braun). The 
homogenates were stored on ice until use. The total amount of protein per well was between 
19 and 43 µg. Wells were prefilled with 70 µL of L15 medium. For total binding, L15 medium 
(10 μL), L15 medium (10 μL) containing the radioligand 10-fold concentrated and cell 
homogenate (10 µL) were added. To determine unspecific binding or the effect of a compound 
of interest on radioligand equilibrium binding, L15 medium (10 μL) containing atropine 10-fold 
concentrated (500-fold excess to the radioligand) or the compound of interest (competitor) 10-
fold concentrated, L15 medium (10 μL) containing the radioligand 10-fold concentrated and 
cell homogenate (10 µL) were added. The applied radioigand concentrations for competition 
binding studies were 2.0 nM ([3H]106) and 0.3 nM ([3H]115). The plates were shaken during 
incubation (2 h for saturation and competition binding experiments). After the incubation the 
homogenates were collected on GF/C filter mats (0.26 mm; Whatman, Maidstone, UK) 
(pretreated with 0.3% aq polyethylenimine) and washed with cold PBS using a Brandel 
Harvester (Brandel, Gaithersburg, MD). Filter pieces for each well were punched out and 
transferred into 1450-401 96-well plates (PerkinElmer). Rotiscint eco plus (Carl Roth) (200 μL) 
was added, the plates were sealed with a transparent sealing tape (permanent seal for 
microplates, PerkinElmer, prod. no. 1450–461), vigorously shaken for at least 3 h, and 
afterwards kept in the dark for at least 1 h prior to the measurement of radioactivity (DPM) with 
a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). In case of saturation binding 
experiments performed with [3H]115 in the presence of 15 (applied at increasing fixed 
concentrations), the total volume per well was 200 µL. Wells were prefilled with 130 µL of L15 
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medium. For total binding, L15 medium (20 μL), L15 medium (20 µL) containing 15 10-fold 
concentrated, L15 medium (20 μL) containing the radioligand 10-fold concentrated and cell 
homogenate (10 µL) were added. To determine unspecific binding, L15 medium (20 μL) 
containing atropine 10-fold concentrated (500-fold excess to [3H]115), L15 medium (20 µL) 
containing 15 10-fold concentrated, L15 medium (20 μL) containing the radioligand 10-fold 
concentrated and cell homogenate (10 µL) were added. 
M2R association and dissociation experiments with [3H]106 and [3H]115 were performed at 
CHO-hM2 cell homogenates in Primaria 96-well plates (Corning Life Sciences) using the 
experimental procedure as for saturation and competition binding experiments at CHO-hM2 
cell homogenates (see above). The concentration of [3H]106 and [3H]115 used for association 
experiments was 2 nM and 0.6 nM, respectively. The incubation was started after different 
periods of time (between 0 and 120 min) and stopped immediately after the last addition of 
radioligand by collecting and washing the homogenates on GF/C filter mats using the 
harvester. Unspecific binding was determined in the presence of 7 (500-fold excess to the 
radioligand). In case of dissociation experiments a preincubation of the cell homogenates with 
the radioligand ([3H]106: 4 nM, [3H]115: 0.6 nM) was performed for 60 min. The preincubation 
was started after different periods of time ([3H]106: between 1 and 180 min, [3H]115: between 
0 and 150 min) by the addition of the radioligand to the wells prefilled with L15 medium and 
cell homogenates. The dissociation was started by addition of 7 (1000-fold excess to the 
radioligand) dissolved in L15 medium (10 μL) (10-fold concentrated). The dissociation was 
stopped by collecting and washing the homogenates using the harvester. For the 
determination of unspecific binding 7 (1000-fold excess to the radioligand) was added during 
the preincubation step. 
 
3.4.6. IP1 accumulation assay  
 
The measurement of M2R stimulated activation of the G-protein mediated pathway was 
performed applying the IP-One HTRF® assay (Cisbio, Codolet, France) according to the 
manufacturer’s protocol. In brief, HEK-293 cells were grown to a confluence of approx. 70% 
and transiently co-transfected with the cDNAs of the human M2 receptor (Missouri S&T cDNA 
Rescourse Center) and the hybrid G-protein Gαqi5-HA (Gαq protein with the last five amino acids 
at the C-terminus replaced by the corresponding sequence of Gαi; gift from the J. David 
Gladstone Institutes, San Francisco, CA)71-72 applying TransIT-293 Mirus transfection reagent 
(MoBiTec, Goettingen, Germany). After one day cells were detached from the culture dish with 
Versene (Life Technologies GmbH, Darmstadt, Germany), seeded into black 384-well plates 
(10,000 cells/well) (Greiner Bio-One, Frickenhausen, Germany) and maintained for 24 h at 37 
oC. After incubation with the test compounds dissolved in stimulation buffer (final concentration 
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range from 1 pM up to 100 µM) at 37 °C for 1 h the detection reagents were added (IP1-d2 
conjugate and Anti-IP1cryptate TB conjugate each dissolved in lysis buffer), and incubation 
was continued at room temperature for 60 min. Time resolved fluorescence resonance energy 
transfer (HTRF) was determined using the Clariostar plate reader (BMG, Ortenberg, Germany) 
measuring fluorescence at 620 (± 10) nm and 670 (± 10) nm (excitation at 330 nm). In the 
agonist mode each compound (106, 115) was tested in duplicate in three individual 
experiments in comparison to the reference compound carbachol (1, eight experiments). 
Antagonist properties of 7, 106 and 115 were determined after preincubation of the cells with 
7, 106 or 115 for 30 min, subsequent addition of the MR agonist 1 (at a final concentration of 
300 nM) and continued incubation at 37 °C for 1 h (five independent experiments each). 
 
3.5. Data processing  
 
Retention (capacity) factors were calculated from retention times (tR) according to k = (tR−t0)/t0 
(t0 = dead time). Data of the IP1 accumulation assay (agonist mode) were processed by 
plotting the ratios (emission 670 nm/emission 620 nm) of the HTRF measurements against 
log(concentration 1) and analysis by a four-parameter logistic equation (GraphPad Prism 
Software 6.0, GraphPad Software, San Diego, CA), followed by normalization (0% = ‘top’ 
(maximum of IP1 accumulation), 100% = ‘bottom’ (basal activity)) of the four-parameter logistic 
fit and analysis of the normalized data by a four-parameter logistic equation (log(agonist) vs. 
response - variable slope). Data of the IP1 accumulation assay (antagonist mode) were 
processed by plotting the fluorescence ratio against log(concentration antagonist) and 
analysis by a four-parameter logistic equation (GraphPad Prism), followed by normalization 
(0% = ‘top’ (IP1 accumulation elicited by 1 (0.3 µM)) of the four-parameter logistic fit, 100% = 
‘bottom’ (basal activity)) and analysis of the normalized data by a four-parameter logistic 
equation (log(inhibitor) vs. response - variable slope). pIC50 values were converted into pKb 
values according to the Cheng-Prusoff equation73 (logarithmic form). Specific binding data 
(DPM) from saturation binding experiments were plotted against the free radioligand 
concentration and analyzed by a two-parameter equation describing hyperbolic binding (one 
site-specific binding, GraphPad Prism) to obtain Kd and Bmax values. The free radioligand 
concentration (nM) was calculated by subtracting the amount of specifically bound radioligand 
(nM) (calculated from the specifically bound radioligand in dpm, the specific activity and the 
volume per well) from the total radioligand concentration per well. Unspecific binding data from 
saturation binding experiments were fitted by linear regression. In case of saturation binding 
experiments with [3H]115 in the presence of compound 15, specific binding data (in DPM) were 
additionally normalized to the Bmax value and specific binding (%) was plotted against 
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log(concentration [3H]115) followed by analysis using a four-parameter logistic fit (log(agonist) 
vs. response, applied constraints: bottom = 0%, top = 100%; GraphPad Prism) (cf. Figure 
10A). Data for the ‘Schild’ analysis were obtained from the rightward shift (ΔpKd) of the 
saturation isotherm and transformation into log(r-1) (where r = 10ΔpKd). Log(r-1) was plotted 
against log(concentration 15) and the data were analyzed by linear regression to obtain the 
slope and the ‘pA2’ value (intercept with the X axis). Specific binding data from association 
experiments with [3H]106 and [3H]115 were analyzed by a two-parameter equation describing 
an exponential rise to a maximum (one-phase association, GraphPad Prism) to obtain the 
observed association rate constant kobs and the maximum of specifically bound radioligand 
(Beq), which was used to calculate specifically bound radioligand (Bt) in %. Data from 
dissociation experiments (% specifically bound radioligand (Bt) plotted over time) were 
analyzed by a three-parameter equation (one phase decay, GraphPad Prism) (in case of 
[3H]106 ‘plateau’ was defined as 0) to obtain the dissociation rate constant koff. The association 
rate constants (kon) were calculated from kobs, koff and the radioligand concentration ([RL]) 
according to the correlation: kon = (kobs-koff)/[RL]. Total binding data (DPM) from radioligand 
competition binding experiments (determination of the effect of various MR ligands on the 
equilibrium binding of [3H]NMS, [3H]106 or [3H]115) were plotted against log(concentration 
competitor) and analyzed by a four-parameter logistic equation (log(inhibitor) vs. response-
variable slope, GraphPad Prism) followed by normalization (100% = ‘top’ of the four-parameter 
logistic fit, 0% = unspecifically bound radioligand (DPM) in case of using [3H]NMS, or 0% = 
‘bottom’ of the four-parameter logistic in case of using [3H]106 and [3H]115) and analysis of 
the normalized data by a four-parameter logistic equation. IC50 were converted to Ki values 
according to the Cheng-Prusoff equation using Kd values of 1.1 nM ([3H]106) and 0.12 nM 
([3H]115)73. Statistical significance was assessed by a one-sample t-test. Propagated errors 
were calculated according to the Gaussian law of errors. 
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4. Dibenzodiazepinone-type fluorescently labeled 
muscarinic receptor ligands 
4.1.  Introduction 
 
Fluorescent GPCR ligands are considered as useful molecular tools complementary to 
radioligands for studying GPCRs. Compared with radioligands, fluorescent ligands are 
advantageous, for instance, with respect to safety issues and high costs for disposal. Moreover, 
appropriate fluorescent ligands can serve to study the localization of receptors in cells by 
fluorescence microscopy, and to probe the geometry and mechanisms of ligand-receptor 
interactions and functional responses at a single cell1-2. Typically, fluorescent ligands are 
composed of a pharmacophore (a known agonist or antagonist for the receptor of interest), a 
linker and the fluorophore2. To design fluorescent ligands with receptor binding properties 
comparable to the parent ligand, several factors need to be taken into consideration (in 
particular in case of low molecular weight/non-peptide ligands): the attachment site and length 
of the linker as well as the type of the fluorophore (size, lipophilicity, net charge, etc.)3 can be 
crucial. Numerous fluorescent ligands for GPCRs have been reported, for example probes for 
NPY4-8, histamine9-13, opioid14-16, dopamine17 and muscarinic receptors18-26.  
Muscarinic acetylcholine receptors (MRs), in humans constituting five subtypes (M1R-M5R), 
are widely distributed in both the peripheral and central nervous systems27-29, and are involved 
in the regulation of various physiological functions. The development of MR ligands, which 
bind with high selectivity to one of the five subtypes, proved to be highly challenging due to 
the high conservation of the orthosteric binding site among MRs. As allosteric binding sites 
are less conserved, the design of allosterically or dualsterically binding MR ligands is 
considered a promising approach to develop ligands with higher subtype selectivity30-31. For 
instance, improved MR subtype binding or functional selectivity was reported for 
dualsterically/bitopically interacting antagonists such as pirenzepine derivatives32-34 and the 
dimeric compound methoctramine35, as well as for agonists such as McN-A-34336 and 
derivatives of AC-4221, 37. 
Various fluorescent MR antagonists such as telenzepine conjugated to Eosin-5 or Cascade 
Blue dyes38-39, and pirenzepine labeled with Bodipy FL40 were used to study the distribution 
and expression of M1 receptors in cultured neurons derived from rat visual cortex or presented 
as alternatives to radiotracers. A series of fluorescent ligands derived from the M1R-preferring 
antagonist pirenzepine were synthesized by Ilien and coworkers23, 41. The fluorophores were 
linked with pirenzepine through linkers of varying chain length. Among these compounds, 
derivative Bo(15)PZ (compound 121, cf. Figure 1) was suggested to bind M1R in a bitopic 
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manner, addressing the orthosteric site (via the pirenzepine moiety) and additionally a brucine 
accessible allosteric site23. Compound 122 (para-LRB-AC42, cf. Figure 1), representing a 
derivative of the bitopic agonist AC-42 labeled with lissamine rhodamine B21, inhibited 
orthosteric [3H]NMS binding at the M1R under equilibrium conditions, and was suggested to 
be competitive with the allosteric modulator 14 (cf. Chapter 3). A putative bitopic/dualsteric 
binding pose for 122 at the human M1 receptor was supported by molecular modeling studies21. 
In contrast to the M1R, reports on fluorescent M2-M5 receptor ligands are rare.  
The observation that dibenzodiazepinone-type heterodimeric ligands, composed of the 
dibenzodiazepinone scaffold (DIBA, compound 9), a linker and a second (varying) MR 
pharmacophore, exhibited throughout high M2R affinity (Ki < 10 nM) (cf. Chapter 3), stimulated 
us to prepare fluorescently labeled ligands derived from 942, a high affinity M2R antagonist. As 
the bulky ‘side chain’ (comprising the linker and the second pharmacophoric group) in DIBA-
derived dimeric ligands was well tolerated with respect to M2R binding, we anticipated that 
also bulky fluorophores attached to 9 will not or only marginally affect binding to the M2R. As 
the radiolabeled homo- and heterodimeric dibenzodiazepinone-type MR ligands [3H]11 and 
[3H]115, respectively (cf. doctoral thesis of Andrea Pegoli and Chapter 3), were shown to bind 
dualsterically to the M2R, the fluorescent ligands presented in this chapter were supposed to 
exhibit a dualsteric binding mode, too, and were characterized in this respect. 
Seven DIBA-derived fluorescent MR ligands were synthesized by linking red-fluorescent 
fluorophores (cf. Figure 2) to the dibenzodiazepinone scaffold using different types of linkers. 
MR binding data were determined by equilibrium competition binding with [3H]NMS. Two 
selected fluorescent ligands were characterized by flow cytometry- and high content imaging-
based binding studies (saturation and competition binding). Moreover, MR binding was 
visualized using confocal microscopy. 
 
Figure 1. Structures of the fluorescently labeled MR ligands 121 and 122, which were suggested to 
exhibit a bitopic/dualsteric binding mode at the M1 receptor21, 23. 
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4.2.  Results and discussion 
4.2.1. Chemistry 
 
The fluorescent dibenzodiazepinone-type MR ligands were prepared using red fluorescent 
dyes (emission wavelength > 590 nm) in order to have low background fluorescence when 
applying the fluorescent ligands at cells. Three different Cy5-related cyanine dyes, i.e. S0223, 
S0436 and S0387 (emission maximum > 650 nm) (cf. Figure 2) as well as the pyrylium dye 
Py-5 (emission maximum > 600 nm) (cf. Figure 2) were used to prepare the fluorescent ligands.  
The cyanine dyes S0223, S0436 and S0387, exhibiting a low Stokes’ shift, can be excited at 
635 nm with a red diode laser. Pyrylium dyes such as Py-5, originally developed for the staining 
of proteins43, react readily with primary amines at pH > 8 to give the corresponding pyridinium 
adducts (cf. Scheme 1), which are characteristic of a large Stokes’ shift and can be excited 
with an argon laser (488 nm). 
 
Figure 2. Structures of the fluorescent dyes (123, 124, 126 and 128) and corresponding succinimidyl 
esters (125, 127 and 129) which were used for the preparation of the fluorescent dibenzodiazepinone-
type MR ligands. 
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Treatment of the DIBA-derived primary amine precursor 1044 and 96 (synthesis presented in 
chapter 3) with the pyrylium dye Py-5 (123) (cf. Figure 2) gave the fluorescent ligands 130 and 
133 (cf. Scheme 2). Likewise, treatment of 10 and 96 with the succinimidyl esters 125, 127 or 
129 (cf. Figure 2), resulted in the fluorescently labeled DIBA derivatives 131-136 (cf. Scheme 
2).  
 
Scheme 1. Conversion of pyrylium to pyridinium entities through reaction with primary amines. 
 
 
Scheme 2. Synthesis of the fluorescently labeled MR ligands 130-136. Reagents and conditions: (a) 
triethylamine, DMF, rt, 2 h, 21% for 130, 34% for 133; (b) DIPEA, DMF, rt, 1-2 h, 28-41% for 131, 132 
and 134-136. 
 
4.2.2. Stability of the fluorescent ligand 136 
 
The fluorescent M2R ligand 136 was investigated with respect to its stability under assay-like 
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conditions (PBS pH 7.4, 22 oC). No decomposition was observed within the incubation period 
of 48 h (cf. Figure 3). 
 
Figure 3. HPLC analysis of 136 after incubation in PBS (pH 7.4) at 23 °C for up to 48 h. 136 showed 
no decomposition. HPLC conditions see experimental section. 
 
4.2.3. Muscarinic receptor affinity and selectivity 
 
The dibenzodiazepinone-type amine precursors 10 and 96, and the fluorescent ligands 130-
136 were investigated in equilibrium competition binding experiments using the orthosteric 
antagonist radioligand [3H]N-methylscopolamine ([3H]NMS, [3H]6) and live CHO cells stably 
expressing the human MR subtypes M1-M5. The results, expressed as Ki values, are listed in 
Table 1. Figure 4A shows the sigmoidal curves of fluorescent ligands 130-136 at M2R. The 
fluorescent ligands derived from amine precursor 96 (133-136), containing the basic 
piperazine moiety, exhibited higher M2R affinities compared to the compounds derived from 
amine precursor 10 (130-132) (cf. Table 1), which is reflected by the affinities of the precursors 
10 and 96 (Ki = 14 and 0.22 nM, respectively). Compound 136, which bears two sulfonic acid 
groups at the fluorophore, proved to be the fluorescent ligand with the highest M2R affinity (Ki 
= 0.76 nM), suggesting that a negative net charge at the fluorophore is advantageous for M2R 
binding. The [3H]NMS displacement curves of ligand 136 at intact CHO-hMx cells (x = 1-5) are 
shown in Figure 4B. Obviously, the bulky fluorophore in 136 doesn’t prevent receptor binding 
of the dibenzodiazepinone pharmacophore. Whereas the 96-derived fluorescent ligands 133-
136 showed a preference for the M2 receptor, the fluorescent ligands derived from 10 exhibited 
no M2 over M4 receptor preference (cf. Table 1). For all compounds the M2R selectivity was 
most pronounced toward the M3R and the M5R. Interestingly, compared to the amine precursor 
96, the M2R preference of all fluorescent ligands was less pronounced (cf. Table 1), indicating 
that a putative dualsteric binding mode of these ligands didn’t result in increased M2R 
selectivity. 
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Figure 4. (A) Concentration-dependent effects of compounds 130-136 on [3H]NMS (c = 0.2 nM) 
equilibrium binding at intact CHO-hM2 cells. (B) Concentration-dependent effects of compound 136 on 
equilibrium binding of [3H]NMS at intact CHO-hMx cells (x = 1-5) (concentration of [3H]NMS: 0.2 nM 
(M1R-M3R), 0.1 nM (M4R), 0.3 nM (M5R)). Data were analyzed by four-parameter logistic fits. Data 
represent mean values ± SEM from at least three independent experiments (performed in triplicate). 
 
Table 1. MR affinities (Ki values) of the amine precursors 10 and 96, and the fluorescent ligands 130-
136 obtained from equilibrium competition binding studies with [3H]NMS at live CHO-hMx cells (x = 
1-5). 
Comp. dyea 
M1R M2R M3R M4R M5R 
Ki 
[nM] 
slopeb Ki [nM] slope
b Ki 
[nM] 
slopeb 
Ki 
[nM] 
slopeb 
Ki 
[nM] 
slopeb 
10 - n.d. n.d. 
14 ± 
3.2 
-0.98 ± 
0.07 
n.d. n.d. n.d. n.d. n.d. n.d. 
96 - 
7.4 ±  
1.6 
-0.87 ± 
0.12 
0.22 ± 
0.03 
-1.0 ± 
0.14 
190 ± 
0.67 
-0.77 ± 
0.11 
3.6 ± 
0.67 
-0.83 ± 
0.09 
230 ± 
17 
-1.1 ± 
0.10 
130 Py-5 
36 ±  
6.1 
-1.5 ± 
0.24 
17 ± 
3.2 
-1.2 ± 
0.20 
86 ± 
12 
-1.3 ± 
0.06 
16 ± 
1.1 
-1.3 ± 
0.04 
200 ± 
30 
-1.6 ± 
0.09 
131 S0223 
140 ±  
22 
-1.3 ± 
0.12 
54 ± 
5.4 
-1.6 ± 
0.14 
640 ± 
38 
-1.7 ± 
0.11 
68 ± 
3.2 
-1.4 ± 
0.09 
290 ± 
63 
-1.7 ± 
0.16 
132 S0436 
400 ±  
37 
-1.8 ± 
0.29 
150 ± 
24 
-1.5 ± 
0.25 
960 ± 
230 
-1.0 ± 
0.11 
220 ± 
9.6 
-1.3 ± 
0.22 
930 ± 
240 
-1.1 ± 
0.24 
133 Py-5 
16 ±  
1.6 
-1.8 ± 
0.19 
3.1 ± 
0.41 
-1.9 ± 
0.23 
150 ± 
9.9 
-1.8 ± 
0.02 
12 ± 
4.6 
-1.4 ± 
0.18 
400 ± 
71 
-1.3 ± 
0.20 
134 S0223 
18 ±  
1.7 
-2.2 ± 
0.08 
4.5 ± 
0.47 
-2.3 ± 
0.16 
88 ± 
13 
-1.4 ± 
0.14 
19 ± 
3.7 
-1.5 ± 
0.09 
69 ± 
7.7 
-1.5 ± 
0.11 
135 S0436 
12 ±  
2.7 
-1.9 ± 
0.17 
1.4 ± 
0.18 
-1.3 ± 
0.14 
68 ± 
2.4 
-1.1 ± 
0.03 
4.8 ± 
2.5 
-1.1 ± 
0.07 
140 ± 
1.9 
-1.5 ± 
0.15 
136 S0387 
5.9 ±  
1.1 
-1.4 ± 
0.17 
0.76 ± 
0.11 
-1.3 ± 
0.12 
82 ± 
5.4 
-0.99 ± 
0.12 
2.5 ± 
0.99 
-1.0 ± 
0.12 
150 ± 
53 
-0.99 ± 
0.16 
aFluorescent dye used for the preparation of the respective fluorescent ligand. bCurve slope of the four-
parameter logistic fit. Mean values ± SEM from 3-5 independent experiments (each performed in 
triplicate). Kd values44 / applied concentrations of [3H]NMS: M1R: 0.12 / 0.2 nM; M2R: 0.090 / 0.2 nM; 
M3R: 0.089 / 0.2 nM; M4R: 0.040 / 0.1 nM; M5R: 0.24 / 0.3 nM. 
 
4.2.4. Fluorescence properties of compounds 133-136. 
 
The fluorescence quantum yields were determined (reference: cresyl violet perchlorate) for 
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the fluorescent ligands 133-136 in PBS (pH 7.4) and in PBS with 1% bovine serum albumin 
(BSA) to study the influence of proteins on the quantum yield (cf. Table 2). By selecting 
compounds 133-136 all types of fluorophores, used in this work, were covered.   
 
Table 2. Fluorescence properties of the fluorescent ligands 133-136 in PBS and PBS containing 1% 
BSA: excitation/emission maxima and fluorescent quantum yields Φ (reference: cresyl violet 
perchlorate). 
Compound Dyea 
PBS PBS+1% BSA 
λex/λem Φ (%) λex/λem Φ (%) 
133 Py-5 460/713 8.9 484/643 23.8 
134 S0223 645/663 19.1 655/675 42.1 
135 S0436 648/665 20.9 660/678 30.1 
136 S0387 653/669 17.7 656/672 29.0 
aFluorescent dye used for the preparation of the respective fluorescent ligand. 
 
All the investigated fluorescent ligands showed a higher quantum yield in PBS with 1 % BSA 
compared to neat PBS (cf. Table 2). The increase in fluorescence quantum yield by adding 
BSA was most pronounced for 133 and 134 (> 2-fold). This phenomenon can be explained by 
hydrophobic and electrostatic interactions between the fluorophores and the protein resulting 
in a reduced molecular motion of the fluorophore and a changed chemical environment. 
 
Figure 5. Excitation and corrected emission spectra (recorded at 22 °C) of the fluorescent ligands 133-
136 dissolved in PBS supplemented with 1% BSA. 
 
The excitation and corrected emission spectra of 133-136 in PBS containing 1% BSA are 
depicted in Figure 5, which demonstrates the considerable difference in Stoke’s shifts between 
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the Py-5 labeled ligand (133) and the cyanine dye labeled ligands (134-136), as well as the 
suitability of 133 to be excited with an argon laser (488 nm) and the compatibility of 134-136 
with an excitation by the red diode laser (635 nm). 
 
4.2.5. Flow cytometric M2R binding studies with the fluorescent MR 
ligands 135 and 136 
4.2.5.1. Saturation binding studies  
 
Fluorescent ligands 135 and 136, which showed excellent M2R affinity (Ki values < 1.5 nM, cf. 
Table 1) were used for binding studies with flow cytometry. Saturation binding experiments 
performed with 135 and 136 at intact CHO-hM2R cells, afforded Kd values of 2.4 nM and 1.0 
nM, respectively (cf. Figure 6A and 6B, Table 3), which were in good agreement with the Ki 
values (1.4 and 0.76 nM, respectively, cf. Table 1) obtained from competition binding 
experiments with [3H]NMS at live CHO-hM2R cells. At concentrations corresponding to the Kd 
value, unspecific binding amounted to around 10% of total binding for both fluorescent ligands 
(cf. Figure 6A and 6B). The orthosteric antagonist atropine (7), used to determine unspecific 
binding, was capable of completely preventing one-site (monophasic) specific binding of the 
fluorescent ligands, indicating that 135 and 136 bind to the orthosteric binding pocket of the 
M2R. 
In addition, saturation binding experiments were performed with 136 at intact CHO-hM1R cells 
as well as at intact CHO-hM4R cells (cf. Figure 6C and 6D), resulting in Kd values of 6.5 nM 
and 8.9 nM, respectively, which were in good agreement with the Ki values (M1R: 5.9 nM, M4R: 
2.5 nM) obtained from competition binding experiments with [3H]NMS at live CHO-hM1R and 
CHO-hM4R cells (cf. Table 1). 
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Figure 6. Representative saturation isotherms (specific binding, dashed line) obtained from flow 
cytometric saturation binding experiments performed with 135 (A) and 136 (B) at intact CHO-hM2 cells 
as well as with 136 at intact CHO-hM1 cells (C) and intact CHO-hM4 cells (D). Unspecific binding was 
determined in the presence of atropine (500-fold excess). Cells were incubated with the fluorescent 
ligands at 22 oC in the dark for 2 h. Experiments were performed in duplicate. Measurements were 
performed with a FACSCalibur flow cytometer (Becton Dickinson). Specific binding data were analyzed 
by an equation describing one-site (monophasic) binding. Error bars of specific binding represent 
propagated errors calculated according to the Gaussian law of errors. Error bars of total and unspecific 
binding represent the mean ± SEM from at least two independent experiments (each performed in 
duplicate). 
 
The association and dissociation kinetics of 136 was determined at intact CHO-hM2R cells at 
22 °C using flow cytometry. The association curve reached a plateau after approx. 120 min 
(cf. Figure 7A). The dissociation of 136 from the M2R was slow (t1/2 = 52 min) and incomplete, 
reaching a plateau at 83% of initial specific binding of 136 (cf. Figure 7B). However, the 
kinetically derived dissociation constant Kd(kin), calculated according to Kd(kin) = koff/kon, 
amounted to 2.4 nM and was in good agreement with the Kd value (1.0 nM) obtained from 
saturation binding experiments. An overview of the M2R binding characteristics of ligand 136, 
determined by flow cytometric binding studies, is provided in Table 3. 
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Figure 7. Association and dissociation kinetics of 136 determined at intact CHO-hM2 cells at 22 oC 
using a FACSCalibur flow cytometer. A: Association of 136 (c = 3 nM) to the M2R as a function of time. 
Inset: ln[Beq/(Beq−Bt)] versus time, kobs = slope = 0.027 min−1. B: Dissociation of 136 (preincubation: 5 
nM, 120 min) from the M2R as a function of time; analyzed by a three-parameter equation describing 
an (incomplete) monophasic exponential decline (t1/2 = 53 min, plateau (dotted line) = 83%). Inset: 
ln[Bt/B0] versus time, slope·(−1) = koff = 0.0013 min−1. Data represent the mean ± SEM from two 
independent experiments (each performed in duplicate). 
 
Table 3. M2R binding data of the fluorescent ligand 136 determined using flow cytometry. 
Saturation binding Binding kinetics 
Kd(sat) [nM]a Kd(kin) [nM]b kon [min-1·nM-1]c koff [min-1]d t1/2 [min-1]d 
1.0 ± 0.2 2.4 ± 0.22 0.012 ± 0.0015 0.014 ± 0.0024 52 ± 9.2 
aDissociation constant determined by saturation binding at live CHO-hM2 cells; mean ± SEM from three 
independent experiments (performed in duplicate). bKinetically derived dissociation constant ± propagated error 
(Kd(kin) = koff/kon). cAssociation rate constant ± propagated error, calculated from kobs, koff and the applied 
fluorescent ligand concentration (cf. experimental section). dDissociation rate constant and half-life; mean ± SEM 
from two independent experiments (performed in duplicate). 
 
4.2.5.2. Competition binding.  
 
The suitability of fluorescent ligand 136 as reference compound for the determination of M2R 
ligand affinities was explored in competition binding experiments. The fluorescent ligand 136 
was used at a concentration corresponding to its Kd value (1 nM). Selected standard MR 
agonists (2), antagonists (7, 8, 11) and allosteric modulators (14, 15, 16) were investigated by 
equilibrium competition binding at live CHO-hM2R cells using flow cytometry. All types of MR 
ligands (orthosteric (2, 7), dualsteric (8, 11) and allosteric (14, 15 and 16)) were capable of 
completely inhibiting specific binding of 136, resulting in sigmoidal curves that reached 0% 
specific binding of 136 (cf. Figure 8A and 8B). These results were indicative of a competitive 
mechanism between 136 and the investigated MR ligands. The apparent Ki values (shown in 
Table 4) were consistent with the Ki or IC50 values obtained from equilibrium binding studies 
with [3H]NMS in the presence of the MR ligands 2, 7, 8, 11 and 14-16. 
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Figure 8. Concentration-dependent effects of various reported orthosteric (2, 7) and dualsteric (8, 11) 
(A), as well as allosteric (14, 15, 16) (B) MR ligands on M2R equilibrium binding of 136 (c = 1 nM) 
determined at intact CHO-hM2 cells using a FACSCalibur flow cytometer.  
 
Table 4. M2R binding data (Ki or IC50 values) of various orthosteric (2, 7), allosteric (14, 15, 16) and 
dualsteric (8, 11) MR ligands determined with 136 or [3H]NMS. 
Compound 
136 
Ki [nM]a 
[3H]NMS 
Ki* or IC50** [nM] 
2 210 ± 5.3 210 ± 59*b 
7 1.9 ± 0.55 0.94 ± 0.19*b 
8 6.2 ± 2.4 2.0 ± 0.2*b 
11 2.1 ± 0.27 0.79 ± 0.10*b 
14 2700 ± 450 2200 ± 410**c 
15 250 ± 44 460 ± 130**c 
16 6900 ± 1200 >10000**c 
aDetermined by flow cytometric equilibrium binding studies with 136 (c = 1 nM) in the presence of increasing 
concentrations of the respective MR ligand at live CHO-hM2 cells; mean values ± SEM from at least two 
independent experiments (performed in duplicate). bDetermined by equilibrium competition binding with 
[3H]NMS (c = 0.2 nM) at live CHO-hM2 cells; mean ± SEM from at least three independent experiments 
(performed in triplicate). cIC50 values obtained from nonlinear four-parameter logistic curve analyses of data 
characterizing the inhibition of [3H]NMS (c = 0.2 nM) equilibrium binding at live CHO-hM2 cells; mean ± SEM 
from at least 3 independent experiments (performed in triplicate). 
 
4.2.5.3. Saturation binding of the fluorescent ligand 136 in the presence of the 
allosteric modulator 15.  
 
On one hand, saturation binding experiments with 136 at the M2R, using the orthosteric 
antagonist 7 to determine unspecific binding (cf. Figure 6B), suggested an interaction of 136 
with the orthosteric site of the M2R. On the other hand, M2R equilibrium binding of 136 in the 
presence of the allosteric modulators 14, 15 and 16 indicated a competitive mechanism 
between 136 and the allosteric modulators (cf. Figure 8B). These findings are consistent with 
a dulasteric binding mode of ligand 136 at the M2R. To further elucidate the competitive 
mechanism between ligand 136 and the allosteric modulator W84 (15), saturation binding 
experiments were performed with the fluorescent ligand 136 in the presence of 15. This kind 
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of experiment is equivalent to the Schild analysis based on functional studies with agonists in 
the presence of antagonists, and was used, e.g. to prove the hypothesis of a competitive 
interplay between the allosteric modulator brucine and the fluorescent pirenzepine derivative 
Bo(22)Pz at the M1R41. Figure 9 shows the saturation isotherms of binding of 136 to the M2R 
in the absence or presence of different concentrations (0.1, 0.3, 1 and 3 μM) of the allosteric 
modulator 15. 15 caused a parallel rightward shift of occupancy curves, going along with an 
apparent decrease in the affinity of 136. Based on the shift of the Kd value a ‘Schild’ plot was 
constructed (cf. Figure 9). The slope factor was not significantly different from unity (slope = 
0.85 ± 0.06 (n = 2), P > 0.2), supporting the hypothesis of a competitive mechanism between 
15 and 136 and dualsteric binding of 136 at the M2R.  
 
Figure 9. Saturation binding of 136 in the presence of increasing concentrations of 15. Presented are 
saturation isotherms of specific binding of 136 to the M2R in linear scale (left) and semi-logarithmic 
scale (middle), as well as the “Schild” regression (right) resulting from the rightward shifts (ΔpKd) of the 
saturation isotherms (log(r-1) plotted vs. log(concentration 15), where r = 10ΔpKd). The presence of the 
allosteric modulator 15 led to a parallel rightward shift of the saturation isotherms of 136. The slope of 
the linear “Schild” regression was not different from unity (P > 0.2, assessed based on the slope mean 
value ± SEM (0.85 ± 0.06) from two sets of independent saturation binding experiments (performed in 
duplicate)) indicating a competitive interaction between 136 and 15. Data represent mean values ± SEM 
from at least two independent experiments (performed in duplicate). 
 
4.2.6. Application of the fluorescent ligands 135 and 136 to high 
content imaging 
4.2.6.1. Saturation binding.  
 
The fluorescent ligands 135 and 136 were also applied in plate reader-based, high-content 
imaging M2R binding assays, using live CHO-hM2R cells. The fluorescent ligands 135 and 136 
were incubated with CHO-hM2R cells for 60 min at 22 oC, and directly (without washing of the 
cells) imaged by the ImageXpress (IX) Ultra plate reader. Figures 10A and 10B show 
representative saturation binding curves of 135 and 136. The Kd values amounted to 13 nM 
and 4.8 nM, respectively. Due to the strong adsorption of the fluorescent ligands 135 and 136 
to the 96 well plate (Grenier 655090), high levels of unspecific binding were detected (cf. 
Figure 10A and 10B). The application of a washing step (HBSS+0.1% BSA) after the 
incubation for 60 min at 22 oC, followed by immediate acquisition of the images, resulted in 
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considerably lower unspecific binding (at concentrations around the Kd value ca 5% (135) and 
ca 2% (136) of total binding) and unaffected Kd values (cf. Figure 10C and 10D). The 
disadvantage of the washing step is the loss of equilibrium conditions, however, as the 
fluorescent ligands exhibit low off rates (cf. Figure 7B), the fraction of dissociated ligand during 
the washing step is marginal.  
The Kd values obtained by high content imaging were slightly higher than the Ki values (1.4 
nM for 135 and 0.76 nM for 136) derived from radioligand competition binding experiments 
with [3H]NMS at the M2R, as well as compared to Kd values (2.4 nM for 135 and 1.0 nM for 
136) obtained from saturation binding using flow cytometry. This deviation might be caused by 
the strong adsorption of the fluorescent ligands to the plates used for high-content imaging, 
leading to a decrease in the concentration of ‘free’ fluorescent ligand. Figure 11 shows 
representative images acquired with the IX Ultra plate reader after incubation with the 
fluorescent ligand 136 (c = 10 nM) for 60 min followed by a washing step at M2R. A clear 
difference between total and unspecific binding of 136 was observed. Ki and Kd values of 135 
and 136 are summarized in Table 5. 
 
Figure 10. Representative saturation isotherms (specific binding, dashed line) of 135 and 136 obtained 
from high-content imaging saturation binding experiments at intact CHO-hM2 cells. (A) (B) Cells were 
incubated with the fluorescent ligand at 22 oC in the dark for 1 h and directly imaged. Unspecific binding 
was determined in the presence of atropine (1 μM). (C) (D) Cells were incubated with the fluorescent 
ligand at 22 oC in the dark for 1 h, plates were washed with HBSS+0.1% BSA before acquisition of the 
images. Unspecific binding was determined in the presence of atropine (500-fold excess). Experiments 
were performed in triplicate. Measurements were performed with an IX Ultra Confocal Plate Reader 
(Molecular Devices). Specific binding data were analyzed by an equation describing one-site 
(monophasic) binding. Error bars of specific binding represent propagated errors calculated according 
to the Gaussian law of errors. Error bars of total and unspecific binding represent the SEM (n = 3). 
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Figure 11. Binding of the fluorescent ligand 136 (c = 10 nM) to live CHO-hM2 cells investigated by high-
content imaging. Images (400 ˣ 400 pixels from original 1000 ˣ 1000 acquisition) were acquired with an 
IX Ultra platereader after 60 min of incubation in the dark at 22 °C from one of saturation binding 
experiments performed with 136. The cells were washed with HBSS+0.1% BSA before imaging. 
Unspecific binding of 136 was determined in the presence of 500-fold excess of atropine (lower panel). 
Presented are Hoechst-33342-stained nuclei in greyscale (left), the fluorescence detected in the Cy5 
channel in greyscale (centre), and the overlay (right). 
 
Table 5. Comparison of M2R binding data of 135 and 136. 
Compound Ki [nM]a Kd [nM]b Kd [nM]c Kd [nM]d 
135 1.4 ± 0.2 2.4 ± 0.6 13 ± 2.5 8.9 ± 1.2 
136 0.76 ± 0.11 1.0 ± 0.2 4.8 ± 1.5 3.9 ± 0.78 
aKi values taken from Table 1. bDissociation constant from flow cytometric saturation binding studies at 
live CHO-hM2 cells; mean ± SEM from three independent experiments (performed in duplicate). 
cDissociation constant from high-content imaging saturation binding studies at live CHO-hM2 cells 
(without performing washing step); mean ± SEM from three independent experiments (performed in 
triplicate). dDissociation constant from high-content imaging saturation binding studies at live CHO-hM2 
cells (washing step was applied); mean ± SEM from three independent experiments (performed in 
triplicate). 
 
4.2.6.2. Competition binding.  
 
Ligands 135 and 136 were used as fluorescent probes to study of a range of known muscarinic 
receptor ligands (including orthosteric antagonist 6 and 7, orthosteric agonist 2 and 3, 
allosteric modulators 14, 15 and 16). CHO-hM2 cells were grown in 96-well plates and 
incubated with 135 or 136 (fixed concentration, 10 nM) and 2, 3, 6, 7, 14, 15 or 16 at increasing 
concentrations at room temperature for 1 h. Images were directly acquired with the 
128                                       Chapter 4 
ImageXpress (IX) Ultra plate reader after incubation without washing. Representative images, 
obtained from competition binding of 136 with 2, 6 or 7 are depicted in Figure 12A. Competition 
binding curves were generated using the mean of arbitrary intensity units from each well (cf. 
Figure 12B and 12C), and Ki values were calculated using the Cheng-Prusoff equation, using 
the Kd values (8.9 nM for 135 and 3.9 nM for 136) determined in high-content imaging 
saturation binding studies (cf. Table 5). All the orthosteric ligands 2, 3, 6 or 7 investigated were 
capable of totally inhibiting (displacing) specific M2R binding of ligands 135 and 136, which 
suggested a competitive-like mode between the studied compounds and the fluorescent 
labeled ligands at the orthosteric receptor site. Moreover, the allosteric modulators 14, 15 and 
16 also fully displaced 136 from the M2 receptor. In the case of using 136 as the fluorescent 
probe, the Ki values of 2, 7, 14, 15 and 16 (cf. Table 6) correlated well with the Ki values 
obtained from flow cytometric competition binding studies (cf. Table 4). However, when using 
135 as fluorescent probe, the Ki values obtained for 2, 6 and 7 were slightly higher (ca 3-fold) 
than the Ki values obtained from competition binding experiments with 136. The binding 
constants (Ki values) of several MR ligands obtained in these experiments are shown in Table 
6.  
 
 
Figure 12. (A) Representative thumbnail fluorescence images acquired with an IX Ultra plate reader of 
a high-content imaging competition binding assay performed with the fluorescent ligand 136 (c = 10 nM) 
and 2, 6 or 7 at live CHO-hM2 cells in a 96-well plate. Each image from one well represents an area 
400 x 400 μm. (B) Concentration-dependent effects of the orthosteric MR ligands 2, 6 or 7 on M2R 
equilibrium binding of 135 determined at intact CHO-hM2 cells using high-content imaging. (C) 
Concentration-dependent effects of various reported orthosteric (2, 3, 6 or 7), allosteric (14-16) MR 
Chapter 4                                           129 
ligands on equilibrium binding of 136 determined at intact CHO-hM2 cells using high-content imaging. 
 
Table 6. Comparison of M2R binding data (Ki or IC50 values) of various orthosteric (2, 3, 6 and 7), 
allosteric (14-16) MR ligands determined with 135, 136 or [3H]NMS. 
Compound 
135 
Ki [nM]a 
136 
Ki [nM]a 
[3H]NMS 
Ki* or IC50** [nM] 
2 950 ± 220 360 ± 26 210 ± 59*b 
3 - 800 ± 330 9300*c 
6 2.6 ± 1.4 0.69 ± 0.14 0.2*d 
7 15 ± 4.8 4.8 ± 0.92 0.94 ± 0.19*b 
14 - 3900 ± 760 2200 ± 410**e 
15 - 1000 ± 130 460 ± 130**e 
16 - 5000 ± 1000 >10000**e 
aDetermined by high-content imaging equilibrium binding studies with 135 (c = 10 nM) or 136 (c = 10 nM) in the 
presence of increasing concentrations of the respective MR ligand at live CHO-hM2 cells; mean ± SEM from 
three independent experiments (performed in duplicate). bKi values taken from Table 4. cJakubík et al.45. dDei et 
al.46. eIC50 values obtained from nonlinear four-parameter logistic curve analyses of data characterizing the 
inhibition of [3H]NMS (c = 0.2 nM) equilibrium binding at live CHO-hM2 cells; mean ± SEM from at least three 
independent experiments (performed in triplicate). 
 
4.2.6.3. Study of the effect of the allosteric modulator 15 on saturation binding 
of fluorescent ligand 136.  
 
A series of saturation binding experiments to investigate the effect of the allosteric modulator 
15 on the M2R saturation binding properties of fluorescent ligand 136 was also performed 
using high content imaging. Figure 13 shows the curves of saturation binding of 136 in the 
absence or presence of varied concentrations (0.3, 1, 2 and 3 μM) of 15 performed at CHO-
hM2 cells. The results were comparable with the results obtained from the same type of 
experiment performed using flow cytometry. The presence of 15 led to a parallel rightward shift 
of the saturation isotherms of ligand 136. The slope of the linear ‘Schild’ regression was not 
different from unity (slope = 0.93 ± 0.11 (n = 3), P > 0.5), suggesting again a competitive 
interaction between ligand 136 and 15. The ‘pA2’ value of 15 derived from the ‘Schild’ 
regression (‘pA2’ = 6.80, Figure 13) was in good agreement with the ‘pA2’ value obtained from 
the flow cytometry-based ‘Schild’ analysis (‘pA2’ = 7.27, Figure 9). 
 
Figure 13. Saturation binding of 136 in the presence of increasing concentrations of 15. Presented are 
saturation isotherms of specific binding of 136 to the M2R in linear scale (left) and semi-logarithmic 
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scale (middle), as well as the “Schild” regressions (right) resulting from the rightward shifts (ΔpKd) of 
the saturation isotherms (log(r-1) plotted vs. log(concentration 15), where r = 10ΔpKd). The presence of 
the allosteric modulator 15 led to a parallel rightward shift of the saturation isotherms of 136. The slope 
of the linear “Schild” regression was not different from unity (P > 0.5, assessed based on the slope 
mean value ± SEM (0.93 ± 0.11) from three sets of independent saturation binding experiments) 
indicating a competitive interaction between 136 and 15. Data represent mean values ± SEM from three 
independent experiments (performed in triplicate). 
 
4.2.7. Application of the fluorescent ligand 136 to confocal 
microscopy 
 
The fluorescent ligand 136 was also applied in confocal microscopy using live CHO-hM2R 
cells. As shown in Figure 14, a clear difference between the total and unspecific binding of 
136 (30 nM) to CHO-hM2R cells was detected by confocal microscopy after different incubation 
times (5-45 min). Unspecific binding of 136 was determined in the presence of the MR 
antagonist atropine (10 μM; Figure 14A vs. 14B). The major fraction of fluorescence appeared 
to be associated to the cell membrane. An increase in intracellular fluorescence was not 
observed over time. 
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Figure 14. Binding of the fluorescent ligand 136 to CHO-hM2R cells at 30 °C, visualized by confocal 
microscopy after 5, 15, 25, 35 and 45 min. (A) Total binding of 136 (30 nM). (B) Unspecific binding 
of 136 (30 nM) determined in the presence of atropine (10 μM). Images were acquired with a Zeiss 
LSM710 confocal microscope. 
 
4.3. Conclusion 
 
This work represents the first report on fluorescently labeled dibenzodiazepinone-type M2 
subtype-preferring MR ligands. The dibenzodiazepinone scaffold was linked to fluorophores 
via two different linkers with respect to lengths and chemical nature (non-basic vs. basic), 
yielding seven fluorescent ligands. Six of these fluorescent probes exhibited high M2R affinity 
(Ki < 55 nM). Variations of the chemical structure of the fluorophores had less impact on M2R 
affinity than the type of the linker. The attachment of the cyanine dyes S0436 and S0387 
through a linker containing a piperazine moiety yielded the fluorescent ligands with the highest 
affinity (135 and 136: Ki ≈ 1 nM) at M2R. Application of 135 and 136 to flow cytometry and high 
content imaging proved that these new fluorescent probes are suited for such techniques. The 
fluorescent ligand 136 was identified as a valuable, non-radiolabeled pharmacological tool for 
the determination of MR affinities of MR ligands. M2R binding studies with 136 in the presence 
of allosteric modulators strongly suggested that 136 and structurally related ligands bind 
simultaneously to both the orthosteric (through the dibenzodiazepinone scaffold) and the 
‘common’ allosteric binding site (most likely through the fluorophores) of the M2R (dualsteric 
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binding mode). Owing to the low M2R selectivity, the fluorescent ligand 136 represents a 
potential fluorescent probe for binding studies at the M1R and M4R as well, which was 
supported by saturation binding studies at the M1R and M4R revealing Kd values of 6.5 and 
8.9 nM, respectively. Moreover, this work suggests that anchoring an allosteric moiety (here 
mimicked by the fluorophore) through a linker to the dibenzodiazepinone scaffold might be a 
promising perspective to develop selective M2R antagonists according to the dualsteric ligand 
approach31, 47-49. 
 
4.4. Experimental section 
4.4.1. General experimental conditions 
 
Acetonitrile for HPLC (gradient grade) was obtained from Merck (Darmstadt, Germany). 
Millipore water was used throughout for the preparation of stock solutions, buffers and HPLC 
eluents. Bovine serum albumin (BSA) was from Serva (Heidelberg, Germany). DMF, 
trimethylamine and trifluoroacetic acid were obtained from (Sigma-Aldrich (Deisenhofen, 
Germany), and N,N-diisopropylethylamine (DIPEA) (99%) was purchased from ABCR 
(Karlsruhe, Germany). The pyrylium dye Py-5 was synthesized by Mengya Chen in our 
research group as part of her master thesis. The succinimidyl esters of the fluorescent dyes 
S0223 (equates to S2197), S0536 (S0436-NHS) and S0586 (S0387-NHS) were obtained from 
FEW Chemicals (Bitterfeld-Wolfen, Germany). [3H]N-methylscopolamine ([3H]NMS) (specific 
activity = 80 Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. (St. Louis, 
MO) via Hartman Analytics GmbH (Braunschweig, Germany). Atropine, N-methylscopolamine 
(NMS), W84 and gallamine were purchased from Sigma-Aldrich (Deisenhofen, Germany). 
Oxotremorine sesquifumarate was from MP Biomedicals (Eschwege, Germany). LY2119620 
was from Absource Diagnostic (Munich, Germany) and AF-DX 384 was purchased from 
Abcam (Cambridge, UK). Xanomeline (2) was prepared according to described procedures50 
(purity = 97%). Compound 11 was prepared in our lab according to a reported protocol44. 
Polypropylene reaction vessels (1.5 mL) with screw cap (Süd-Laborbedarf, Gauting, Germany) 
were used for the synthesis of fluorescent ligands, for the investigation of chemical stabilities 
(136) and for the preparation and storage of stock solutions. 1H-NMR spectra were recorded 
on a Bruker Avance 600 (1H: 600 MHz) (Bruker, Karlsruhe, Germany) with TMS as external 
standard. High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 
6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA) 
using an ESI source. Preparative HPLC was performed on a system from Knauer (Berlin, 
Germany) consisting of two K-1800 pumps and a K-2001 detector. A Kinetex-XB C18, 5 μm, 
250 mm × 21 mm (Phenomenex, Aschaffenburg, Germany) served as stationary phase at a 
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flow-rate of 15 mL/min using mixtures of acetonitrile and 0.1% aq TFA as mobile phase. A 
detection wavelength of 220 nm was used throughout. Lyophilisation of the collected fractions 
was performed with an Alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany) 
equipped with a RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, Germany). Analytical 
HPLC analysis was performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) 
composed of a L-6200-A pump, an AS-2000A autosampler, a L-4000A UV detector, a D-6000 
interface. A Kinetex-XB C18, 5 μm, 250 mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) 
was used as stationary phase at a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% 
aq TFA (B) were used as mobile phase (degassed by Helium purging). The following linear 
gradient was applied: 0-30 min: A/B 5:95-85:15, 30-32 min: 85:15-95:5, 32-40 min: 95:5. 
Detection was performed at 220 nm throughout. The oven temperature was 30 °C. The stock 
solutions (concentrations: 1, 5 or 10 mM) of fluorescent ligands were prepared in DMSO/H2O 
(1:1 v/v) and were stored at -80 oC. 
The fluorescent ligands were characterized by 1H-NMR spectroscopy, HRMS, and RP-HPLC 
analysis. The purity (RP-HPLC, detection at 220 nm) of the fluorescent ligands amounted 
to >96%. Annotation concerning the 1H-NMR spectra of the fluorescent ligands (130-136): due 
to a slow rotation about the exocyclic amide group on the NMR time scale, two isomers (ratios 
provided in the experimental protocols) were evident in the 1H-NMR spectra. 
 
4.4.2. Chemistry: experimental protocols and analytical data 
 
4-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dien-1-yl)-2,6-dimethyl-1-(4-(1-(2-oxo-
2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)pyridin-1-ium hydrotrifluoroacetate trifluoroacetate (130)  
The reaction was carried out in a 1.5-mL eppendorf reaction vessel equipped with a micro stir 
bar. Compound 10 (2.0 mg, 4.92 μmol) and triethylamine (4.98 mg, 6.8 μL, 49.2 μmol) were 
dissolved in anhydrous DMF (300 μL) followed by the addition of Py-5 × 1 BF4− (123) (5.4 mg, 
14.8 μmol) in anhydrous DMF (120 μL) and stirring at room temperature in the dark for 2 h. 
10% aq TFA (corresponding to 49.2 µmol of TFA) were added. Purification of the product by 
preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% 
aq TFA 5:95-62:38, tR = 22 min). afforded 130 as a red solid (0.91 mg, 21%). Ratio of 
configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): 
δ (ppm) 1.38-1.44 (m, 2H), 1.46-1.61 (m, 4H), 1.79-1.85 (m, 2H), 1.92-2.06 (m, 2H), 2.78 (s, 
6H), 2.88-2.99 (m, 1H), 3.02 (s, 6H), 3.18-3.19 (m, 1H), 3.40-3.42 (m, 1H), 3.42-3.52 (m, 1H), 
3.68-3.85 (m, 2H), 4.33-4.37 (m, 2H), 4.40 (d, J 18 Hz, 0.6H), 4.43 (d, J 18 Hz, 0.4H), 6.57 (d, 
J 18 Hz, 1H), 6.76 (d, J 12 Hz, 2H), 6.92-7.01 (m, 2H), 7.25-7.40 (m, 3H), 7.43 (d, J 12 Hz, 
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2H), 7.47-7.54 (m, 2H), 7.61-7.67 (m, 2H), 7.68-7.76 (m, 3H), 7.90-7.91 (m, 0.6H), 7.97-7.98 
(m, 0.4H). RP-HPLC (220 nm): 98% (tR = 19.4 min, k = 5.8). HRMS (ESI): m/z [M]+ calcd. for 
[C43H50N5O2]+: 668.3959, found: 668.3963. C43H50N5O2+ · C4HF6O4− (668.91 + 227.04). 
 
2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)hexyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-1,3,3-trimethyl-3H-indol-1-ium hydrotrifluoroacetate 
trifluoroacetate (131) 
Compound 131 was prepared from 10 (2.2 mg, 5.42 μmol) and S2197 (2.4 mg, 3.63 μmol) 
according to the procedure for the synthesis of 130, but DIPEA (4.69 mg, 6.3 μL, 36.3 μmol) 
was used instead of triethylamine. Purification by preparative HPLC (column: Kinetex XB-C18 
5 µm 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-90.5:9.5, tR = 22 min) 
afforded the product as a blue solid (1.62 mg, 40%). Ratio of configurational isomers evident 
in the NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.25-1.35 (m, 5H), 1.42-
1.47 (m, 4H),1.47-1.52 (m, 1H), 1.63-1.69 (m, 2H), 1.69 (s, 12H), 1.78-1.84 (m, 2H), 1.85-1.98 
(m, 2H), 2.17 (t, J 6.0 Hz, 2H), 2.84-2.93 (m, 1H), 2.98-3.04 (m, 1H), 3.11 (t, J 6.0 Hz, 2H), 
3.18-3.19 (m, 0.5H), 3.31-3.33 (m, 1H), 3.41-3.42 (m, 1H), 3.42-3.44 (m, 0.5H), 3.61 (s, 3H), 
3.68-3.74 (m, 1H), 4.08 (t, J 12 Hz, 2H), 4.37 (d, J 18 Hz, 0.6H), 4.41 (d, J 18 Hz, 0.4H), 6.26 
(d, J 12 Hz, 2H), 6.60 (t, J 12 Hz, 1H), 7.24-7.35 (m, 6H), 7.36-7.53 (m, 7H), 7.60-7.64 (m, 
1H), 7.67-7.76 (m, 1H), 7.89-7.90 (m, 0.6H), 7.95-7.97 (m, 0.4H), 8.21-8.26 (m, 2H). RP-HPLC 
(220 nm): 97% (tR = 25.9 min, k = 8.0). HRMS (ESI): m/z [M]+ calcd. for [C56H67N6O3]+: 
871.5269, found: 871.5265. C56H67N6O3+ · C4HF6O4- (872.19 + 227.04). 
 
4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)amino)hexyl)indolin-2-
ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-ium-1-yl)butane-1-
sulfonatedi(hydrotrifluoroacetate) (132)  
Compound 132 was prepared from 10 (1.9 mg, 4.67 μmol) and S0536 (2.2 mg, 3.14 μmol) 
according to the procedure for the synthesis of 130, but DIPEA (4.05 mg, 5.5 μL, 31.3 μmol) 
was used instead of triethylamine. Purification by preparative HPLC (column: Kinetex 5µ-XB-
C18 250 × 21 mm; gradient: 0-30 min: MeCN/0.1% aq TFA 5:95-90.5:9.5, tR = 19 min) afforded 
the product as a blue solid (1.43 mg, 37%). Ratio of configurational isomers evident in the 
NMR spectra: ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): δ (ppm) 1.26-1.35 (m, 5H), 1.43-1.47 
(m, 4H), 1.48-1.54 (m, 2H), 1.64-1.69 (m, 2H), 1.71 (s, 6H), 1.72 (s, 6H), 1.77-1.84 (m, 2H), 
1.84-1.89 (m, 1H), 1.92-1.99 (m, 4H), 2.18 (t, J 6.0 Hz, 2H), 2.88-2.95 (m, 2H), 3.02-3.06 (m, 
1H), 3.13 (t, J 6.0 Hz, 2H), 3.18-3.19 (m, 0.5H), 3.31-3.32 (m, 1H), 3.41-3.42 (m, 0.5H), 3.43-
3.46 (m, 1H), 3.66-3.80 (m, 2H), 4.08 (t, J 6.0 Hz, 2H), 4.10-4.16 (m, 2H), 4.37 (d, J 18 Hz, 
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0.6H), 4.43 (d, J 18 Hz, 0.4H), 6.25 (d, J 18 Hz, 1H), 6.33-6.36 (m, 1H), 6.60-6.66 (m, 1H), 
7.19-7.27 (m, 4H), 7.31-7.35 (m, 2H), 7.36-7.41 (m, 2H), 7.41-7.54 (m, 5H), 7.59-7.65 (m, 1H), 
7.66-7.75 (m, 1H), 7.88-7.89 (m, 0.6H), 7.94-7.96 (m, 0.4H), 8.19-8.24 (m, 2H). RP-HPLC 
(220 nm): 96% (tR = 24.2 min, k = 7.4). HRMS (ESI): m/z [M+H]+ calcd. for [C59H73N6O6S]+: 
993.5307, found: 993.5317. C59H72N6O6S · C4H2F6O4 (993.32 + 228.05). 
 
4-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dien-1-yl)-2,6-dimethyl-1-(2-(4-(4-(1-(2-
oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-
yl)butyl)piperazin-1-yl)ethyl)pyridin-1-ium tris(hydrotrifluoroacetate) trifluoroacetate 
(133)  
Compound 133 was prepared from 96 (3.0 mg, 3.08 μmol), Py-5 × 1BF4- (3.65 mg, 9.90 μmol) 
and triethylamine (5.36 mg, 7.4 μL, 52.9 μmol) according to the procedure for the synthesis of 
130. Purification of the product by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 
mm; gradient: 0-30 min: MeCN/0.1% aq TFA 20:80-64:36, tR = 12 min) afforded the product 
as a red solid (1.31 mg, 34%). Ratio of configurational isomers evident in the NMR spectra: 
ca 1.5:1. 1H-NMR (600 MHz, MeOH-d4): (ppm) δ 1.27-1.31 (m, 4H), 1.35-1.38 (m, 1H), 1.45-
1.63 (m, 1H), 1.65-1.77 (m, 2H), 1.86-1.99 (m, 2H), 2.00-2.02 (m, 1H), 2.13-2.22 (m, 1H), 2.59 
(t, J 12 Hz, 2H), 2.82 (s, 6H), 2.88-2.97 (m, 3H), 3.02 (s, 6H), 3.06-3.16 (m, 4H), 3.17-3.18 (m, 
1H), 3.41-3.42 (m, 1H), 3.43-3.47 (m, 1H), 3.53-3.56 (m, 2H), 3.67-3.80 (m, 2H), 4.38 (d, J 18 
Hz, 0.6H), 4.42 (d, J 18 Hz, 0.4H), 4.55 (t, J 6.0 Hz, 2H), 6.57 (d, J 18 Hz, 1H), 6.75 (d, J 6.0 
Hz, 2H), 6.92-7.03 (m, 2H), 7.24-7.40 (m, 3H), 7.43 (d, J 6.0 Hz, 2H), 7.46-7.54 (m, 2H), 7.51-
7.70 (m, 3H), 7.72-7.75 (m, 2H), 7.88-7.93 (m, 0.6H), 7.96-7.98 (m, 0.4H). RP-HPLC (220 nm): 
98% (tR = 16.6 min, k = 4.8); HRMS (ESI): m/z [M]+ calcd. for [C49H62N7O2]+: 780.4960, found: 
780.4961. C49H62N7O2+ · C8H3F12O8- (781.08 + 456.09). 
 
2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)hexyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-1,3,3-trimethyl-3H-indol-1-
ium tris(hydrotrifluoroacetate) trifluoroacetate (134)  
Compound 134 was prepared from 96 (5.8 mg, 5.95 μmol) and S2197 (3.0 mg, 4.54 μmol) 
according to the procedure for the synthesis of 130, but DIPEA (5.87 mg, 7.9 μL, 45.3 μmol) 
was used instead of trimethylamine and the incubation time period was 1 h instead of 2 h. 
Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-
30 min: MeCN/0.1% aq TFA 5:95-90.5:9.5, tR = 19 min) afforded the product as a blue solid 
(2.06 mg, 31%). Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-
NMR (600 MHz, MeOH-d4): δ (ppm) 1.28-1.40 (m, 5H), 1.42-1.57 (m, 5H), 1.57-1.69 (m, 4H), 
1.72 (s, 12H), 1,77-1.85 (m, 2H), 1.85-2.02 (m, 2H), 2.21 (t, J 6.0 Hz, 2H), 2.63-2.65 (m, 2H), 
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2.81-2.97 (m, 2H), 2.98-3.05 (m, 3H), 3.18-3.20 (m, 2H), 3.31-3.36 (m, 5H), 3.38-3.50 (m, 2H), 
3.62 (s, 3H), 3.66-3.79 (m, 2H), 4.09 (t, J 6.0 Hz, 2H), 4.39 (d, J 18 Hz, 0.6H), 4.40-4.45 (d, J 
18 Hz, 0.4H), 6.26 (d, J 12 Hz, 2H), 6.59-6.63 (m, 1H), 7.23-7.32 (m, 5H), 7.32-7.43 (m, 3H), 
7.46-7,54 (m, 4H), 7.61-7.65 (m, 2H), 7.67-7.76 (m, 1H), 7.89-7.90 (m, 0.6H), 7.96-7.97(m, 
0.4H), 8.21-8.26 (m, 2H). RP-HPLC (220 nm): 97% (tR = 21.9 min, k = 6.6). HRMS (ESI): m/z 
[M]+ calcd. for [C62H79N8O3]+: 983.6270, found: 983.6275. C62H79N8O3+ · C8H3F12O8- (984.37 + 
455.09). 
 
4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-
5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)hexyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-indol-1-
ium-1-yl)butane-1-sulfonatetetrakis(hydrotrifluoroacetate) (135)  
Compound 135 was prepared from 96 (3.72 mg, 3.81 μmol) and S0536 (2.4 mg, 3.42 μmol) 
according to the procedure for the synthesis of 130, but DIPEA (4.42 mg, 5.9 μL, 34.2 μmol) 
was used instead of trimethylamine and the incubation time period was 1 h instead of 2 h. 
Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-
30 min: MeCN/0.1% aq TFA 5:95-90.5:9.5, tR = 18 min) afforded the product as a blue solid 
(1.59 mg, 30%). Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1.1H-
NMR (600 MHz, MeOH-d4): δ (ppm) 1.28-1.42 (m, 5H), 1.42-1.61 (m, 5H), 1.67-1.71 (m, 4H), 
1.71 (s, 6H), 1.72 (s, 6H), 1.73-1.75 (m, 1H), 1.79-1.84 (m, 2H), 1.88-1.92 (m, 2H), 1.93-2.00 
(m, 5H), 2.23 (t, J 6.0 Hz, 2H), 2.63-2.76 (m, 2H), 2.78-2.98 (m, 3H), 3.02-3.07 (m, 3H), 3.18-
3.19 (m, 0.5H), 3.30-3.32 (m, 3H), 3.33-3.37 (m, 3H), 3.41-3.42 (m, 0.5H), 3.43-3.45 (m, 1H), 
3.69-3.79 (m, 2H), 4.09 (t, J 6.0 Hz, 2H), 4.12-4.17 (m, 2H), 4.38 (d, J 18 Hz, 0.6H), 4.42 (d, 
J 18 Hz, 0.4H), 6.27 (d, J 18 Hz, 1H), 6.34 (d, J 12 Hz, 1H), 6.61-6.67 (m, 1H), 7.25-7.29 (m, 
4H), 7.31-7.34 (m, 2H), 7.35-7.43 (m, 3H), 7.44-7.55 (m, 4H), 7.59-7.65 (m, 1H), 7.67-7.76 (m, 
1H), 7.88-7.90 (m, 0.6H), 7.96-7.97 (m, 0.4H), 8.19-8.26 (m, 2H). RP-HPLC (220 nm): 96% 
(tR = 21.3 min, k = 6.4). HRMS (ESI): m/z [M+H]+ calcd. for [C65H85N8O6S]+: 1105.6307, found: 
1105.6309. C65H84N8O6S · C8H4F12O8 (1105.50 + 456.09). 
 
(E)-2-((2E,4E)-5-(3,3-Dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)penta-2,4-dien-
1-ylidene)-3,3-dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-
dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-
yl)ethyl)amino)hexyl)indoline-5-sulfonate trakis(hydrotrifluoroacetate) (136)  
Compound 136 was prepared from 96 (4.46 mg, 4.58 μmol) and S0586 (2.3 mg, 2.94 μmol) 
according to the procedure for the synthesis of 130, but DIPEA (4.24 mg, 5.7 μL, 32.8 μmol) 
was used instead of trimethylamine and the incubation time period was 1 h instead of 2 h. 
Purification by preparative HPLC (column: Kinetex XB-C18 5 µm 250 × 21 mm; gradient: 0-
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30 min: MeCN/0.1% aq TFA 5:95-90.5:9.5, tR = 15 min) afforded the product as a blue solid 
(1.45 mg, 30%). Ratio of configurational isomers evident in the NMR spectra: ca 1.5:1. 1H-
NMR (600 MHz, MeOH-d4): δ (ppm) 1.26-1.40 (m, 4H), 1.40-1.56 (m, 4H), 1.59-1.70 (m, 3H), 
1.73 (s, 6H), 1.74 (s, 6H), 1.75-1.77 (m, 3H), 1.77-1.87 (m, 2H), 1.89-2.05 (m, 6H), 2.18 (t, J 
6.0 Hz, 2H), 2.31-2.41 (m, 2H), 2.89 (t, J 6.0 Hz, 2H), 2.95-3.01 (m, 2H), 3.01-3.13 (m, 3H), 
3.18-3.19 (m, 1H), 3.19-3.22 (m, 1H), 3.19-3.22 (m, 1H), 3.31-3.33 (m, 4H), 3.41-3.42 (m, 1H), 
3.45 (d, J 10 Hz, 1H), 3.68-3.83 (m, 2H), 4.07 (t, J 6.0 Hz, 2H), 4.21-4.23 (m, 2H), 4.38 (d, J 
18 Hz, 0.6H), 4.43 (d, J 18 Hz, 0.4H), 6.21 (d, J 12 Hz, 1H), 6.50 (d, J 12 Hz, 1H), 6.65-6.71 
(m, 1H), 7.22-7.31 (m, 2H), 7.31-7.34 (m, 2H), 7.36-7.46 (m, 3H), 7.44-7.54 (m, 3H), 7.60-
7.67 (m, 1H), 7.67-7.75 (m, 1H), 7.81-7.86 (m, 2H), 7.89-7.91 (m, 0.6H), 7.96-7.97 (m, 0.4H), 
8.12-8.32 (m, 2H). RP-HPLC (220 nm): 99% (tR = 17.6 min, k = 5.1). HRMS (ESI): m/z [M+H]+ 
calcd. for [C65H85N8O9S2]+: 1185.5875, found: 1185.5896. C65H83N8O9S2- · C8H4F12O8 (1184.55 
+ 456.09). 
 
4.4.3. Determination of fluorescence quantum yields  
 
The determination of the fluorescence quantum yields of 133-136 in PBS and PBS containing 
1% BSA was performed with a Cary Eclipse spectrofluorimeter and a Cary 100 UV/VIS 
photometer (Varian Inc., Mulgrave, Victoria, Australia) as described previously with minor 
modifications6. All spectra were recorded using acryl cuvettes (10 × 10 mm, Ref. 67.755, 
Sarstedt, Nümbrecht, Germany). Fluorescence spectra were recorded at the slit adjustments 
(excitation/emission) 10/5 nm and 10/10 nm. Table 7 provides an overview of the used 
concentrations of the fluorescent ligands and the applied excitation wavelengths. The 
concentration of cresyl violet perchlorate in EtOH was 2 µM. Fluorescence spectra of cresyl 
violet perchlorate were recorded using an excitation wavelength of 575 nm. 
 
Table 7. Concentrations and excitation wavelengths used for the determination 
of fluorescence quantum yields. 
Compound 
concentration [µM] excitation wavelength [nm] 
PBS PBS + 1% BSA PBS PBS + 1% BSA 
133 15 12 445 470 
134 5 5 600 610 
135 3 2 610 620 
136 2 2 610 610 
 
4.4.4. Investigation of the chemical stability 
 
The stability of the fluorescent ligand 136 was investigated in phosphate buffered saline (pH 
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7.4). The incubation was started by addition of 10 μL of a 5 mM stock solution of 136 (in 
DMSO/H2O 1:1 v/v) to 490 μL of PBS to give a final concentration of 100 μM. After 0 h, 6 h, 
24 h, 48 h, an aliquot (120 μL) was taken and added to acetonitrile/H2O/2% aq TFA (2:4:4 
v/v/v) (120 μL). 100 μL of the resulting solution (pH < 4) were analyzed by analytical HPLC on 
a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-6200-A pump, 
an AS-2000A autosampler, a L-4000A UV detector and a D-6000 interface. A Kinetex-XB C18, 
5 μm, 250 mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) served as stationary phase 
at a flow rate of 0.8 mL/min. The following linear gradient was applied: 0-20 min: 
acetonitrile/0.1% aq TFA 10:90-36:64, 20-28 min: 36:64-95:5, 28-35 min: 95:5. Detection was 
performed at 220 nm and the oven temperature was 30 °C. 
 
4.4.5. [3H]NMS competition binding assay  
 
Radioligand binding studies with [3H]NMS were performed at 22 ± 1 °C. Leibovitz L-15 medium 
(Gibco, Life Technologies GmbH, Darmstadt, Germany) supplemented with 1% BSA (Serva, 
Heidelberg, Germany) (in the following referred to as L15 medium) was used as binding buffer. 
The effects of the fluorescent ligands 130-136 on the equilibrium binding of [3H]NMS 
(equilibrium competition binding assay) were determined at intact adherent CHO-hMxR cells 
(x = 1-5) in white 96-well plates with clear bottom (Corning Life Sciences, Tewksbury, MA; 
Corning cat. no. 3610) using the protocol of previously described MR binding studies with 
[3H]NMS44 with the following modification: the total volume of L15 medium per well was 200 
µL instead of 188 µL, i.e. the cells were covered with L15 medium (160 µL) followed by the 
addition of L15 medium (20 µL) neat or containing competitors or atropine (10-fold 
concentrated), and L15 medium (20 µL) containing the radioligand 10-fold concentrated. The 
concentration of [3H]NMS was 0.2 nM (M1, M2, M3), 0.1 nM (M4) or 0.3 nM (M5) and the 
incubation time was 3 h throughout.  
 
4.4.6. Flow cytometric binding experiments 
 
All flow cytometric binding studies were performed with a FACSCaliburTM flow cytometer 
(Becton Dickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) and a red 
diode laser (635 nm), instrument settings were: FSC, E-1; SSC, 280 V; Fl-4, 700−800 V. All 
samples were prepared and incubated in 1.5 mL reaction vessels (Sarstedt, Nümbrecht, 
Germany). Samples were prepared in duplicate throughout. Fluorescence signals were 
recorded in channel FL-4 (excitation: 635 nm, emission: 661 ± 18 nm). Measurements were 
stopped after counting of 20,000 gated events (highest flow rate).  
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4.4.6.1. Saturation binding studies at the M1R, M2R and M4R and competition 
binding with fluorescent ligand 136 at the M2R  
 
CHO-hMxR (x = 1, 2 and 4) cells were seeded in a 175-cm2 culture flask 5-6 days prior to the 
experiment. Cells were treated with trypsin, suspended in culture medium and centrifuged. 
The cell pellet was re-suspended in Leibovitz’s L15 culture medium (Gibco, Life Technologies, 
Darmstadt, Germany) supplemented with 1% bovine serum albumin (Serva, Heidelberg, 
Germany), in the following referred to as L15 medium. The cell density was adjusted 1 ∙ 106 
cells/mL. For saturation binding experiments, 490 μL of the cell suspension were added to 
reaction vessels, 5 µL of a solution of the fluorescent ligand (100-fold concentrated) in 
DMSO/H2O (1:1 v/v) and 5 μL of DMSO/H2O (1:1 v/v), were added to determine total binding. 
For the determination of unspecific binding (in the presence of atropine at 500-fold access to 
the fluorescent ligand), 490 μL of the cell suspension were added to reaction vessels, 5 µL of 
a solution of the fluorescent ligand (100-fold concentrated) in DMSO/H2O (1:1 v/v) and 5 μL of 
a solution of atropine (100-fold concentrated) in DMSO/H2O (1:1 v/v) were added. Compound 
135 or 136 was applied at final concentrations of 0.1-15 nM and 0.1-10 nM, respectively, for 
M2R binding experiments, and 136 was applied at final concentrations of 0.15-80 nM for M1R 
and M4R binding studies. The incubation period was 2 h. 
For competition binding experiments with 136 (c = 1.0 nM) at CHO-hM2R cells, 5 µL of a 
solution of the fluorescent ligand (100-fold concentrated) in DMSO/H2O (1:1 v/v) and 5 μL of 
a solution of atropine (100-fold concentrated) in DMSO/H2O (1:1 v/v), to determine unspecific 
binding (500-fold excess of atropine to 136), or 5 μL of a solution of the compound of interest 
(including 2, 7, 8, 11, 14, 15 and 16) (100-fold concentrated) in DMSO/H2O (1:1 v/v), for 
competition binding, were premixed in the reaction vessels followed by addition of 490 μL of 
the cell suspension. The incubation period was 2 h. 
M2R saturation binding experiments with 136 in the presence of various fixed concentrations 
of 15 were performed as described above with the following modification: vessels were 
prefilled with 485 µL of M2R cell suspension. For total binding, L15 medium (5 μL), L15 medium 
(5 µL) containing 15 100-fold concentrated, L15 medium (5 μL) containing 136 100-fold 
concentrated were added. For unspecific binding, L15 medium (5 μL) containing compound 
136 (100-fold concentrated), L15 medium (5 μL) containing 15 (100-fold concentrated) and 
L15 medium (5 μL) containing atropine 100-fold concentrated (500-fold excess to compound 
136) were added. 
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4.4.6.2. Association and dissociation kinetics of 136 at CHO-hM2R cells  
 
For association experiments with 136 (c = 3 nM) at CHO-hM2R cells reaction vessels were 
prefilled with 490 μL of the cell suspension. For total binding DMSO/H2O (1:1 v/v) (5 μL) and 
DMSO/H2O (1:1 v/v) (5 μL) containing 136 (0.3 μM) were added. To determine unspecific 
binding DMSO/H2O (1:1 v/v) (5 μL) containing atropine (30 μM) and DMSO/H2O (1:1 v/v) (5 
μL) containing 136 (0.3 μM) were added to the cell suspension. The incubation was stopped 
after different periods of time (0-140 min) by measurement of the samples. In the case of 
dissociation experiments, cells were preincubated with 136 at a final concentration of 5 nM for 
2 h (500 µL total volume per vessel). Unspecific binding was determined in the presence of 
atropine at a final concentration of 1 μM. After incubation, the cells were centrifuged at room 
temperature for 3.5 min, the supernatant was removed by suction and the cells were covered 
with L15 medium (500 μL) containing atropine (2.5 μM) followed by shaking in the dark. After 
different periods of time (0-150 min), the samples were subjected to measurement by flow 
cytometry.  
 
4.4.7. High content imaging binding experiments 
4.4.7.1. Saturation and competition binding assay  
 
One day prior to the experiment CHO-hM2R cells were seeded at 35,000-40,000 cells per well 
into the central 60 wells of a black/transparent 96-well plate (Grenier 655090). The medium 
was removed by suction, the cells were washed with HBSS containing 0.1 % BSA (in the 
following referred to as HBSS-BSA) (50 μL), and covered with 80 μL of HBSS-BSA containing 
the permeable nuclear dye H33342 (2 μg/mL, Sigma). To determine total binding HBSS-BSA 
(10 μL) and HBSS-BSA (10 μL) containing the fluorescent ligand (10-fold concentrated) were 
added. For the determination of unspecific binding and to study the effect of a compound of 
interest on M2R binding of the fluorescent ligand (competition binding assay) HBSS-BSA (10 
μL) containing atropine or the ‘competitor’ (10-fold concentrated) and HBSS-BSA (10 μL) 
containing the fluorescent ligand (10-fold concentrated) were added. After incubation at room 
temperature in the dark for 60 min, images were acquired with the IX Ultra confocal plate 
reader (Molecular Devices, Sunnyvale CA) to obtain “non-washing” saturation binding curves 
(cf. Figure 10A and 10B), unspecific binding was determined in the presence of atropine (1 
µM). After incubation at room temperature in the dark for 60 min, the medium was removed 
by suction and the cells were washed with HBSS-BSA (50 μL) and covered with HBSS-BSA 
(50 μL) followed by immediate acquisition of the images using the IX Ultra confocal plate 
reader to obtain “washing step applying” saturation binding curves (cf. Figure 10C and 10D), 
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unspecific binding was determined in the presence of atropine (500-fold excess to the 
fluorescent ligand). The washing process was performed within < 2 min. For competition 
binding experiments, unspecific binding was determined in the presence of atropine (1 µM), 
plates were directly imaged after incubation for 1 h. Saturation binding experiments were 
performed in triplicate and competition binding assays were performed in duplicate. In case of 
competition binding studies the ‘competitor’ was added to the cells 2 min prior to the addition 
of fluorescent ligand. One site/well was measured with the plate reader in case of competition 
binding with 2, 6 and 7, and two sites/well were measured in case of saturation binding studies 
and competition binding experiments with 3, 14, 15 and 16. The excitation laser lines of the 
Ultra were 405 nm (H33342), 488 nm (FITC), 561 nm (Texas Red) and 635 nm (Cy5), the 
emission laser lines of the Ultra were 447/60 nm (H33342), 525/50 nm (FITC), 593/40 nm 
(Texas Red) and 685/40 nm (Cy5). 
M2R saturation binding experiments with 136 in the presence of various fixed concentrations 
of 15 were performed as described above with the following modification: the cells were 
covered with 70 µL of HBSS-BSA instead of 80 µL to compensate the extra addition of HBSS-
BSA (10 µL) containing 15 (10-fold concentrated). The washing step prior to the measurement 
was performed. 
 
4.4.8. Confocal Microscopy 
 
One day prior to the experiment CHO-hM2R cells were trypsinized and seeded in Nunc 
LabTekTM II chambered coverglasses with 8 chambers (Thermo fisher scientific) (ca. 80000 
cells/well). The culture medium was removed, the cells were washed with HBSS-BSA (200 μL) 
and covered with HBSS-BSA (320 μL). HBSS-BSA (40 μL) and HBSS-BSA (40 μL) with the 
fluorescent probe (10 fold concentrated) was added for total binding. For unspecific binding 
HBSS-BSA (40 μL) with the competing agent atropine (final concentration: 10 μM) and HBSS-
BSA (40 μL) with the fluorescent probe (10 fold concentrated) were added. Images of total 
and unspecific binding were acquired after an incubation period of 5-45 min. Confocal 
microscopy was performed with a zeiss LSM710 confocal microscope. The objective was 63x 
magnification with oil (1.4NA). The excitation laser lines were 405 nm (2.0%) and 633 nm 
(10.0%), filter settings were 410-514 nm and 638-759 nm, pinhole settings are 44 μm for both 
DAPI and Cy5 channels. 
 
4.5. Data processing 
 
Retention (capacity) factors k were calculated from retention times (tR) according to k = 
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(tR−t0)/t0 (t0 = dead time). Raw data from flow cytometric experiments were processed with the 
aid of FloJo software to obtain geometrical mean values of FL-4. Fluorescence images from 
high content imaging were analyzed using the granularity analysis (2-3-μm-diameter granules; 
MetaXpress 5.3, Molecular Devices) to obtain values of arbitrary intensity units. Intensity 
thresholds were adapted to maximize the identification of specifically bound fluorescent ligand 
(without distinguishing membrane from intracellular localization), by reference to total and 
unspecific plate controls. Specific binding data from saturation binding experiments (flow 
cytometry, high content imaging) were plotted against the fluorescent ligand concentration and 
analyzed by a two-parameter equation describing hyperbolic binding (one site-specific binding, 
GraphPad Prism) to obtain Kd values. Unspecific binding data from saturation binding 
experiments were fitted by linear regression. In case of saturation binding experiments with 
fluorescent labeled ligand 136 in the presence of compound 15, specific binding data were 
analyzed by a two-parameter equation describing hyperbolic binding (one site-specific binding, 
GraphPad Prism) to obtain Kd and Bmax values. Additionally, specific binding data were 
normalized to the Bmax value, specific binding (%) was plotted against log(concentration of 136) 
followed by analysis using a four-parameter logistic fit (log(agonist) vs. response, applied 
constraints: bottom = 0%, top = 100%; GraphPad Prism). Data for the ‘Schild’ plot were 
obtained from the rightward shift (ΔpKd) of the saturation isotherm and transformation into 
log(r-1) (where r = 10ΔpKd). Log(r-1) was plotted against log(concentration of 15) and the data 
were analyzed by linear regression to obtain the slope and the ‘pA2’ value (intercept with the 
X axis). Specific binding data from association experiments with 136 were analyzed by a two-
parameter equation describing an exponential rise to a maximum (one-phase association, 
GraphPad Prism) to obtain the observed association rate constant kobs and the amount of 
specifically bound 136 at equilibrium (Beq), which was used to calculate specifically bound 136 
(Bt) in %. Data from dissociation experiments (% specifically bound 136 (Bt) plotted over time) 
were analyzed by a three-parameter equation (one phase decay, GraphPad Prism) to obtain 
the dissociation rate constant koff. The association rate constant (kon) of 136 was calculated 
from kobs, koff and the concentration of 136 used for the association experiment according to 
the correlation: kon = (kobs-koff)/[FL]. Total binding data from competition binding experiments 
(determination of the effect of various MR ligands on the equilibrium binding of [3H]NMS, 135 
or 136) were plotted against log(concentration competitor) and analyzed by a four-parameter 
logistic equation (log(inhibitor) vs. response-variable slope, GraphPad Prism) followed by 
normalization (100% = ‘top’ of the four-parameter logistic fit, 0% = unspecifically bound 
fluorescent ligand determined in the presence of 7) and analysis of the normalized data by a 
four-parameter logistic equation. IC50 values were converted to Ki values according to the 
Cheng-Prusoff equation51. Statistical significance was assessed by a one-sample t-test.  
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5. Summary 
 
In humans, the family of muscarinic acetylcholine receptors (mAChR, MRs) comprises five 
subtypes (M1R-M5R), which are members of the class A GPCR superfamily and mediate the 
action of the neurotransmitter acetylcholine in the central and peripheral nervous system. For 
instance, the M2R, which binds to Gi/o heterotrimeric G-proteins, acts as a presynaptic 
autoreceptor in the brain and in the periphery. Accordingly, selective M2R antagonism in the 
CNS, resulting in enhanced cholinergic transmission, was suggested as an approach to 
increase cholinergic function in Alzheimer patients. MRs represent important drug targets, 
however, there is still a need for highly subtype selective MR ligands, as the development of 
selective agents has been challenging due to the high conservation of the acetylcholine 
(orthosteric) binding site. Due to the less conserved allosteric binding sites, the dualsteric 
ligand approach, i.e. the design of compounds, which simultaneously address the orthosteric 
and allosteric binding sites, is considered a promising strategy to develop MR ligands with 
improved subtype selectivity. 
This work was aiming at the synthesis and pharmacological characterization of 
dibenzodiazepinone-type heterodimeric MR ligands, which were prepared by linking different 
monomeric MR ligands (agonists, antagonists, orthosteric and allosteric ligands) through 
various linkers to a pharmacophoric moiety derived from the dibenzodiazepinone DIBA. The 
synthesis afforded heterodimeric ligands (‘DIBA-xanomeline’, ‘DIBA-TBPB’, ‘DIBA-77-LH-28-
1’, ‘DIBA-propantheline’ and ‘DIBA-4-DAMP’) and ‘DIBA-DIBA’-type homodimeric ligands. 
Equilibrium competition binding studies with [3H]NMS at live CHO cells expressing the 
respective human MxR subtype (x = 1-5) revealed a M2R preference of all dimeric ligands with 
high M2R affinities (Ki values: 0.08-5.8 nM). These data demonstrated that the type of the linker 
(short vs. long, basic vs. non-basic, etc.) and the type of the second pharmacophoric group 
had only little impact on M2R binding. As non-DIBA-type monomeric and homodimeric 
reference compounds exhibited considerably lower M2R affinities than the synthesized DIBA-
derived ligands, the high M2R affinity of the heterodimeric dibenzodiazepinone-type ligands is 
most likely conferred by the ‘dibenzodiazepinone’ pharmacophore. 
Two tritium-labeled DIBA-derived heterodimeric ligands (‘DIBA-xanomeline’- and DIBA-
TBPB’-type) were prepared and characterized by saturation and kinetic binding studies at the 
hM2R. Saturation binding experiments showed that these ligands address the orthosteric site 
of the M2R. The ‘DIBA-TBPB’-type dimeric radioligand ([3H]115) exhibited a very high M2R 
affinity (Kd value 0.13 nM). The investigation of the effect of allosteric MR ligands (gallamine, 
W84, LY2119620) on the equilibrium binding of [3H]115, and saturation binding studies with 
[3H]115 in the presence of the allosteric MR ligand W84 (Schild-like analysis) strongly 
Chapter 5                                           149 
suggested a competitive mechanism between [3H]115 and the investigated allosteric ligand. 
Consequently, these data revealed that DIBA-derived heterodimeric ligands such as 115 
exhibit a dualsteric binding mode at the M2R. 
Moreover, a series of fluorescently labeled, monomeric DIBA-derived ligands was prepared 
by conjugation of cyanine dyes or a pyrylium dye via different linkers to the 
dizenzodiazepinone scaffold. Except for one compound, the fluorescent probes exhibited high 
M2R affinity (Ki < 55 nM). Interestingly, the structure of the fluorophores had less impact on 
the M2R affinity than the nature of the linker. The fluorescent ligands 135 and 136, bearing 
red-emitting cyanine dyes attached via linkers with a basic piperazine moiety, exhibited the 
highest M2R affinity (Ki ca. 1 nM). The M2R preference of the fluorescent ligands was less 
pronounced compared to the amine-functionalized precursor molecules, i.e. attachment of the 
lipophilic fluorophores resulted in a decrease in M2R selectivity. Application of 135 and 136 to 
flow cytometry and high content analysis proved that these new fluorescent probes are suited 
for such techniques. The fluorescent ligand 136 was identified as a valuable molecular tool for 
the determination of MR affinities of MR ligands. M2R binding studies with 136 in the presence 
of allosteric modulators strongly suggested that 136 and structurally related ligands bind 
simultaneously to both the orthosteric (via the dibenzodiazepinone scaffold) and the ‘common’ 
allosteric binding site (most likely via the fluorophores) of the M2R, thus exhibiting a dualsteric 
binding mode, too. 
In conclusion, this work afforded new radiolabeled and fluorescently labeled molecular tools 
for the M2R and suggests dibenzodiazepinone-type MR ligands as an interesting compound 
class to develop highly selective M2R ligands according to the dualsteric ligand approach. 
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6. Appendix 
6.1. 1H-NMR and 13C-NMR spectra of compounds 41, 46, 
53-55, 67, 95-102, 105a, 106-108, 110-120 and 130-136 
 
1H-NMR spectrum (400 MHz, [D4]MeOH) of compound 41. 
 
13C-NMR spectrum (100 MHz, [D4]MeOH) of compound 41. 
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1H-NMR spectrum (300 MHz, CDCl3) of compound 46. 
 
 
13C-NMR spectrum (75 MHz, CDCl3) of compound 46. 
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1H-NMR spectrum (300 MHz, CDCl3) of compound 53. 
 
 
13C-NMR spectrum (75 MHz, CDCl3) of compound 53. 
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1H-NMR spectrum (300 MHz, CDCl3) of compound 54. 
 
 
13C-NMR spectrum (75 MHz, CDCl3) of compound 54. 
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1H-NMR spectrum (300 MHz, CDCl3) of compound 55. 
 
 
13C-NMR spectrum (75 MHz, CDCl3) of compound 55. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 67. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 67. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 95. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 95. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 96. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 96. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 97. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 97. 
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1H-NMR spectrum (300 MHz, [D4]MeOH) of compound 98. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 98. 
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1H-NMR spectrum (300 MHz, [D4]MeOH) of compound 99. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 99. 
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1H-NMR spectrum (300 MHz, [D4]MeOH) of compound 100. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 100. 
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1H-NMR spectrum (300 MHz, [D4]MeOH) of compound 101. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 101. 
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1H-NMR spectrum (300 MHz, [D4]MeOH) of compound 102. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 102. 
 
166                                        Chapter 6 
 
1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 105a. 
 
 
13C-NMR spectrum (75 MHz, [D4]MeOH) of compound 105a. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 106. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 106. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 107. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 107. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 108. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 108. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 110. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 110. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 111. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 111. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 112. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 112. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 113. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 113. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 114. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 114. 
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1H-NMR spectrum (600 MHz, [D6]DMSO) of compound 115. 
 
 
13C-NMR spectrum (150 MHz, [D6]DMSO) of compound 115. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 116. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 116. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 117. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 117. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 118. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 118. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 119. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 119. 
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1H-NMR spectrum (600 MHz, [D4]MeOH) of compound 120. 
 
 
13C-NMR spectrum (150 MHz, [D4]MeOH) of compound 120. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 130. 
 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 131. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 132. 
 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 133. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 134. 
 
 
1H-NMR spectrum (600 MHz, MeOH-d4) of compound 135. 
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1H-NMR spectrum (600 MHz, MeOH-d4) of compound 136. 
 
 
6.2. RP-HPLC chromatograms of compounds 41, 46, 53-55, 
67, 95-102, 105a, 106-108, 110-120 and 130-136  
 
 
RP-HPLC analysis (purity control) of 41 and 46. 
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RP-HPLC analysis (purity control) of 53 and 54. 
 
 
RP-HPLC analysis (purity control) of 55 and 67. 
 
RP-HPLC analysis (purity control) of 95 and 96. 
 
 
RP-HPLC analysis (purity control) of 97 and 98. 
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RP-HPLC analysis (purity control) of 99 and 100. 
 
RP-HPLC analysis (purity control) of 101 and 102. 
 
 
RP-HPLC analysis (purity control) of 105a and 106. 
 
 
RP-HPLC analysis (purity control) of 107 and 108. 
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RP-HPLC analysis (purity control) of 110 and 111. 
 
 
RP-HPLC analysis (purity control) of 112 and 113. 
 
 
RP-HPLC analysis (purity control) of 114 and 115. 
 
 
RP-HPLC analysis (purity control) of 116 and 117. 
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RP-HPLC analysis (purity control) of 118 and 119. 
 
 
RP-HPLC analysis (purity control) of 120 and 130. 
 
 
RP-HPLC analysis (purity control) of 131 and 132. 
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RP-HPLC analysis (purity control) of 133 and 134. 
 
 
RP-HPLC analysis (purity control) of 135 and 136. 
 
 
6.3. Abbreviations 
 
α intrinsic activity or selectivity factor 
A agonist 
abs absolute 
AC adenylyl cyclase 
aq aqueous 
atm atmosphere 
Boc tert-butoxycarbonyl 
Boc2O di-tert-butyl dicarbonate 
Bq becquerel 
Bmax the maximal specific binding of a ligand 
BRET bioluminescence resonance energy transfer 
brs broad singlet 
BSA bovine serum albumin 
[Ca2+]i intracellular calcium ion concentration 
calcd. calculated 
cAMP cyclic 3’, 5’-adenosine monophosphate 
CH2Cl2 dichloromethane 
CHCl3 chloroform 
CH3CN acetonitrile 
CHO-cells Chinese hamster ovary cells 
Ci curie 
CNS central nervous system 
COSY correlated spectroscopy 
cpm counts per minute 
d day(s) or doublet 
DAG diacylglycerol 
δ chemical shift 
DCC N,N’-dicyclohexylcarbodiimide 
DCM dichloromethane 
dd doublet of doublets 
DIPEA diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
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DMSO-d6 per-deuterated dimethylsulfoxide 
EC50 agonist concentration which induces 50 % of the maximum 
response 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 
eq equivalents 
EtOAc ethylacetate 
Et2O diethylether 
EtOH ethanol 
FACS fluorescence activated cell sorter 
FCS fetal bovine serum 
Fl-1, Fl-2, Fl-3, Fl-4 fluorescence channels (Flow cytometer) 
FRET fluorescence resonance energy transfer 
G G-Protein 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
GPCR G-protein coupled receptor 
h hour(s) or human 
HCl hydrochloric acid 
HMBC heteronuclear multiple bond correlation 
HSQC heteronuclear single quantum correlation 
HOBt 1-Hydroxybenzotriazole hydrate 
HPLC high-performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz hertz 
IC50 radioligand binding assay: ligand concentration inhibiting 
the binding of a radioligand by 50 % 
IP3 inositol-1,4,5-trisphosphate 
IR infrared 
J coupling constant 
k capacity factor 
Kb dissociation constant (functional assay) 
KBr potassium bromide 
K2CO3 potassium carbonate 
Kd dissociation constant (saturation binding) 
KHSO4 potassium bisulfate 
Ki dissociation constant (competition binding) 
kobs observed rate constant 
koff dissociation rate constant 
kon association rate constant 
L liter 
LiAlH4 Lithiumaluminiumhydrid 
L15 Leibovitz medium without phenol red 
m multiplet 
M molar (mol/L) 
mAU milli absorbance units 
MeCN acetonitrile 
MeOH methanol 
MeOH-d4 per-deuterated methanol 
MeI methyl iodide 
mol mole (s) 
min minute(s) 
μ micro 
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mp melting point 
MR Muscarinic receptor 
MxR Muscarinic Mx receptor (x = 1, 2, 3, 4, 5) 
MS mass spectrometry 
n nano or amount of substance 
NaHCO3 sodium bicarbonate 
NaI sodium iodide 
Na2SO4 sodium sulfate 
NEt3 triethylamine 
NHS N-hydroxysuccinimide 
NMR nuclear magnetic resonance 
NPY neuropeptide Y 
OBD orthosteric binding domain  
PBS phoshpate buffered saline 
PE petroleum ether 
pEC50 negative decadic logarithm of the molar concentration of 
the agonist causing 50 % of the maximal response 
Ph phenyl 
Ph3P triphenylphosphine 
PIP2 Phosphatidylinositol-4,5-bisphosphate 
PKC protein kinase C 
PLCβ phospholipase Cβ 
pKb negative decadic logarithm of the dissociation constant 
(functional assay) 
pKi negative decadic logarithm of the dissociation constant 
(competition binding assay) 
ppm parts per million 
Py pyridyl or pyrylium 
q quartet 
ref reference 
Rf retardation factor 
RGS regulator of G-protein signaling 
RP reversed phase 
rpm revolutions per minute 
rt room temperature 
s singulet  
sat. saturated 
SEM standard error of the mean 
t triplet 
t0 dead time 
TBDPS tert-butyldiphenysily 
TBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography  
TM transmembrane 
TM transmembrane 
TMS trimethylsilyl 
tR retention time 
UV ultraviolett 
 
 
